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“Imagination is more important than knowledge.  
For knowledge is limited, whereas imagination embraces the 
entire world, stimulating progress, giving birth to evolution. 
It is, strictly speaking, a real factor in scientific research.” 
A. Einstein 
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Preface 
 
 
 
A chiral object is one that has a non-superimposable mirror image. This concept, easily 
exemplified with the hands, as they are mirror images but not superimposable one with the other, 
can be extended as well to molecules (Figure 1). In chemistry, each of the two images is known as 
enantiomer. This inherent property of some molecules has a dramatic effect on our existence and 
everyday life: DNA, proteins, amino acids, sugars, are all chiral entities. Probably the most famous 
example in our society is thalidomide, a drug prescribed to pregnant women during the 60’s. In 
this unfortunate case, while one of the enantiomers had a sedative effect, the other was 
teratogenic, i.e. caused malformations to the fetus. Another interesting example is the different 
odor perceived for the two enantiomers of carvone. Since our olfactory receptors also contain 
chiral groups, we are able to differentiate (R)-carvone, with a spearmint leaves smell, from the 
(S)-carvone, which smells like caraway seeds. 
 
 
 
 
               
Figure 1. The two enantiomers of different chiral molecules. 
Since Le Bel and van’t Hoff, in 1874, proposed that a carbon with four different substituents 
in a tetrahedral disposition can exist as a pair of isomers (the so called enantiomers), scientist 
have been fascinated by the challenge to achieve full stereocontrol during chemical 
transformations starting from achiral compounds. This has led to the development of 
enantioselective synthesis, an important subfield in organic synthesis. 
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Catalysis is the increase in the rate at which a chemical reaction takes place by lowering the 
energy barrier between the reactants and the products. This is achieved by employing a 
substance, known as catalyst, which participates in the reaction but that is not consumed. In this 
way, ideally, a catalyst can catalyze a reaction an infinite number of times without being 
consumed. The field of catalysis has found many applications in our society: when we make 
cheese or beer, in the cars to reduce the emission of toxic chemicals or in the industry to 
synthesize drugs more efficiently. But catalysts are not a human invention, as enzymes are 
extremely highly efficient catalysts present in all organisms. 
The application of catalysis to enantioselective synthesis led to the important field of 
asymmetric catalysis. Among all different enantioselective transformations that have been 
studied, catalytic asymmetric hydrogenation, consisting on the addition of molecular hydrogen to 
a compound in a stereoselective fashion, is by far the most industrially relevant. The first 
industrial application was the production of the amino acid L-DOPA (Figure 1), which had 
proven useful in the treatment of the Parkinson’s disease.  
 
Scheme 1. Industrial process for the synthesis of L-DOPA by Rh-catalyzed asymmetric hydrogenation. 
Paradoxically, although this is an operationally simple 100% atom economic process, it has 
only been implemented in a limited number of industrial processes. Most of the hydrogenations 
are still performed in a non-enantioselective way and followed by a separation of the two 
enantiomers formed in a 50:50 ratio. This implies the disposal of half of the reacted material and 
elevated solvent wastes and energy consumption. There are three reasons that might explain this 
situation: (i) the lack of efficient methodologies for the asymmetric hydrogenation of challenging 
substrates, (ii) the high price of noble metals commonly used as catalysts (Rh, Ru, Ir, Pd, Pt…) 
and (iii) the time-to-market pressure, which does not allow sufficient time for the development of 
a catalytic process. 
This thesis has aimed to overcome some of these limitations focusing on the development of 
new metal-catalyzed asymmetric hydrogenation methodologies.  
In Part A (Chapters I to III), the studies on the asymmetric hydrogenation of substituted 
pyridines are described. These heteroaromatic compounds have proven very challenging to 
hydrogenate enantioselectively, however, the resulting chiral piperidines are of high industrial 
interest. In Chapter I, the state of the art and the mechanistic studies carried out on related N-
heteroaromatic substrates are extensively discussed. In Chapter II, a new method for the 
asymmetric hydrogenation of 2-substitued pyridines is reported, together with complementary 
mechanistic studies that shed light on the origin of the enantioselectivity. In Chapter III, a 
method for the highly enantioselective hydrogenation of 3-substituted pyridines is disclosed. 
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Furthermore, a deep mechanistic study reveals how this high level of stereocontrol can be 
achieved on substrates where no good results had been reported until now. 
Part B (Chapter IV to VI) is centered on the problems associated with the high prices of 
noble metals. Two different solutions have been envisioned in the scientific community to 
overcome this problem. The first one relies on the replacement of the more commonly used 
expensive metals for cheap and abundant 1st row transition metals, such as Fe, Co, Ni or Cu. The 
second approach consists in recycling or reusing the noble metals for more than one reaction. In 
this regard, tandem catalysis is a commonly applied methodology, where the same metal is used 
to catalyze at least two different reactions in one pot. In our case, we focused on developing an 
asymmetric version of the tandem olefin metathesis–hydrogenation. Chapter IV contains an 
introduction on the topic. In Chapter V and VI, the conversion of different Ru-olefin metathesis 
catalysts to efficient asymmetric hydrogenation and asymmetric transfer hydrogenation catalysts 
is described, respectively. These transformations have been subsequently applied to the tandem 
metathesis-asymmetric hydrogenation and to the metathesis-asymmetric transfer hydrogenation. 
 
____________________  
The work reported in this thesis has been carried out between DSM Innovative Synthesis (NL), 
for 18 months, and the University of Milan (IT), for 18 months more, within the “Marie 
Skłodowska Curie” EID-ITN Network “REDUCTO”, involving the mentioned industrial and 
academic partners. During the months spent at the University of Milan I have also been involved 
in a project aiming at the development of new chiral (cyclopentadienyl)iron complexes active in 
asymmetric hydrogenation of different prochiral substrates. 
 
 
 
   
 
 
Part A. 
Asymmetric Hydrogenation of 
Pyridines 
 
 
 
 
 
 
 
 
 
Abstract: 
A general overview on the state of the art in the asymmetric hydrogenation of pyridines is 
discussed in Chapter I. This is accompanied by a review on the asymmetric hydrogenation of N-
heteroarenes, which will set the basis for understanding the following investigations. In Chapter 
II and III, the results of the study towards the development of new systems for the asymmetric 
hydrogenation of 2- and 3-substituted pyridines are presented, respectively. Mechanistic studies 
on both systems allow for a deeper comprehension of the subject. 
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CHAPTER I. 
OVERVIEW ON THE ASYMMETRIC  
HYDROGENATION OF N-HETEROARENES 
 
 
Nitrogen-containing molecules are very common in nature and, besides, every single one of 
the 25 best-selling drugs in 2014 contains at least one nitrogen atom. Although many of these 
biologically active molecules are chiral and contain nitrogen heterocyclic moieties, the 
asymmetric hydrogenation (AH) of N-heteroaromatic compounds has been very little explored 
compared to other prochiral substrates, such as imines or enamides. There are few reasons that 
make N-heteroarenes a real challenge: (i) their high aromatic resonance stability requires 
elevated temperatures and pressures in hydrogenation, which adversely affects the 
enantioselectivity. (ii) The nitrogen atom has a strong tendency to coordinate and thus poison 
the metal catalyst. (iii) The lack of secondary coordinating groups which could interact with the 
metal center makes more difficult to achieve good enantioselectivities.  
Among all N-heteroaromatic compounds, the hydrogenation of pyridines is of special 
interest for the industry, since enantiomerically pure piperidines are ubiquitous structural motifs 
in many biologically active compounds (Figure 1). 
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Figure 1. Selected chiral piperidine-containing drugs. 
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However, pyridines are also one of the most challenging substrates: they possess high 
aromatic stabilization energies (close to that of benzene)1 and, in contrast to benzene-fused 
heteroaromatics, they require the hydrogenation of three double bonds to afford the saturated 
piperidine products. This difficulty to enantioselectively hydrogenate pyridines can be easily 
deduced from the number of reports published regarding the enantioselective hydrogenation of 
pyridines (Figure 2). While the number of publications of enantioselective hydrogenation of N-
heteroarenes has increased constantly during the last ten years, the number of reports about 
pyridines has remained constant. 
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Figure 2. Number of publications regarding the enantioselective hydrogenation of pyridines and other N-
heteroarenes. Source: SciFinder. 
I.1 ASYMMETRIC HYDROGENATION OF PYRIDINES – STATE 
OF THE ART 
The first approach for the synthesis of chiral piperidines from pyridines was a two-step 
hydrogenation disclosed by Studer and co-workers in 1999 (Scheme 1). An initial partial 
hydrogenation of ethyl nicotinate with Pd/C furnished the corresponding 1,4,5,6-
tetrahydropyridine. In the second step, employing Pd/C and 10,11-dihydrocinchonidine as chiral 
modifier under harsh hydrogenation conditions, they obtained ethyl nipecotinate with 17% ee.2 
In 2006, Zhang and co-workers proposed a modified version of this approach, using a chiral 
homogeneous catalyst for the second hydrogenation step (Scheme 1). Although the 
tetrahydropyridine had to be first protected as a carbamate, the final nipecotinate derivative was 
obtained with 99% ee.3 
  Part A – Chapter I 15 
 
 
Scheme 1. Two-step methodologies for the hydrogenation of ethyl nicotinate. 
It was not until 2000 when the first examples of one-step asymmetric hydrogenation (AH) 
of pyridines were published. Johnson and co-workers achieved full hydrogenation of ethyl 
nicotinate with 17% ee using a Pd-diphenylphopshino-ferrocene catalyst anchored to 
mesoporous silica.4 Hegedűs et al., by means of a heterogeneous catalyst, were able to 
hydrogenate nicotinic and picolinic acids derivatized with (S)-proline, achieving diastereomeric 
ratios up to 97:3 (Scheme 2).5 Some years later, three more diastereoselective procedures were 
published using a heterogeneous catalyst and a chiral auxiliary attached to the substrate. Two of 
them consisted in the hydrogenation of 2-methylnicotinic acid derivatives,6 and the third one 
involved the hydrogenation of 2-oxazolidinonepyridines. In the latter example, reported by 
Glorius et al.,  ee’s up to 98% were obtained (Scheme 2) and the chiral auxiliary could be removed 
by simple acidic work-up.7  
More importantly, in a pioneering work by Studer et al., the homogeneous AH of 
unprotected ethyl nicotinate and picolinate was reported to occur with ee’s up to 17% and 27%, 
respectively, using a Rh-diphosphine complex (Scheme 2).8  
 
Scheme 2. Reports on the asymmetric homogeneous and heterogeneous hydrogenation of pyridines. 
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In 2008, Zhou and co-workers also reported the asymmetric partial hydrogenation of the 
pyridine derivative 7,8-dihydro-quinolin-5(6H)-one (Scheme 3). The most interesting feature of 
this system is that no activation of the pyridine was required. Using an iridium catalyst with (S)-
MeO-Biphep as ligand, they were able to partially hydrogenate the mentioned pyridine 
derivatives substituted in the 2-position with ee’s up to 97%.9 Two years later, Chan and co-
workers published two more papers using exactly the same system, with the only variation of the 
ligand and the solvent. Comparable ee’s and a TON up to 960 in the case of (S)-Difluorophos 
were obtained.10 Unfortunately, this methodology is restricted to this particular kind of substrates 
and no examples with other pyridine substrates were reported. 
 
Scheme 3. Asymmetric partial hydrogenation of 7,8-dihydro-quinolin-5(6H)-one derivatives. 
Apart from these latter examples, in the last years, almost all newly developed methodologies 
have relied on the activation of the pyridines by quaternization, i.e. the formation of a covalent 
bond with the pyridine nitrogen, to form the corresponding pyridinium derivative (Figure 3). 
This strategy overcomes all problems associated with the hydrogenation of N-heteroarenes: (i) 
the positive charge in the nitrogen destabilizes the aromaticity of the ring making it more reactive 
towards hydrogenation. (ii) The first hydrogenation step becomes irreversible. (iii) 
The quaternization of the pyridine eliminates completely its coordination ability and 
significantly reduces that of the product. (iv) The activating group might also act as 
a secondary coordinating unit, which by interaction with the metal center could 
improve the enantioselectivity of the reaction. Vidal-Ferran and co-workers recently 
published a review assessing the different activation strategies of N-heteroarenes.11 
The activation of pyridines by acylation, alcoxycarbonylation or alkylation is a strategy that 
had already been extensively used in nucleophilic dearomatization reactions.12 Nonetheless, it 
Figure 3 
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was not until 2005 when Charette and co-workers decided to apply a similar activation protocol 
for the asymmetric homogeneous hydrogenation of pyridines (Scheme 4). Converting pyridines 
into N-benzoyliminopyridinium ylides and using an Ir-phosphinooxazoline complex, they were 
able to hydrogenate a range of 2-alkyl-N-benzoyliminopyridinium ylides with good conversions 
and modest to high ee’s (54-90%).13 More recently, Andersson and co-workers published an 
almost identical system, with the only difference of the ligand and the solvent (Scheme 4).14 
 
Scheme 4. Asymmetric hydrogenation of N-benzoyliminopyridinium ylides. 
In 2007, Pfizer filed a patent on the synthesis of the drug Tofacitinib where one of the steps 
involved the hydrogenation of a 3-methoxycarbonylamino-4-methylpyridine (Scheme 5). The 
reported approach involved the activation of the pyridine by benzylation followed by AH with a 
Rh-Josiphos catalyst, which led to 84% of the cis product with 68% ee.15 The advantage of this 
strategy is that the benzyl group could be later removed by simple hydrogenation.  
 
Scheme 5. Intermediate step in the synthesis of the drug Tofacitinib by Pfizer, involving the AH of the N-
benzylated pyridinium salt. 
Surprisingly, five more years passed until somebody used this convenient activation strategy 
to expand the scope. Zhou and co-workers found that N-benzyl-pyridinium salts were suitable 
substrates for AH employing an Ir-diphosphine catalyst (Scheme 6). After some solvent 
optimization and realizing that Br- was the only suitable counterion, they achieved the 
hydrogenation N-benzyl-2-phenylpyridinium bromide with 75% ee. To increase the 
enantioselectivity of the reaction they decided to modify the activating group. When introducing 
a methyl ester in the 2-position of the benzyl the ee increased to 89% – probably due to the 
directing effect of this new coordinating group – and when the isopropyl ester was used instead 
92% ee was obtained as a result of the increased steric hindrance. Finally, after a fine tuning of the 
ligand, the substrate scope was assessed obtaining full conversion in almost all cases and excellent 
ee’s for the aromatic substituents.16 
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Scheme 6. Asymmetric hydrogenation of N-benzylated 2-substituted pyridinium salts. 
As already discussed, N-benzylation might be one of the best activation strategies since the 
final piperidine can be easily deprotected. Nevertheless, an efficient and flexible method to 
hydrogenate N-alkylpyiridinium salts would be of interest also when the target compounds is N-
alkylated, avoiding in this way the protection/deprotection steps. This is what Zhang and co-
workers reported in 2014, where by means of [Ir(cod)Cl]2 and an uncommon chiral phosphole-
based ligand, they hydrogenated a wide range of N-alkyl-2-arylpyridinium salts improving 
substantially the results from Zhou. With this system they were able to obtain higher ee’s without 
the need of a directing group in the benzylic moiety. The use of iodide as counterion was also 
tolerated and, even more remarkably, high enantioselectivities could be obtained using different 
N-benzyl or N-alkyl activating groups (Scheme 7). Finally, it was demonstrated that this robust 
system can hydrogenate N-benzyl-2-phenylpyridinium bromide with a catalyst loading as low as 
0.25 mol%.17 
 
Scheme 7. Asymmetric hydrogenation of different N-substituted 2-phenylpyridinium bromides or iodides. 
a) 1,2-dichloroethane/acetone (1:1) as solvent. b) 1,2-dichloroethane/acetone (5:1) as solvent. y. = yield. 
Recently, two more papers were published in the AH of multisubstituted pyridines and in 
both cases pyridines were activated as hydrohalide salts. Mashima and co-workers used a 
halogen-bridged iridium dinuclear complex developed in their group for the hydrogenation of 
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different 2,6- and 2,3-disubtituted pyridinium iodides with good yields, high diastereoselectivities 
(dr >95:5) and enantioselectivities ranging from modest to good (28-82% ee) (Scheme 8).18 
 
Scheme 8. Asymmetric hydrogenation of disubstituted pyridinium iodides. y. = yield. 
The most recent one was published by Zhou and co-workers in 2015. Using [Ir(cod)Cl]2 
and also Difluorophos as ligand, they succeeded in hydrogenating different multisubstituted 3-
trifluoromethylpyridinium chlorides with excellent yields, diastereoselectivities and 
enantioselectivities (Scheme 9).19 
 
Scheme 9. Asymmetric hydrogenation of multisubstituted 3-trifluoromethylpyridinium chlorides. TCCA: 
trichloroisocyanuric acid. 
As it has been shown, metal-catalyzed AH is the most common strategy to reduce pyridines 
enantioselectively. Other reduction methodologies, such as the metal-catalyzed asymmetric 
transfer hydrogenation, are still underexploited, as only one non-enantioselective example has 
been reported so far.20 Moreover, the metal free hydrogenations are starting to gain importance, 
like the partial hydrogenation of pyridines developed by Rueping et al., where a catalytic amount 
of phosphoric acid and stoichiometric amounts of Hantzsch ester are used to achieve ee’s up to 
92%. 21  More recently, a metal-free borane-catalyzed diastereoselective hydrogenation of 
pyridines was published by Du and co-workers, where dr’s up to 98:2 are obtained.22 
I.2 REVIEW: MECHANISTIC STUDIES ON THE ASYMMETRIC 
HYDROGENATION OF N-HETEROARENES 
In this section, a review on all mechanistic studies performed for the asymmetric 
hydrogenation (AH) of N-heteroarenes will be presented. As no such investigations have been 
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disclosed for the AH of pyridines so far, the aim of it is to facilitate the comprehension of the 
mechanistic studies discussed in Chapter II and III. 
INDOLE 
Facile access to chiral indolines can be achieved by AH of substituted indoles. Indolines are 
interesting molecules since they occur in many natural products and biologically active 
compounds.23 Numerous systems have been described for the AH of protected and unprotected 
indoles using Ir,24 Rh,25 Ru26 or Pd27 catalysts. Unfortunately, only the group of Zhou has put 
some effort into understanding the mechanism of the Pd catalyzed hydrogenation of unprotected 
indoles. In their initial work,27a later expanded with a full paper,27b 2- and 2,3-substituted indoles 
were hydrogenated with the combination of Pd(OCOCF3)2 and (R)-H8-BINAP using a strong 
Brønsted  acid as activator (Scheme 10).  
 
Scheme 10. Asymmetric hydrogenation of unprotected indoles.  
The proposed mechanism can be seen in Scheme 11. Initially the protonated indole 1 would 
tautomerize to the iminium intermediate 3, whose presence was confirmed by NMR and MS. 
Once the aromaticity of the indole is broken, the iminium intermediate would be prone to react 
with the Pd-hydride species in an enantioselective fashion to furnish indoline 2. To get further 
insight into the mechanism, two isotopic labeling experiments were performed (Scheme 12). The 
first one, conducted in deuterated 2,2,2-trifluoroethanol (TFE-d3) and H2, showed that two 
deuterium atoms had been incorporated in the 3-position, suggesting an enamine-iminium 
equilibrium faster than the hydrogenation. The complementary experiment, where non-
deuterated TFE and D2 were employed, showed the incorporation of one deuterium in the 2-
position, confirming the addition of the Pd hydride species to the iminium intermediate.  
 
Scheme 11. Proposed mechanism for AH 2-substituted indoles. 
 
Scheme 12. Isotopic labeling experiments for the AH of 2-substituted indoles. 
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In the case of 2,3-disubstituted indoles, the enantioselectivity depends on the enamine-
iminium equilibrium and the subsequent hydrogenation. It is in fact a dynamic kinetic resolution 
(DKR) where two different enantiomers of the iminium intermediate are formed, one being 
preferentially hydrogenated by the chiral catalyst (Scheme 13). This places the reaction under 
Curtin-Hammett control. To obtain high ee’s, the enamine-iminium equilibrium should be much 
faster than the hydrogenation step, which is indeed something that was proven in the first 
deuterium experiment. This latter concept was also proven experimentally when, by increasing 
the temperature (to accelerate the equilibrium) and decreasing the pressure (to slow down the 
hydrogenation), a higher ee was obtained.  
 
Scheme 13. Proposed mechanism for the hydrogenation of 2,3-disubstituted indoles via dynamic kinetic 
resolution. 
Zhou and co-workers carried out a similar mechanistic study for the tandem reductive 
alkylation-AH of 2-substituted indoles.27d The reaction process was initiated by a Brønsted acid-
promoted Friedel-Crafts reaction of an aldehyde with indole 1 to furnish the corresponding 3-(α-
hydroxyalkyl)indole 5. Then, a dehydration followed by a 1,4-addition of the Pd-hydride to the 
generated vinylogous imine 6 would lead to the 2,3-disubstituted indole 7, which was 
subsequently hydrogenated to indoline 4 via dynamic kinetic resolution (DKR), as previously 
shown in Scheme 13. Indeed, the conversion of 5 to indoline 4 had been already explored and 
optimized in a previous publication.27c 
 
Scheme 14. Tandem reductive alkylation-AH of 2-substituted indoles and proposed mechanism.  
To find more evidences about the mechanism, isotopic labeling experiments with deuterium 
gas or deuterated solvents were carried out (Scheme 15). The reaction performed in TFE-d1 
showed the incorporation of one deuterium in the 3-position of 4a, arising from the 
tautomerization of enamine 7a to the corresponding iminium form. When the same conditions 
were used, but stopping the reaction after 3 h, intermediate 7a could be isolated with no 
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deuterium incorporation. Finally, running the reaction with D2, instead of H2, showed the 
incorporation of one deuterium at the 2-position and at the benzylic position of indoline 4a, 
clearly indicating the positions were the hydride additions take place.  
 
Scheme 15. Isotopic labeling experiments for the tandem reductive alkylation-AH of indoles 1a. 
PYRROLE 
The enantioselective hydrogenation of substituted pyrroles to chiral pyrrolidines was first 
described using heterogeneous catalysts and a chiral auxiliary covalently attached to the pyrrole 
ring.28 Some years later Kuwano et al. disclosed a system for the AH of N-Boc protected 2,3,5-
trisubstituted pyrroles with a Ru catalyst.29 
In 2011, using a similar system to that employed for indoles, Zhou and co-workers 
developed an enantioselective partial hydrogenation of unprotected 2,5-disubstituted pyrroles 
(Scheme 16).30  
 
Scheme 16. Asymmetric hydrogenation of unprotected 2,5-disubstituted pyrroles.  
Isotopic labeling experiments were conducted in order to get a deeper insight into the 
reaction mechanism (Scheme 17).  
 
Scheme 17. Isotopic labeling experiments for the AH of 2,5-disubstituted pyrroles. 
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When deuterated ethanesulfonic acid and TFE-d3 were used, deuterium incorporation was 
observed mainly in the 3- and 4- positions of imine 9a due to the enamine-imine equilibrium. 
When the same experiment was conducted using deuterium gas, the incorporation was mainly 
observed in the 2-position, arising from the enantioselective hydride addition to the iminium 
intermediate. 
Based on the mechanistic studies previously performed for the AH of indoles, the isotopic 
labeling experiments and the NMR identification of the iminium salts 10 and 11, they proposed 
the mechanism shown in Scheme 18. The unprotected pyrrole in presence of a strong Brønsted 
acid is in equilibrium with the two iminium salts, but only 10 is hydrogenated to enamine 12. In 
this acidic media, the enamine isomerizes to the more stable imine 9, which does not further 
react. The observed selectivity was studied by density functional theory calculations (DFT). 
Results showed that iminium 11 is more stable due to the conjugation with the aromatic group 
and the delocalization of the positive charge, making it more unreactive than iminium 10.  
 
Scheme 18. Proposed mechanism for the AH of 2,5-disubstituted pyrroles. 
QUINOXALINE 
The hydrogenation of quinoxalines to furnish biologically active tetrahydroquinoxalines23b,31 
can be formally seen as a double imine hydrogenation. This is probably the reason why many 
systems applied for imine AH are also tested with quinoxalines. Metal-catalyzed hydrogenations 
with Ir,32 Ru33 or Fe,34 and also organocatalysts,35 have been reported for the asymmetric 
reduction of these substrates. 
Zhou and co-workers studied a particular case of AH of quinoxalines.36 By serendipity, they 
found out that dihydroquinoxaline 13 was disproportionating into quinoxaline 14 and 
tetrahydroquinoxaline 15 via a self-transfer hydrogenation. The presence of a chiral phosphoric 
acid (CPA) made this process faster and enantioselective (Scheme 19). 
 
Scheme 19. Self-transfer hydrogenation of dihydroquinoxalines. 
In the view of these results, they decided to establish a protocol for the AH of quinoxalines to 
tetrahydroquinoxalines (Scheme 20). For that, they selected an achiral Ru catalyst able to 
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hydrogenate quinoxaline 14 to dihydroquinoxaline 13 (k1), but that was not very efficient in the 
hydrogenation to tetrahydroquinoxaline 15 (k3). In this way, if the self-transfer hydrogenation 
(k2) was faster than k3, the production of 15 would take place via the highly enantioselective 
pathway.  
 
Scheme 20. Proposed mechanism for the AH of quinoxalines. 
Applying the designed protocol, they were able to hydrogenate a wide range of 2-
arylquinoxalines with excellent yields and enantioselectivities (Scheme 21). Unexpectedly, they 
observed a reverse enantioselectivity compared to the one obtained by Rueping and co-workers 
when using the same enantiomer of the CPA but Hantzsch esters as stoichiometric reductant.35b 
The authors ascribed this fact to the different steric demands present in the transition state of the 
hydride transfer. While Hantzsch esters do a 1,4-hydride transfer, dihydroquinoxalines go via a 
1,2-hydride transfer pathway. DFT calculations supported this latter hypothesis.  
 
Scheme 21. Asymmetric hydrogenation of 2-arylquinoxalines. 
This same concept was later expanded by using 9,10-dihydrophenanthridine as a 
regenerable hydrogen source, in combination with a chiral phosphoric acid, for the AH of 
quinoxalines, benzoxazinones, benzoxazines, and quinolines (Scheme 22).37 
 
Scheme 22. 9,10-dihydrophenanthridine as a transfer hydrogenation catalyst. 
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Mashima and co-workers used a completely different system for the hydrogenation of 2-
arylquinoxalines, consisting of a chiral halide-bridged dinuclear iridium complex in the presence 
of a stoichiometric amount of N-methyl-p-anisidine (MPA) (Scheme 23).32a 
 
Scheme 23. Asymmetric hydrogenation of 2-arylquinoxalines. 
Numerous experiments were performed to gain insight on the reaction mechanism, the role 
of the base and the active species involved. The dinuclear iridium complex 16 was reacting in situ 
with MPA to form the mononuclear species 17, which after releasing HCl, led to the Ir-hydride 
18. The authors propose an outer-sphere mechanism, where catalytic species 18, after reacting 
with H2, would hydrogenate quinoxaline 14 or dihydroquinoxaline 13. It is noteworthy that the 
base not only acts as a non-innocent ligand in the hydrogenation process, but it also quenches the 
in situ generated HCl during the activation of the catalyst. It was found that the generated traces 
of HCl could promote the non-enantioselective disproportionation of dihydroquinoxaline 13, as 
shown by Zhou.36 As expected, quinoxalines and the other intermediates are also able to 
coordinate the catalyst, forming less active and enantioselective species than those formed with 
MPA. For this reason, an important amount of MPA is needed for the reaction to take place with 
high enantiomeric excess. Isotopic labeling experiments using D2 showed the insertion of one 
deuterium in the 2- and 3-positions, as expected for the two hydride additions.  
 
Scheme 24. Proposed catalytic cycle for the AH of 2-arylquinoxalines. 
In further experiments the authors serendipitously found out that the analogous catalytic 
system featuring Josiphos SL-J001-1 instead of (S)-Difluorophos, had a superior performance in 
the enantioselective hydrogenation of 2-phenylquinoxaline, allowing to achieve full conversion 
and 96% ee. 
QUINAZOLINE 
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Only one AH of quinazolines has been disclosed so far. Mashima and co-workers used the 
halide-bridged dinuclear iridium complex that had proven efficient for other N-heteroaromatic 
substrates to enantioselectively hydrogenate 2-arylquinazolinium salts (Table 1).38 
Table 1. Asymmetric hydrogenation of 4-arylquinazolinium salts. 
 
# R yield of 21 (%) ee of 21 (%) yield of 22 (%) yield of 23 (%) 
1 Ph 89 99 11 - 
2 2-MeC6H4 Trace - 2 89 
3 4-MeC6H4 81 97 8 2 
4 4-OMeC6H4 66 98 14 20 
5 4-CF3C6H4 82 99 6 10 
To get some insight into the reaction mechanism, a time-course study of the reaction 
following the distribution of the different intermediates was performed. Within the first 5 hours, 
the quinazolinium hydrochloride was almost completely consumed to give the 1,2-reduction 
product 23, which was then gradually enantioselectively hydrogenated to the 
tetrahydroquinazoline 21 (Scheme 25). Simultaneously, some 3,4-reduction product 22 was also 
slowly formed, reaching an 11% conversion at the end of the reaction. This latter product was not 
hydrogenated, probably due to the stability of its hydrochloride salt. 
 
Scheme 25. Proposed stepwise hydrogenation of quinazolinium hydrochlorides. 
ISOQUINOLINE 
1,2,3,4-Tetrahydroisoquinolines motifs are widely spread in nature and have found many 
applications in pharmaceutical products.39 However, together with pyridines, isoquinolines are 
one of the most challenging substrates for AH. Only a few methods have been reported, all of 
them based on Ir catalysts,40 except one example of Ru catalysis in ionic liquids.41 Even so, 
interesting mechanistic studies have been reported by the groups of Zhou and Mashima 
regarding the enantioselective hydrogenation of isoquinolines. 
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In 2013, Zhou and co-workers disclosed the AH of N-benzylated isoquinolinium salts, 
applying the same strategy that had previously given successful results for pyridines.16 Using an Ir-
diphosphine complex they were able to hydrogenate a wide range of 1- and 3-substituted 
isoquinolinium salts with excellent yields and good to excellent enantioselectivities (Table 2).40c 
Table 2. Asymmetric hydrogenation of 1- and 3-substituted isoquinolinium salts. 
  
# R1 R2 yield (%) ee (%) 
1 Ph H 99 96 
2 4-OMeC6H4 H 99 94 
3 4-CF3C6H4 H 96 93 
4[a] Me H 99 70 
5 H Ph 94 85 
6 H 4-OMeC6H4 99 80 
7 H iPr 99 43 
[a] Ar = phenyl 
To shed light into the reaction mechanism, some experiments were carried out. Initially, in 
order to detect some intermediates, the reaction was stopped after 1.5 h. In the case of N-benzyl-
1-phenylisoquinolinium bromide, only starting material and final product were observed, instead 
when 3-phenyl derivative 24a was used, 1,2-dihydroisoquinoline 26a could be identified 
(Scheme 26A), indicating that the 1,2-reduction occurs first. When the latter intermediate was 
isolated and subjected to hydrogenation in the absence of HBr, no conversion was obtained, 
underscoring the need of the in situ generated HBr for the reaction to proceed. Furthermore, 
when N-benzyl-1-methyl-3,4-dihydroisoquinoline 27b was enantioselectively hydrogenated, 25b 
was obtained only with 24% ee (Scheme 26B, in contrast with the 70% ee from Table 2, entry 4), 
excluding in this way a mechanism involving an initial C3-C4 hydrogenation.  
 
Scheme 26. Mechanistic studies on the AH of isoquinolines. 
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Finally, an isotopic labeling experiment showed the incorporation of almost one deuterium 
atom in the 4-position of 25a (Scheme 26C), suggesting that the enamine intermediate 
tautomerizes to the corresponding iminium and then it is promptly hydrogenated. 
Based on the above evidences, the proposed mechanism would be initiated by a 1,2-hydride 
addition to isoquinolinium 24 to give the 1,2-dihydropyridine 26, which would be subsequently 
isomerized to the iminium salt 28 and readily hydrogenated to the final 1,2,3,4-
tetrahydroisoquinoline 25 (Scheme 27). According to this mechanism, while for the 1-
substituted isoquinolines the enantiodetermining step would be the first hydride addition, for the 
3-substituted it should be the second. As the authors remark, a 1,4-reduction as a first step of the 
mechanism leading directly to iminium 28 cannot be ruled out.  
 
Scheme 27. Proposed mechanism for the AH 1- and 3-substituted isoquinolines. 
In an another publication from the same group, the AH of unprotected 3,4-disubstituted 
isoquinolines is disclosed. By using an Ir-diphosphine complex and 1-bromo-3-chloro-5,5-
dimethyl-hydantoin (BCDMH) as additive, the corresponding tetrahydroisoquinolines were 
obtained with good to excellent yields, diastereoselectivities and ee’s (Scheme 28).40b 
 
Scheme 28. Asymmetric hydrogenation of unprotected 3,4-disubsituted isoquinolines. 
With shorter reaction times, they were able to isolate the intermediate from the 1,2-
reduction 31. When this isolated 1,2-dihydroisoquinoline was hydrogenated under the optimized 
conditions, the final tetrahydroisoquinoline 30 was obtained with the same conversion and ee. 
Furthermore, increasing the temperature and decreasing the pressure led to a higher 
enantioselectivity, suggesting that a dynamic kinetic resolution was involved in the process.  
 
Scheme 29. Proposed mechanism for the hydrogenation of 2,3-disubstituted isoquinolines via dynamic 
kinetic resolution. 
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The proposed mechanism would go as follows (Scheme 29): initially, a 1,2-hydride addition 
to the less sterically hindered carbon would give the enamine intermediate 31. This enamine 
would be in fast equilibrium (due to the high temperature) with the two enantiomers of the imine 
form (32 and 32’) and one of the two would be preferentially hydrogenated to the final 
tetrahydroisoquinoline.  
More recently, Mashima’s group also studied the AH of isoquinolinium chlorides with their 
dinuclear iridium complex. In a first publication of 2013, this new system is described with a 
couple of mechanistic experiments,40e but the full mechanistic investigation was published two 
years later.40f All possible substitution patterns in the hetereoaromatic cycle were tested (Table 
3), obtaining excellent yields and very high enantioselectivities for 1-, 3-, and 1,3-substituted 
isoquinolines. More problematic were the substrates with substituents in the 4-position (Table 3, 
entries 7, 11 and 12), giving poor ee’s or diastereoselectivities.  
Table 3. Substrate scope for the AH of isoquinolinium chlorides. 
 
# R1 R2 R3 yield (%) ee (%) 
1 Ph H H 99 96 
2 4-OMeC6H4 H H 99 99 
3 4-CF3C6H4 H H 99 98 
4 Cy H H 99 79 
5[a] H Ph H 99 96 
6[a] H Cy H 99 79 
7 H H Ph 99 5 
8 Ph Ph H 98 98 
9 Cy Ph H 87 97 
10 Ph nHex H 80 98 
11[b] Ph H Ph 99 90 
12[c] H Ph Ph 99 43 
[a] Reaction performed at 30 °C. [b] syn:anti = 4:1. [c] syn:anti = 20:1. 
To start exploring the mechanism of this reaction, the different possible pathways shown in 
Scheme 30 were proposed. Three different mechanism can be postulated for the first reduction, 
among which 1,2- and 1,4-reduction seem the more plausible, while 3,4-reduction was excluded 
based on the fact that Ir complexes are more prone to hydrogenate C=N bonds rather than C=C 
bonds.42 The two resulting dihydroisoquinolinium salts 31 and 32 would be in equilibrium 
through an enamine-iminium tautomerization. Finally, these two intermediates could be 
hydrogenated via a C=C enamine hydrogenation or a C=N iminium hydrogenation. However, as 
already observed with other substrates,27b,30,40b the AH of unprotected enamines proceeds via an 
enamine-iminium tautomerization and subsequent hydride addition to the iminium ion. 
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Scheme 30. Plausible pathways for the hydrogenation of isoquinolinium salts. 
To gain insight into the reaction mechanism, an isotopic labeling experiment was performed 
using D2, deuterated solvent and 3-phenylisoquinolinium chloride as substrate (Scheme 31). The 
first thing to observe is that more than one deuterium was incorporated in the 1-position, 
suggesting that the first step is reversible. Also in the 4-position, the initial hydrogen atom was 
almost completely replaced for deuterium as a result of a fast enamine-iminium tautomerization. 
The same conclusions could be drawn from a parallel experiment performed using 1-
phenylisoquinolinium chloride as substrate. Although the final hydrogenation of the 
dihydroisoquinoline is generally accepted to proceed via the iminium intermediate, an additional 
experiment using D2 and undeuterated solvent would have confirmed it.  
 
Scheme 31. Deuterium labeling experiment for 3-phenylisoquinolinium chloride 
Additionally, two more experiments were performed and monitored by NMR. When the AH 
of the 3-phenylisoquinolinium salt was carried out under atmospheric pressure of H2, the 
iminium intermediate was formed and slowly converted into the final tetrahydroisoquinoline. 
Instead, when 1- or 4- substrates were used, no reaction took place. According to the authors, 
these results lend credit to the 1,4-reduction pathway rather than the 1,2-reduction, since the 
substituents in the 1- and 4-positions clearly retarded the reaction. 
Two years later, the same authors disclosed the full investigation about the mechanism of 
this reaction40f expressing a different point of view on the controversial 1,2-/1,4-hydride addition 
in the first step. In this study, different interactions of the possible reaction intermediates with the 
active iridium catalyst were investigated. One of the intermediate Ir species of the catalytic cycle 
was identified as the anionic complex 36 with an isoquinolinium derivative as a counterion 
(Scheme 32). The dihydride iridium complex 36 was postulated as the responsible of the 
reductions through a proposed 6-membered cyclic transition state, that implying that only the 
1,2-reduction is possible. This has not been unambiguously demonstrated yet, but these 
apparently contradictory results are just reflecting how difficult is to investigate which one of the 
two paths is leading to the dihydroisoquinoline. 
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In addition, Mashima and co-workers demonstrated that the salt formation of the substrate 
was crucial for the high yields and enantioselectivities. The coordination of unprotonated 
substrate or product led to less enantioselective catalysts or to the formation of inactive iridium 
dimers, which could be reactivated by addition of isoquinolinium chloride salts. Moreover, it was 
found that an Ir dihydride complex was involved in the catalytic cycle.  
Thus, the final catalytic cycle would be the one represented in Scheme 32. The iridium 
dimer 16, in equilibrium with the ionic form 33, dissociates to the Ir-monohydride 34. Upon 
reaction with H2, the Ir-dihydride 35 is formed, and after displacement of the solvent by a 
chloride from the isoquinolinium salt the ionic complex 36 is generated. Finally, the hydride 
addition, via the proposed outer-sphere 6-membered ring transition state, would regenerate 
complex 34 and form the corresponding dihydroisoquinoline. The second reduction would take 
place in a similar manner.  
 
Scheme 32. Proposed catalytic cycle and transition state for the AH of isoquinolinium salts. 
The poor stereoselectivites mentioned before for isoquinolines with substituents in the 4-
position are also in agreement with the proposed mechanism. In the case of 4-subsituted 
isoquinolines, the enamine-iminium isomerization generates a racemic stereocenter at C4 leading 
to a poor 5% ee (Scheme 33). This interpretation holds true also for 1,4-disubstitued 
isoquinolines: the initial highly enantioselective 1,2-reduction gives the 1,2-dihydroisoquinoline 
which, after the enamine tautomerization and subsequent hydrogenation, generates the two 
diastereomers with low diastereoselectivity (syn:anti = 4:1), but with very high ee from the first 
hydrogenation step (syn: 90% ee, anti: 97% ee). Finally, for the 3,4-disubstituted isoquinoline, a 
dynamic kinetic resolution could be expected as has been previously proposed for other 
substrates (analogous to Scheme 29), but probably the system would require further 
optimization to achieve an ee higher than 43%.  
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Scheme 33. Proposed mechanism for the lack of stereoselectivity in 4- and 1,4-subsituted isoquinolines. 
QUINOLINE 
Besides being an ubiquitous motif in natural products, 1,2,3,4-tetrahydroquinolines have 
found many applications in pharmaceutical and agrochemical synthesis.43 That might be the 
reason why quinolines are, by far, the most well studied N-heteroarene substrates in AH. A wide 
range of systems employing homogeneous chiral catalysts have been reported: hydrogenations 
with Ir,10,32g,40a,44,45 Pd46, Ru;37,41,47 transfer hydrogenations with Ir,48 Ru49 and Rh;49,50 exploiting the 
concept of Frustrated Lewis Pair;51 or employing Hantzsch esters as hydride source in 
combination with catalytic amounts of chiral anions (generally chiral phosphates).52 
Zhou and co-workers were the first ones to perform mechanistic studies on the AH of these 
substrates. They developed a system for the reduction of 2-subsituted and 2,3-disubstituted 
quinolines employing an Ir-diphosphine catalyst with I2 as additive (Scheme 34).45a  
 
Scheme 34. Asymmetric hydrogenation of 2-subsituted and 2,3-disubstituted quinolines 
The first aspect they investigated was the role of I2. Two functions were proposed: substrate 
activation or catalyst activation. When 2-methylquinoline was allowed to react with I2 in toluene 
for 24 h, a yellow complex was formed, which upon hydrogenation under the optimized 
conditions did not lead to any product. Instead, when the catalyst was stirred for 12 h in DCM in 
the presence of I2, a mixture of complexes was observed by 31P-NMR (due to the coexistence of 
chloride and iodide) which was able to hydrogenate 2-methylquinoline with 93% ee. These 
results, and the fact that without I2 no reaction occurs, reveal that the catalyst is indeed activated 
by iodine. 
Two possible hydrogenation pathways were proposed (Scheme 35): on the one hand, a 1,2-
hydride addition followed by C=C reduction; on the other hand, a 1,4-addition followed by 
isomerization and C=N reduction. Contrary to what happens with isoquinolines, the products of 
1,2- and 1,4-hydride addition are not tautomers.  
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Scheme 35. Proposed pathways for the hydrogenation of quinolines. 
To demonstrate which was the most probable pathway, the product of 1,2-addition 39 was 
synthesized. Unfortunately, in presence of the Ir catalysts this product was rapidly 
dehydrogenated to give the original quinoline. Thus, the synthesis of the product of 1,4-addition 
to 1-phenyl-2-(quinolin-2-yl)ethanone 37a was attempted by using Pd/C and H2 in MeOH. The 
more stable product 40’a with the conjugated double bond was obtained instead but, when the 
latter was submitted to hydrogenation conditions, the desired product 38a was obtained with 
96% ee (Scheme 36). This same intermediate 40’a was also detected when running the 
hydrogenation of the quinoline at lower pressures and shorter reaction times. DFT calculations 
on the thermodynamic values for the hydride addition to 2-methylquinoline showed a more 
favorable 1,4-addition rather than 1,2-addition.  
 
Scheme 36. Synthesis and hydrogenation of intermediate enamine 40’a. 
Based on these data, an inner-sphere mechanism was proposed by the authors (Scheme 37). 
Initially the active catalyst would be formed via an oxidative addition of I2 followed by a 
heterolytic cleavage of hydrogen, with hydrogen iodide formation.  
 
Scheme 37. Proposed mechanism for the Ir-catalyzed AH quinolines. 
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The quinoline could coordinate to the Ir species 44, and the subsequent 1,4-hydride 
addition would afford intermediate 45, which via heterolytic cleavage of H2, would regenerate 44 
and form the 1,4-dihydroquinoline 40. After isomerization, the formed imine 41 would be 
hydrogenated according to an analogous catalytic cycle, involving an enantioselective 1,2-hydride 
transfer to give the final tetrahydroquinoline 38. It is also worth mentioning that the same Ir-
diphosphine catalyst was able to catalyze the dehydrogenation of the tetrahydroquinoline in 
boiling xylene releasing H2 and affording the corresponding quinoline. 
Regarding the AH of 2,3-disubstituted quinolines, the dynamic kinetic resolution proposed 
for other substrates seemed also valid in this case. Based on the proposed mechanism for the 
hydrogenation of quinolines, the enantioselectivity would depend on the final 1,2-hydride 
addition to the fast-equilibrating imine enantiomers 41 and 41’ , which would be selective for one 
of the two dihydroquinoline (Scheme 38). This is also supported by the increase of enantiomeric 
excess when the reaction was run at higher temperatures and lower pressures. Hydrogenation of 
2,3-dimethylquinoline at 25°C and 48 bar of H2 gave 5% ee, instead, when performed at 70 °C and 
3 bar the ee increased to 73%. 
 
Scheme 38. Proposed mechanism for the AH of 2,3-disubstituted quinolines. 
Some years later, the same group provided more evidences for supporting this mechanism 
during the optimization of the AH of 2-substituted quinoline-3-amines.45b While trying to find the 
more suitable protecting group for the hydrogenation of 2-butylquinolin-3-amines, they realized 
that in all cases the diastereomeric ratios were rather low. They suspected that this poor 
diastereoselectivities could be attributed to a competition between two different possible 
enamine-imine isomerizations (Scheme 39). Once enamine 40’b is formed by 1,4-hydride 
addition, it is in equilibrium with the exocyclic imine 42’b and with the endocyclic imine 41’b. 
The hydrogenation of those two imines may lead to different diastereoselectivities.  
 
Scheme 39. Proposed mechanism responsible for the poor diastereoselectivities obtained. 
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This hypothesis was supported by isotopic labeling experiments using deuterated MeOH as 
co-solvent (Scheme 40). Deuterium incorporation was observed in the 2-position (during the 
tautomerization to the exocyclic imine) and 3-position (tautomerizing to the endocyclic imine). 
 
Scheme 40. Deuterium labeling experiments in the AH of 2-butylquinolin-3-amine. 
The authors foresaw that the isomerization could be impeded by double protecting the 
amino group. Thus, by using the phthaloyl (Phth) group and after some optimization of the 
reaction conditions and ligands, they were able to hydrogenate these aromatic amines with 
excellent yields, diastereoselectivities and enantioselectivities (Scheme 41).  
 
Scheme 41. Asymmetric hydrogenation of 2-substituted quinoline-3-amines. 
Fan and co-workers disclosed a Ru-catalyzed AH of quinolines reaching ee’s up to 99% and 
TON up to 5000 (Table 4).47c This system proved very efficient for a very wide range of 
substrates: 2- and 2,3-disubstituted quinolines were smoothly hydrogenated with excellent 
enantioselectivities. Unfortunately, when 3-substituted quinolines were used, the racemic 
product was obtained and no reaction was observed when employing 4-substituted substrates. 
Table 4. Substrate scope for the AH of quinolines. 
 
# R1 R2 R3 yield (%) ee (%) 
1 Me H H 100 99 
2 Bn H H 100 >99 
3 Ph H H 94 92 
4 2-OMeC6H4 H H 91 95 
5[a] styryl H H 100 99 
6 COOMe H H 0 - 
7 nBu Me H 100 97 (syn)[b] 
8 –(CH2)4–  H 100 17 (syn)[c]  
9 H Me H 100 0 
10 H Ph H 100 0 
11 H H Me 0 - 
12 Me H Me 0 - 
[a] Double bond also hydrogenated [b] dr = 46:54. [c] dr > 20:1. 
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Additionally, a thorough mechanistic study was performed by the authors. Initially, the need 
of activation of the quinolines by protonation was investigated. Performing a stoichiometric 
reaction between 2-methylquinoline (37c) and an excess of the Ru-hydride species (the expected 
active species) in the absence of H2 led to no conversion (Table 5, entry 1). Instead, when the 
protonated substrate was used 44% conversion was obtained (entry 2), and when another 
equivalent of acid was added the conversion increased to 96%, with 96% ee in both cases (entry 
3). These results, which had already been observed when performing the reaction in ionic 
liquid,47a demonstrated that the quinoline should be activated by protonation prior to the hydride 
addition. 
Table 5. Stoichiometric reaction between 2-methylquinoline and Ru-hydride species. 
 
 
 
 
Next, the authors investigated which one of the two possible pathways for the hydrogenation 
of quinolines (Scheme 35) is more likely to take place. On the one hand, the product of 1,2-
addition was synthesized but, as already observed by Zhou,45a it rapidly underwent 
dehydrogenation in presence of the Ru catalyst. To overcome this problem, the 1,2-
dihydropyridine was N-benzoyl-protected, forming a stable compound which was inactive under 
hydrogenation conditions, suggesting that the unpolarized C3=C4 bond could not be reduced by 
this Ru catalyst. On the other hand, the synthesis of the intermediate arising from the 1,4-hydride 
addition and subsequent isomerization was aimed at investigating the other hydrogenation 
pathway. Considering the instability of 2-alkyl-3,4-dihydroquinolines, the more stable 2-phenyl-
3,4-dihydroquinoline (41d) was synthesized and hydrogenated under the optimized conditions, 
giving full conversion and the same ee as the direct hydrogenation of 2-phenylquinoline. 
Although some dehydrogenation of 41d was observed, direct hydrogenation did also occur, as 
proven by the isotopic labeling experiments (see below). Furthermore, intermediate 41d, 
together with the initial quinoline and the final product, was detected by 1H-NMR and ESI-
HRMS analysis after 5 min of reaction. All these experimental data supported a pathway 
involving a 1,4-hydride addition followed by isomerization and 1,2-reduction. 
To further reinforce this mechanism, an isotopic labeling experiment was carried out. 
According to it, hydrides should be incorporated in the 2- and 4-positions, and protons in the 1- 
and 3-positions. This outcome was indeed observed when the hydrogenation of 2-
methylquinoline (37c) was performed either using D2 or deuterated methanol (Scheme 42A and 
B).  
# Substrate Additive yield (%) ee (%) 
1 37c none 0 - 
2 37c·TfOH none 44 96 
3 37c·TfOH R2NH·TfOH (1 equiv) 96 96 
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Scheme 42. Deuterium labeling experiments for the ru-catalyzed ah of quinolines. 
Moreover, the presence of a background transfer hydrogenation was investigated by using 
deuterated isopropanol and a 16e Ru complex recognized as possible active species in the transfer 
hydrogenation of aromatic ketones. No evidences were found for this pathway, which hence was 
excluded.  
Finally, to close up the catalytic cycle, the reversibility of the hydrogenation was studied. 
Although the dehydrogenation of 1,2,3,4-tetrahydroquinolines had been observed using Ir 
catalysts, this Ru system was unable to catalyze the 1,2-dehydrogenation reaction of 
tetrahydroquinolines, thus making the C=N hydrogenation an irreversible step. Instead, when 2-
phenyl-3,4-dihydroquinoline (41d) was hydrogenated with D2, deuterium incorporation was 
observed in the 4-position (Scheme 42C). Besides, less than one deuterium was introduced in 
the 2-position, since some of the hydrogen atoms derived from the dehydrogenation were also 
incorporated in that position. This outcome confirms that the initial 1,4-hydride addition is 
reversible. 
According to these evidences, an ionic outer-sphere mechanism, where the hydrogen 
addition undergoes a stepwise H+/H– transfer process, was proposed (Scheme 43). The Ru 
complex 48 can accommodate a molecule of H2 which, by reaction with quinoline, is 
heterolytically split to give the quinolinium salt and the Ru-hydride species 47. The subsequent 
1,4-addition gives the 1,4-dihydropyridine and regenerates complex 48. These steps are 
reversible and can regenerate the initial quinoline by a dehydrogenation process. The enamine 
intermediate also acts as a base to split another molecule of H2 and isomerize to the iminium 
cation 41. Finally, an irreversible and enantioselective 1,2-hydride addition affords the final 
tetrahydroquinoline 38. According to DFT calculations, this last hydride addition takes place via 
a cyclic 10-membered transition state with participation of the TfO– anion. The 
enantioselectivitiy arises from a CH/π interaction between the fused phenyl ring of the 
dihydroquinoline and a hydrogen of the η6-arene ligand. 
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Scheme 43. Proposed catalytic cycle and transition state for the AH of quinolines. 
Mechanistic studies on the organocatalytic reduction of 2- and 2,3-substituted quinolines 
have been carried out respectively by Rueping et al. (Scheme 44A)52d and by Zhou and co-
workers (Scheme 44B).52g In both cases the reduction was carried out with stoichiometric 
amounts of Hantzsch ester derivatives (HEH) and a chiral phosphoric acid (CPA) as catalyst.  
 
Scheme 44. Organocatalytic asymmetric reduction of quinolines. 
Rueping performed an isotopic labeling experiment using D2O to find out which was the 
source of protons during the enamine-imine tautomerization step (Scheme 45). The analysis of 
the product 38d showed that more than one deuterium had been incorporated in the 3-position, 
which suggests that water is the proton source and that the tautomerization is faster than the 
hydride addition, assuming the same mechanism proposed for the metal-catalyzed reactions. 
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Scheme 45. Deuterium labeling experiments for the organocatalytic reduction of quinolines. 
In Zhou’s investigations, the possible intermediates arising from a 1,4- or a 1,2-hydride 
addition were isolated and submitted to hydrogenation under the optimized conditions (Scheme 
46). In the case of the 1,2-dihydroquinoline 39’’a derivative no reaction took place. Instead, 
when the 1,4-dihydroquinoline 40’’a intermediate was used as substrate, the final 
tetrahydroquinoline 38’’a was obtained with the same conversion and ee than when the 3-nitro-2-
phenylquinoline (37’’a) was used. Finally, the hydrogenation of the latter quinoline with only 
one equivalent of hydride, led to the corresponding 1,4-dihydroquinoline as a major product. 
 
Scheme 46. Mechanistic studies on the asymmetric reduction of quinolines.  
Both studies seem to point towards the same mechanism (Scheme 47). Initially, through a 
1,4-hydride addition, the 1,4-dihydroquinoline 40 would be formed. This one would be in fast 
equilibrium with the imine forms 41 and 41’, as proven by the deuteration experiment shown in 
Scheme 45. Finally, the AH of the iminium salt with a chiral counterion would give the final 
tetrahydroquinoline 38. 
 
Scheme 47. Proposed mechanism for the asymmetric reduction of 2,3-disubstituted quinolines, 
generalizable to 2-substituted.  
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PYRIMIDINE 
The partial AH of pyrimidines gives direct access to chiral amidines, which are recurrent 
motifs in the nature and in pharmaceutical compounds.53 Recently, Kuwano et al. disclosed the 
first partial AH of pyrimidines using the well-known Ir-diphosphine-I2 catalytic system and 
Yb(OTf)3 as activator. With this methodology they were able to hydrogenate a series of 2,4-
disubstituted pyrimidines into the corresponding 1,4,5,6-tetrahydropyrimidines with high 
conversion and enantioselectivities (Scheme 48).54  
  
Scheme 48. Asymmetric hydrogenation of 2,4-disubstituted pyrimidines. 
During the hydrogenation process, 1,6-dihydropyrimidine 51a was observed, suggesting that 
the reduction proceeds via a stepwise hydrogenation of N1=C6 and C4=C5. When this 
intermediate was isolated and submitted to the optimized reaction conditions, the final 1,4,5,6-
tetrahydropyrimidines 50a was obtained with full conversion and high ee. Instead, if Yb(OTf)3 
was not used, the conversion and ee dropped significantly and an important amount of 
dehydrogenation product 49a was observed (Scheme 49). This indicates that the Lewis acid is 
not only required for the initial dearomatization of the pyrimidine, but also for the hydrogenation 
of intermediate 51a and to achieve high ee’s.  
 
Scheme 49. Asymmetric hydrogenation of the 1,6-dihydropyrimidine intermediate. 
To gain more insight into the hydrogenation pathway, intermediate 51a was hydrogenated 
using D2 (Scheme 50). Surprisingly, the pro-S hydrogen of the 6-position was completely 
replaced by deuterium. As full deuteration was also observed in the 4-position, the authors 
proposed that the C4=C5 reduction (Scheme 51, 2nd step) proceeds via an initial iridium-
catalyzed enantioselective isomerization, to give dihydropyrimidine 51, followed by C5=C6 
hydrogenation. This mechanism is also in agreement with the partial deuteration observed at the 
5-position. If the hydrogenation would take place without isomerization, the pro-R hydrogen in 
the 5-position should be fully deuterated. On the contrary, during the migration the deuteride on 
iridium in intermediate 54 can be replaced by a hydride, leading to this observed partial 
deuteration in the isotopic labeling experiment. Finally, the Ir complex in intermediate 55 would 
be released by a σ-bond metathesis with H2 or by a sequential oxidative addition and reductive 
elimination. The conversion of pyrimidine 49 to dihydropyrimidine 51 takes places via an initial 
coordination of the Yb(OTf)3 to N1 and a hydride addition of the hydridoiridium(III) species. 
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Scheme 50. Isotopic labeling experiment for the AH of 1,6-dihydropyrimidine intermediate. 
 
Scheme 51. Proposed mechanism for the AH of 2,4-disubstituted pyrimidines. 
I.3 CONCLUSIONS 
Many systems have been developed in the last years for the AH of pyridines, but still, we are 
far from a highly active and enantioselective system which can be successfully implemented in the 
industry. The costs of these methodologies are still very high and further investigations have to be 
conducted in order to improve the current systems. 
The best way to rationally design more efficient catalysts for the hydrogenation of pyridines 
is to understand the different steps that take place during their hydrogenation, where up to three 
double bonds have to be hydrogenated. Since no mechanism for the AH of pyridines has been 
reported yet (the only mechanistic study on non-enantioselective transfer hydrogenation of 
pyridines is a deuterium experiment from Xiao and co-workers)20 our prior knowledge was 
mainly based on the studies performed on similar N-heteroarenes. Analyzing all mechanistic 
studies described in this introduction some common facts could be observed: 
- All substrates are activated prior to the hydride addition. The substrate is quaternized 
beforehand by alkylation, acylation or protonation, which in some cases is arising from the 
acid generated in situ during the catalyst activation. In this latter case, it might be also a 
heterolytic H2 splitting assisted by the N-heteroarene itself. The only exception being the 
system developed by Mashima and co-workers for the AH of quinoxalines.32a 
- All hydride additions take place when the substrate is in the imine/iminium form, this 
involving sometimes a preliminary tautomerization from the enamine form. No enamine or 
enaminium hydrogenation can be proposed from the experimental data obtained in these 
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studies. In the cases where only partial hydrogenation is observed, this outcome is ascribed to 
the high stability of the intermediate formed. 
- The latter point implies that, if the enamine intermediate of a N-heteroarene substituted only 
in the β-position is formed, its hydrogenation will lead to very poor ee’s, since the enamine-
imine tautomerization will create a racemic stereocenter in that position.  
- α,β-Disubstitued N-heteroarenes can be hydrogenated with high enantioselectivities via a 
dynamic kinetic resolution. Experimentally, this process is optimized at high temperatures, to 
favor a fast equilibration of the two iminium enantiomers, and at lower pressures, to slow 
down the hydrogenation step. 
- For some substrates it is difficult to determine and to generalize if the first hydrogenation step 
takes place via a 1,2- or a 1,4-hydride addition. Which pathway is followed seems to depend 
on both electronic and steric effects. 
- The possibility of dehydrogenation processes involved in the mechanism should never be 
excluded. This competitive process complicates even more the mechanistic studies.  
Summarizing, it can be observed that all these mechanisms consist of basically two types of 
reactions: (i) enamine-imine/iminium tautomerizations and (ii) hydride additions to the imines 
or iminium ions (either 1,2- or 1,4-additions).  
Although consistent efforts have been made to understand these reactions, more 
mechanistic insight is crucial for further development of the field. Special attention should be 
given to the mode of enantioinduction in the enantiodetermining step, to the influence of other 
activating methods and to the mechanism governing the AH of more challenging substrates, such 
as pyridines. The first part of this thesis accounts for my efforts in this sense.  
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CHAPTER II. 
ASYMMETRIC HYDROGENATION OF  
2-SUBSTITUTED PYRIDINES 
 
II.1 INTRODUCTION 
Several efficient approaches have been disclosed for the highly enantioselective 
hydrogenation of 2-substituted pyridines over the last 10 years. However, they are still far from 
becoming industrially viable processes. The reports by Charette13 and by Zhou16 require very 
specific pyridine activations, either as N-benzoyliminopyridinium ylides (Scheme 4) or as N-(2-
(isopropoxycarbonyl)benzyl)pyridinium bromide (Scheme 6), respectively. The approach from 
Zhang,17 is much more versatile, since many different quaternization strategies can be employed 
(Scheme 7), but it requires the use of an uncommon chiral phosphole-based ligand. 
Although bidentate ligands are generally considered superior to monodentate ones, during 
the last 15 years monodentate phosphines, phosphonites, phosphoramidites and phosphites have 
shown to be good competitors. Excellent results have been obtained in the asymmetric 
hydrogenation (AH) of α- and β-dehydroamino acids, itaconic acid derivatives, and 
enamides.42a,55 Among them, monodentate phosphoramidites are especially appealing because 
they are cheap, air stable and can be prepared in parallel synthesis, allowing for an easy 
preparation of structurally diverse chiral phosphoramidite libraries.56 More recently, they have 
also been applied in the AH of substituted N-protected indoles,25e quinoxalines32c and 
quinolines.44o  
Our goal was set to find a method for the hydrogenation of 2-substituted pyridines 
employing monodentate phosphoramidites and a simple pyridine quaternization as N-
benzylpyridinium salts, which could be easily deprotected afterwards. Furthermore, since no 
mechanistic studies have been performed for the AH of pyridines, we decided to perform a study 
of the reaction which could help to understand the overall hydrogenation process.  
II.2 RESULTS AND DISCUSSION 
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For an initial screening of different phosphoramidites available in house, iridium was chosen 
as metal, since it is the metal of choice for almost all examples of AH of pyridines. Hydrogenation 
of N-benzyl-2-phenylpyridinium bromide was conducted in DCM at 50 °C and under 50 bar of 
H2 in a Premex 96er Multireaktor® (Figure 4), where up to 96 hydrogenations can be performed 
simultaneously. 
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Figure 4. Screening of monodentate phosphoramidites for the AH of N-benzyl-2-phenylpyridinium 
bromide. Reaction conditions: 56a (0.05 mmol), [Ir(cod)Cl]2 (1 mol%), phosphoramidite (4.2 mol%), 
DCM (1 mL), 50 °C, 50 bar H2, 20 h. Yield and ee (in absolute values) determined by chiral GC with 
dodecane as internal standard.  
Although no highly enantioselective hydrogenation was achieved in the initial screening, 
some leads could be identified. Looking at the 1,1’-binaphthol backbone, it can be observed that 
substituents in the 3,3’-positions had a negative effect in the enantioselectivity (Figure 4, A1 vs B1 
and D2; D1 vs E1). Similarly, other backbone substitutions, such as the octahydrobinaphthol or 
the taddol derivative, were not successful in this regard, leaving the 1,1-binapthol as the best 
backbone choice. On the other hand, bulky amino groups gave the best performance in this 
reaction, achieving enantioselectivities up to 52% when using the bis(1-phenylethylamine) PA2 
(Figure 4, A3). Thus, we selected three of them (PA1, PA2 and PA3) for the subsequent 
screening.  
A mixed ligand approach is commonly employed when using monodentate ligands. It has 
been shown that the combination of two different monodentate ligands can sometimes improve 
the results obtained using those same ligands individually.44f,o,57 Hence, the three selected 
phosphoramidites were screened in presence of an array of achiral alkyl or aryl phosphines or 
phosphites (Figure 5).  
N Ph N Ph
[Ir(cod)Cl]2 (1 mol%)
PA (4.2 mol%)
PR3 (2.2 mol%)
Bn BnBr DCM, 50 °C, H2 (50 bar)
56a 57a
*
 
 
 
 
 
 
 
 
 
 
Figure 5. Screening of different achiral phosphines and phosphites in combination with three different 
chiral phosphoramidites for the asymmetric hydrogenation of 56a. Reaction conditions: 56a (0.05 mmol), 
[Ir(cod)Cl]2 (1 mol%), phosphoramidite (4.2 mol%), phosphine/phosphite (2.2 mol%), DCM (1 mL), 50 
°C, 50 bar H2, 20 h. Yield and ee (in absolute values) determined by chiral GC with dodecane as internal 
standard. PA2 gave in all cases the opposite enantiomer than PA1 and PA3. 
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Surprisingly, diverse behaviors were obtained for the different phosphoramidites. When 
using PA1 in combination with an achiral phosphine or phosphite, no major changes were 
observed in the outcome of the reaction. When PA2 was employed, the best results were 
obtained with PPh3, which increased substantially the yield without affecting the ee. Instead, the 
combination PA3 and PPh3 did not improve the yield, although it slightly increased the 
enantiomeric excess. Considering these results, PA2 and PA3 were screened with a range of 
electronically and sterically different aromatic phosphines. In both cases, para-substituted 
aromatic phosphines gave the best results, the combination PA3 and tris(4-
trifluoromethylphenyl)phosphine being the best performing (86% yield and 60% ee). 
Next, we investigated the optimal equivalents of phosphoramidite and phosphine per atom 
of iridium (Table 6). Initially, only using PA3 as ligand (entries 1-3), we observed that 2 
equivalents were optimal. If more equivalents were used, both activity and ee decreased 
substantially, probably due to saturation of the coordination sites of Ir. When employing only the 
achiral phosphine, P(p-CF3C6H4)3, almost no conversion was observed. This means that, 
although achiral Ir complexes might be formed, they are not active in the hydrogenation of 56a, 
and thus no erosion of the ee arising from an achiral complex takes place in this case.  
Table 6. Equivalents of phosphoramidite and phosphine per Ir. 
 
# 
PA3 
(equiv./Ir) 
P(p-CF3C6H4)3
(equiv./Ir) 
yield (%) ee (%) 
1 1 - 60 17 
2 2 - 86 39 
3 4 - 31 2 
4 - 1 3 - 
5 - 2 2 - 
6 - 4 0 - 
7 1 1 100 76 
8 1 1.5 100 77 
9 1 2 71 77 
10 1 5 33 75 
11 1.5 1 100 77 
12 2 1 86 60 
13 2.5 1 23 38 
Reaction conditions: 56a (0.05 mmol), [Ir(cod)Cl]2 (1 mol%), PA3, P(p-CF3C6H4)3, DCM (1 mL), 50 °C, 
50 bar H2, 20 h. Yield and ee determined by chiral GC with dodecane as internal standard. 
Then, different phosphoramidite/phosphine ratios were screened. The best results were 
obtained with ratios of 1:1, 1.5:1 or 1:1.5 (entries 7, 8 and 11), which leads to think that, in the 
most active and enantioselective catalyst, Ir probably bears one phosphoramidite and one 
phosphine coordinated. When the amount of phosphine was increased, keeping the equivalents 
of phosphoramidite constant to one, the enantioselectivity of the reaction was not affected, but 
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the activity decreased considerably (entries 8-10). This is in agreement with the fact that achiral 
complexes are not active, so no erosion of the ee is observed, but big amounts of ligands saturate 
the coordination sites of the Ir complex making it less active. Instead, when the amount of 
phosphine was kept constant and the equivalents of phosphoramidite were increased, both the 
activity and the ee decreased substantially (entries 11-13). This fact is in agreement with the 
previously observed poor enantioselectivity of the Ir-bis(phosphoramidite) complex. Also in this 
case an excess of ligands quenches the activity of the catalyst. 
Since the obtained results (100% yield, 77% ee) were still far from optimal, we tried to 
optimize other reaction parameters, such as the solvent, the pressure and the temperature (Table 
7). Changing the solvent led in all cases to lower yields and lower ee’s (entries 1-6). When 
decreasing the pressure of H2, the ee remained constant but the yield was slightly affected (entries 
7 and 8). Instead, when decreasing the temperature, the enantioselectivity rose to 83% ee, but the 
activity decreased considerably (entries 9 and 10). 
Table 7. Screening of different solvents and pressure and 
temperature optimization. 
 
# Solvent T (°C) PH2 (bar) yield (%) ee (%) 
1 DCM 50 50 100 77 
2 CF3CH2OH 50 50 1 43 
3 iPrOH 50 50 95 68 
4 MeOH 50 50 39 5 
5 CH3CN 50 50 22 54 
6 Toluene 50 50 47 67 
7 DCM 50 22 89 77 
8 DCM 50 5 85 77 
9 DCM 25 22 47 83 
10 DCM 25 5 7 81 
Reaction conditions: 56a (0.05 mmol), [Ir(cod)Cl]2 (1 mol%), PA3 (2.2 mol%), P(p-CF3C6H4)3 (2.2 
mol%), solvent (1 mL), H2, 20 h. Yield and ee determined by chiral GC with dodecane as internal standard. 
The effect of the counterion of the pyridinium salt was also assessed. 56a was reacted for 10 
min with AgBF4, AgOTf or AgSbF6 in DCM to exchange the counterion. After filtering off the 
generated AgBr, the catalyst was added and the hydrogenation was carried out normally. In the 
three cases, worse yields and ee’s were obtained than when using bromide as counterion. 
Apparently, the presence of bromide is crucial to achieve good results, as Zhou and co-workers 
demonstrated with their system.16 
In our last attempt to improve the enantiomeric excess, a few additives were tested. The 
addition of piperidine hydrochloride showed a positive effect in the hydrogenation of 
quinoxalines and quinolines with Ir-phosphoramidite catalysts.32c,44o Unfortunately, it did not 
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have any effect in our case, probably because our substrate is already quaternized, while in the 
mentioned reports the acid might have the role of activating the unprotected quinolines and 
quinoxalines. The addition of I2 to an IrI precursor in the presence of a diphosphine ligand has 
proven to be highly beneficial for the iridium-catalyzed AH of imines and N-
heteroarenes.14,9,10b,32b,44e,y,45a,b After the investigations by Osborn and co-workers, where they 
showed that IrIII-complexes bearing a chelating diphosphine and iodo ligands are active catalyst 
for the AH of imines, it was proposed that I2 was oxidatively added to IrI to form the catalytically 
active IrIII complexes.58 In our system, the addition of I2 had a negative effect in the activity and 
the enantioselectivity. Finally, the effect of water in the reaction was assessed, not because we 
expected an improvement, but because pyridinium salts are very hygroscopic substrates. 
Fortunately, the results showed that the presence of water had little effect on the reaction 
outcome.  
Table 8. Effect of different additives. 
 
# Additive (mol%) yield (%) ee (%) 
1 Piperidine · HCl (10) 100 75 
2 Piperidine · HCl (100) 100 75 
3 Piperidine · HCl (200) 100 75 
4 I2 (4) 21 17 
5 I2 (8) 8 4 
6 H2O (1000) 100 73 
Reaction conditions: 56a (0.05 mmol), [Ir(cod)Cl]2 (1 mol%), PA3 (2.2 mol%), P(p-CF3C6H4)3 (2.2 
mol%), DCM (1 mL), 50 °C, 50 bar H2, 20 h. Yield and ee determined by chiral GC with dodecane as 
internal standard. 
Since we were not able to further optimize the reaction, we decided to perform a small 
substrate screening, to proof that this system was applicable to other aromatic substituted 
pyridines (Table 9). Actually the system was not very sensitive to the different electronics of the 
substituents, since full conversion was obtained in almost all cases and the enantioselectivities 
obtained ranged from 70 to 82% ee, with the exception of the 2-naphthyl substituted which gave 
only 58% ee (entry 7). Furthermore, an experiment performed on a 500 mg scale of substrate gave 
the expected enantiomeric excess with an isolated yield of 92% (entry 1). 
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Table 9. Asymmetric hydrogenation 2-substituted pyridinium salts.  
 
# Ar yield (%) ee (%) 
1 Ph (56a) >99 (92)[a] 77 (R) 
2 4-MeC6H4 (56b) >99 71 (+) 
3 4-MeOC6H4 (56c) >99 82 (+) 
4 3,5-diMeOC6H3 (56d) 99 70 (+) 
5 4-CF3C6H4 (56e) 97 74 (+) 
6 4-ClC6H4 (56f) >99 74 (+) 
7 2-naphthyl (56g) >99 58 (–) 
Reaction conditions: 56 (0.1 mmol), [Ir(cod)Cl]2 (1 mol%), PA3 (2.2 mol%), P(p-CF3C6H4)3 (2.2 mol%), 
DCM (2 mL), 50 °C, 50 bar H2, 20 h. Yield and ee determined by chiral GC, HPLC or SFC with dodecane 
as internal standard. [a] Isolated yield of a 500 mg scale experiment.  
Even though the obtained enantiomeric excesses are not excellent, this methodology 
allowed to undertake, for the first time, a mechanistic study on the AH of 2-substituted pyridines, 
which might be then extrapolated to other Ir-diphosphine systems. Initially, to gain some 
understanding on the reaction, we monitored the yield and ee of different reaction species over 
time (Figure 6). We observed that after six hours the pyridinium salt 56a had been almost totally 
converted to the chiral piperidine 57a, the ee of this latter being constant all along the reaction 
course.  
 
Figure 6. Evolution of the yield and ee of different reaction species over time. Reaction conditions: 56a (1.5 
mmol), [Ir(cod)Cl]2 (1 mol%), PA3 (2 mol%), P(p-CF3C6H4)3 (2 mol%), DCM (30 mL), 50 °C, 50 bar 
H2, 20 h. Yield and ee of 57a and the tetrahydropyridine 58a determined by chiral GC with dodecane as 
internal standard. Disappearance of 56a monitored by NMR with dimethyl terephthalate as internal 
standard.  
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During the first two hours another compound was formed, which was then slowly 
consumed, with a kinetic profile typical of a reaction intermediate. Indeed, as expected, this 
compound was identified by GC-MS as a tetrahydropyridine (m/z = 249). Furthermore, during 
the screening of phosphoramidites, some of the reactions that were not completed contained a 
substantial amount of tetrahydropyridine 58a, which was observable by NMR, along with 56a, 
57a and other impurities. Although 58a could not be isolated, consistently with the known 
instability of these kind of enamines,59 NMR analysis of the crude (after basic work-up) gave 
enough evidences to identify 58a as N-benzyl-6-phenyl-1,2,3,4-tetrahydropyridine (Figure 7): 
the triplet at 4.98 ppm (corresponding to C3)† coupling with the triplet-doublet at 2.08 
(corresponding to C4) cannot be assigned to any other tetrahydropyridine than the mentioned 
one. The protons in C6 and the ones in the benzylic position are also observed. Instead, the C5 
protons, expected between 1 and 2 ppm, overlap with the piperidine protons. Furthermore, all 
the observable geminal protons are homotopic, suggesting that no stereogenic center is present in 
the molecule, which fits with the proposed tetrahydropyridine. 
 
 
Figure 7. Identification of tetrahydropyridine 58a by 1H NMR analysis of a crude mixtures. 
                                                                
† For clarity, the carbon numbering on the tetrahydropyridine 58a follows the same numbering than the final 
piperidine 57a and the initial pyiridinium salt 56a and not the IUPAC rules. 
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In all sampled points, the sum of 56a, 57a and 58a is almost 100%, which suggests that the 
consumption of the dihydropyiridine intermediate is very fast and that the bottleneck of the 
reaction is the consumption of the tetrahydropyridine.  
To further investigate the steps 1a → TH and TH → 2a, isotopic labeling experiments were 
performed. The assignment of all protons of 57a was not easy, as all hydrogen atoms in the 
piperidine ring are diastereotopic. Thus, to be able to ascertain the extent of deuterium 
incorporation in all positions it was necessary to record the 1H NMR in two different solvents 
(CD3OD and toluene-d8). In each of these solvents, different protons were separated from the 
rest, allowing for an accurate integration, and the assignment of the chemical shift of each proton 
was done by multidimensional NMR analysis. Geminal protons were differentiated knowing that 
in 6-membered rings the axial protons are upfield of the equatorial ones. This shift effect is based 
on the anisotropy cone of C-C single bonds, as shown in Figure 8. While equatorial protons 
reside in the deshielding region (+δ), axial protons are in the –δ region. 
  
Figure 8. Anisotropy cone of a C-C single bond in a cyclohexyl ring. 
When the optimized reaction was carried out in presence of 10% CD3OD (Scheme 52), 
most of the deuterium was incorporated in C3 (1.07 deuteriums) and C5 (0.30 deuteriums), 
compared to the other carbons (<0.12 deuteriums each). This observation suggests that two 
enamine-iminium tautomerizations take place during the reaction, incorporating in this way the 
deuterium in the β-position of the nitrogen atom. Furthermore, the hydride addition is probably 
occurring in the iminium form, as previously reported for other N-heteroaromatic 
substrates.40b,c,f;45a,b;47c;54  
 
Scheme 52. Isotopic labeling experiment in the AH of 56a with CD3OD. 
This deuteration pattern leads to hypothesize a mechanism as the one shown in Scheme 53. 
An initial formation of N-benzyl-2-phenyl-1,4-dihydropyridine intermediate (59a) via a 1,4-
hydride addition to 56a is consistent with the low deuterium incorporation at C4. 
Dihydropyridine 59a would be in equilibrium with the two iminium ions 59a’ and 59a’’, as 
suggested by deuterium incorporation in C3 and C5 after H/D exchange with CD3OD. 
Moreover, the subsequent hydride addition to 59a’ occurs faster than to 59a’’, whose iminium 
carbon is more sterically hindered due to the presence of the phenyl substituent, and thus the 
detected tetrahydropyridine 58a would be the formed intermediate. Finally, another enamine-
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iminium tautomerization of 58a, with further deuterium incorporation in C3, and subsequent 
1,2-hydride addition would lead to the formation of piperidine 57a.  
 
Scheme 53. Proposed mechanism for the formation of 57a from 56a. 
A second isotopic labeling experiment was carried out in presence of D2 instead of H2. In this 
case, all the ring positions were deuterated, with a total amount of five deuterium atoms 
incorporated (Scheme 54). From here we deduced that, when the reaction is performed without 
protic solvents, the protons formed during the H2 or D2 splitting are the ones inserted in the C3 
and C5 positions. Moreover, the fact that no ring-face preference is observed for the deuterium 
incorporation in any of the carbons suggests that the stereogenic center in C2 is not formed until 
the last step. Otherwise, the presence of a stereocenter in an early reaction intermediate would 
direct the hydride attacks preferentially to one of the two faces of the heterocycle. 
 
Scheme 54. Isotopic labeling experiment in the AH of 56a with D2. 
Altogether, the above-discussed isotopic labeling experiment suggests that an initial 1,4-
hydride addition to 56a probably takes place, forming the dihydropyridine 59a. The latter is 
readily hydrogenated to 58a, which is the only reaction intermediate detected by NMR and GC. 
Finally, the enantioselective 1,2-hydride addition to the iminium 58a’ would lead to the final 
piperidine 57a, as shown in the proposed mechanism in Scheme 53. 
II.3 CONCLUSIONS 
To sum up, we have been able to develop a new system for the asymmetric hydrogenation of 
N-benzyl-2-arylpyridinium bromides using an iridium catalyst and a mixed ligand system, 
containing a chiral phosphoramidite and an achiral phosphine. Although only ee’s up to 82% were 
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achieved, this approach demonstrates that the use of cheap and easy to prepare monodentate 
ligands is also suitable for this challenging transformation. Furthermore, the performed 
mechanistic study sheds light on the pyridine hydrogenation pathway, and shows that the 
enantioselective step does not occur until the very last step. This will hopefully allow for a better 
understanding of the system and the rational design of more active and enantioselective systems. 
II.4 EXPERIMENTAL SECTION 
Dry DCM was obtained using an MBraun SPS system. Dry MeOH, EtOH, iPrOH and 
toluene (over molecular sieves in bottles with crown cap) were purchased from Sigma Aldrich 
and stored under nitrogen. 2,2,2-trifluoroethanol (TFE) was dried over molecular sieves. 
Commercially available reagents (from TCI Chemicals, ACROS, Sigma Aldrich, Strem) were 
used as received, without any further purification.  
Flash column chromatography was performed using Grace Reveleris® X2 Flash 
Chromatography System (silica gel cartridges with particle size 40 μm). Gas chromatography was 
performed on an Agilent Technologies 7890A equipped with a flame ionization detector. HPLC 
analyses were performed using a Waters HPLC with a dual λ absorbance detector working at 210 
and 254 nm. SFC analyses were performed using a THAR SFC. 
1H-NMR spectra were recorded using two different spectrometers operating at 400 or 500 
MHz. Proton chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard (CDCl3 δ = 7.26 ppm; CD2Cl2 δ = 
5.32 ppm, CD3OD δ = 3.31 ppm, toluene-d8 δ = 7.09, 7.01, 6.97 and 2.08). 13C-NMR spectra 
were recorded on a 400 MHz spectrometer operating at 101 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective 
solvent resonance as the internal standard (CDCl3, δ = 77.16 ppm, CD2Cl2 δ = 53.84 ppm, 
CD3OD δ = 49.00 ppm). 19F-NMR spectra were recorded on a 300 MHz spectrometer operating 
at 282 MHz, with complete proton decoupling. Fluorine chemical shifts are reported in ppm (δ) 
relative to external CFCl3 at 0 ppm (positive values downfield). The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
dd = doublet-doublet, ddd = doublet-doublet-doublet, dt = doublet-triplet, td = triplet-doublet. 
Coupling constant values are given in Hz. 
Optical rotation signs were determined on an automatic polarimeter with a 1 dm cell at the 
sodium D line (λ = 589 nm). High resolution mass spectra (HRMS) were performed on a 
Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass 
software (Bruker Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI source. Infrared 
spectra were recorded on a standard FT/IR spectrometer.  
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General procedure for the synthesis of 2-arylpyridines 
A mixture of 2-bromopyridine 63 (1 ml, 9.9 mmol), the boronic acid (14.9 mmol, 1.5 
equiv.), Pd(OAc)2 (22 mg, 0.1 mmol), K3PO4 (4.2 g, 19.8 mmol) and 75 mL of ethylene glycol 
were stirred at 80 °C for 5 h. Once the reaction was completed, the reaction mixture was poured 
into 150 mL of brine and extracted with 150 mL of Et2O. NaOH (7.5 g) was added to the 
ethereal phase and the mixture was stirred for 15 min. Then it was poured into 150 mL of brine, 
the ethereal phase was again separated and stirred in the presence of NaOH (7.5 g). After 15 min 
more, the mixture was poured one last time into 150 mL of brine and the ethereal phase was 
separated, dried over Na2SO4, filtered and concentrated several times in the presence of MeOH. 
The obtained 2-arylpyridine was used in the next step without any further purification. 
 
General procedure for the benzylation of pyridines  
Pyridinium salts 56 were prepared according to known literature methods.16,60 A mixture of 
2-arylpyridine (12.9 mmol), benzyl bromide (15.5 mmol, 1.2 equiv.) and 5.0 mL acetone were 
stirred under reflux temperature for 18-48h. If the product precipitated, it was filtered, washed 
several times with acetone and dried under high vacuum. If the product did not precipitate, the 
solvent was removed and the resulting sticky oil was recrystallized from MeOH/AcOEt (9:1). 
The desired products were obtained with yields ranging from 42-95% yield. 
 
N-Benzyl-2-phenylpyridinium bromide (56a):  
Known compound. Spectroscopic data are superimposable to those reported in 
the literature.61 
N-Benzyl-2-(p-tolyl)pyridinium bromide (56b): White solid; m.p. = 172 °C; 
1H NMR (400 MHz, MeOD) δ 9.15 (dd, 3J(H,H) = 6.3 Hz, 4J(H,H) = 0.7 Hz, 
1H), 8.67 (td, 3J(H,H) = 7.9 Hz, 4J(H,H) = 1.3 Hz, 1H), 8.16 (td, 3J(H,H) = 
7.0 Hz, 4J(H,H) = 1.3 Hz, 1H), 8.05 (dd, 3J(H,H) = 7.9 Hz, 4J(H,H) = 0.8 Hz, 1H), 7.45 – 7.37 
(m, 4H), 7.35 – 7.27 (m, 3H), 7.02 – 6.95 (m, 2H), 5.83 (s, 2H), 2.47 (s, 3H); 13C NMR (101 
MHz, MeOD) δ 157.9, 147.4, 143.4, 134.8, 132.3, 131.0, 130.3, 130.3, 130.2, 130.1, 129.0, 128.3, 
63.3, 21.5; IR (film): ν = 3079.8, 3035.4, 1622.8, 1496.5, 1455.0 cm-1; MS (ESI+): m/z 246.2 
[M]+ (calcd. for C19H18N: 260.14). 
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N-Benzyl-2-(4-methoxyphenyl)pyridinium bromide (56c): White solid; 
m.p. = 162 °C; 1H NMR (400 MHz, MeOD) δ 9.13 (dd, 3J(H,H) = 6.3 Hz, 
4J(H,H) = 0.9 Hz, 1H), 8.65 (td, 3J(H,H) = 7.9 Hz, 4J(H,H) = 1.4 Hz, 1H), 
8.13 (ddd, 3J(H,H) = 7.7 Hz, 3J(H,H) = 6.4 Hz, 4J(H,H) = 1.5 Hz, 1H), 8.05 (dd, 3J(H,H) = 8.0 
Hz, 4J(H,H) = 1.1 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.35 – 7.30 (m, 3H), 7.16 – 7.09 (m, 2H), 7.03 
– 6.95 (m, 2H), 5.86 (s, 2H), 3.90 (s, 3H); 13C NMR (101 MHz, MeOD) δ 163.6, 157.9, 147.4, 
147.3, 134.9, 132.4, 132.0, 130.3, 130.3, 129.0, 128.0, 125.0, 115.8, 63.2, 56.2; IR (film): ν = 
3068.2, 3006.5, 1621.8, 1608.3, 1495.5, 1456.0, 1255.4, 1182.2 cm-1; MS (ESI+): m/z 276.2 [M]+ 
(calcd. for C19H18NO: 276.14). 
N-Benzyl-2-(3,5-dimethoxyphenyl)pyridinium bromide (56d): Orange 
solid; m.p. = 69 °C; 1H NMR (400 MHz, MeOD) δ 9.18 (d, 3J(H,H) = 5.9 
Hz, 1H), 8.70 (t, 3J(H,H) = 7.6 Hz, 1H), 8.20 (t, 3J(H,H) = 6.6 Hz, 1H), 
8.09 (d, 3J(H,H) = 7.7 Hz, 1H), 7.42 – 7.32 (m, 3H), 7.09 – 6.99 (m, 2H), 
6.72 (m, 1H), 6.62 (t, 3J(H,H) = 1.9 Hz, 2H), 5.85 (s, 2H), 3.78 (s, 6H); 13C NMR (101 MHz, 
MeOD) δ 161.5, 156.1, 146.2, 146.1, 133.6, 133.0, 130.7, 129.0, 128.9, 127.6, 127.3, 106.8, 102.9, 
62.2, 55.0; IR (film): ν = 3093.3, 1626.7, 1603.5, 1455.0, 1424.2, 1206.3, 1159.0 cm-1; MS 
(ESI+): m/z 306.2 [M]+ (calcd. for C20H20NO2: 306.15).  
N-Benzyl-2-(4-(trifluoromethyl)phenyl)pyridinium bromide (56e): 
White solid; m.p. = 185 °C; 1H NMR (400 MHz, MeOD) δ 9.28 (d, 3J(H,H) 
= 5.7 Hz, 1H), 8.77 (td, 3J(H,H) = 7.9 Hz, 4J(H,H) = 1.3 Hz, 1H), 8.27 
(ddd, 3J(H,H) = 7.7 Hz, 3J(H,H) = 6.3 Hz, 4J(H,H) = 1.4 Hz, 1H), 8.13 (dd, 3J(H,H) = 7.9 Hz, 
4J(H,H) = 1.1 Hz, 1H), 7.87 (d, 3J(H,H) = 8.3 Hz, 2H), 7.73 (d, 3J(H,H) = 8.2 Hz, 2H), 7.38 – 
7.24 (m, 3H), 6.97 (d, 3J(H,H) = 7.0 Hz, 2H), 5.86 (s, 2H); 13C NMR (101 MHz, MeOD) δ 
155.8, 148.0, 147.9, 136.7 (q, 4J(C,F) = 1.6 Hz), 134.4, 134.0 (q, 2J(C,F) = 32.8 Hz), 132.3, 
131.3, 130.3, 129.2, 129.1, 127.2 (q, 3J(C,F) = 3.7 Hz), 125.0 (q, 1J(C,F) = 272.0 Hz), 63.9; 19F 
NMR (282 MHz, MeOD) δ -64.9; IR (film): ν = 3057.6, 2967.9, 1623.8, 1616.1, 1458.9, 1323.9, 
1169.6, 1123.3, 1071.3, 849.5 cm-1; MS (ESI+): m/z 314.1 [M]+ (calcd. for C19H15F3N: 314.12). 
N-Benzyl-2-(4-chlorophenyl)pyridinium bromide (56f): White solid; m.p. 
= 101 °C; 1H NMR (400 MHz, CDCl3) δ 9.56 (dd, 3J(H,H) = 6.2 Hz, 4J(H,H) 
= 0.8 Hz, 1H), 8.61 (td, 3J(H,H) = 7.8 Hz, 4J(H,H) = 1.2 Hz, 1H), 8.19 (ddd, 
3J(H,H) = 7.7 Hz, 3J(H,H) = 6.4 Hz, 4J(H,H) = 1.4 Hz, 1H), 7.82 (dd, 3J(H,H) = 7.9 Hz, 4J(H,H) 
= 1.3 Hz, 1H), 7.55 – 7.47 (m, 2H), 7.47 – 7.37 (m, 2H), 7.29 – 7.13 (m, 3H), 6.99 – 6.87 (m, 
2H), 5.98 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 154.7, 147.5, 146.3, 138.1, 133.0, 130.8, 
130.5, 129.8, 129.8, 129.5, 129.5, 128.5, 128.1, 62.7; IR (film): ν = 3068.2, 3039.3, 1621.8, 
1483.0, 1455.0, 1090.6 cm-1; MS (ESI+): m/z 280.1 [M]+ (calcd. for C18H15ClN: 280.09). 
N-Benzyl-2-(naphthalen-2-yl)pyridinium bromide (56g): White solid; 
m.p. = 175 °C; 1H NMR (400 MHz, MeOD) δ 9.24 (dd, 3J(H,H) = 6.3 Hz, 
4J(H,H) = 1.0 Hz, 1H), 8.72 (td, 3J(H,H) = 7.8 Hz, 4J(H,H) = 1.4 Hz, 1H), 
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8.20 (ddd, 3J(H,H) = 7.8 Hz, 3J(H,H) = 6.3, 4J(H,H) = 1.5 Hz, 1H), 8.11 (dd, 3J(H,H) = 7.9 Hz, 
4J(H,H) = 1.3 Hz, 1H), 8.08 – 8.01 (m, 2H), 7.98 (d, 3J(H,H) = 7.6 Hz, 1H), 7.93 (d, 3J(H,H) = 
7.6 Hz, 1H), 7.69 – 7.53 (m, 3H), 7.29 – 7.15 (m, 3H), 6.92 (d, 3J(H,H) = 7.3 Hz, 2H), 5.88 (s, 
2H); 13C NMR (101 MHz, MeOD) δ 157.4, 147.5, 135.2, 134.5, 133.8, 132.4, 131.0, 130.3, 
130.2, 130.2, 130.1, 129.8, 129.5, 129.0, 129.0, 128.7, 128.5, 125.9, 63.4; IR (film): ν = 3055.7, 
1619.9, 1573.6, 1498.4, 1455.0, 1273.8, 1159.0 cm-1; MS (ESI+): m/z 296.2 [M]+ (calcd. for 
C22H18N: 296.14). 
General procedure for the asymmetric hydrogenation of pyridinium salts 
 
A solution of [Ir(cod)Cl]2 (0.001 mmol), PA3 (0.0022 mmol) and P(p-CF3C6H4)3 (0.0022 
mmol) in DCM (1 mL) was stirred at 45 °C for 30 min. The preformed catalyst was added to a 5 
mL vial containing a solution of the corresponding N-benzyl-2-arylpyridinium bromide (0.1 
mmol) in DCM (1 mL). The vial was capped with a PTFE septum, removed from the glovebox 
and placed into a Premex 96er Multireaktor®. After flushing it 5 times with N2 and 5 times with 
H2, it was pressurized to 50 bar of H2 and stirred at 50 °C for 18 h. 
(R)-(+)-N-Benzyl-2-phenylpiperidine (57a): Known compound. Spectroscopic 
data are superimposable to those reported in the literature.20 Absolute configuration 
assigned by comparison of the sign of the optical rotation with literature data.62 Yield 
and enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); 
carrier: helium; gas flow: 2.7 bar; isotherm at 150 °C: tS = 27.3 min., tR = 27.8 min., tTH = 38.5 
min. Alternative enantiomeric excess determination by SFC: Lux Cellulose-3 (250 x 4.6 mm); 
200 Bar; 254 nm; 40 °C; isocratic CO2/MeOH with 25 mM DEA = 9:1, 4 mL/min: tR = 2.0 min., 
tS = 2.3 min. 
(+)-N-Benzyl-2-(4-tolyl)piperidine (57b): Known compound. Spectroscopic 
data are superimposable to those reported in the literature.17 Yield determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 
bar; oven temperature: isotherm at 160 °C: t57b = 25.1 min. Enantiomeric excess determined by 
SFC: Lux Cellulose-3 (250 x 4.6 mm); 200 Bar; 254 nm; 40 °C; isocratic CO2/MeOH with 25 
mM DEA = 9:1, 4 mL/min: t(+) = 1.7 min., t(–) = 2.1 min. 
(+)-N-Benzyl-2-(4-methoxyphenyl)piperidine (57c): Known compound. 
Spectroscopic data are superimposable to those reported in the literature.17 
Yield determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); 
carrier: helium; gas flow: 2.7 bar; oven temperature: isotherm at 170 °C: t57c = 31.1 min. 
Enantiomeric excess determined by HPLC: Lux Cellulose-3 (250 x 4.6 mm); 254 nm; isocratic 
Hexane/iPrOH/DEA 98:2:0.05, 0.7 mL/min: t(+) = 8.2 min., t(–) = 9.3 min. 
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(+)-N-Benzyl-2-(3,5-dimethoxyphenyl)piperidine (57d): 1H NMR (400 
MHz, CD2Cl2) δ 7.33 – 7.23 (m, 4H), 7.18 (m, 1H), 6.65 (s, 2H), 6.32 (m, 
1H), 3.79 (m, 6H), 3.06 (d, J = 10.8 Hz, 1H), 2.92 (d, J = 11.6 Hz, 1H), 2.80 
(d, J = 13.6 Hz, 1H), 1.93 (td, J = 11.4, 2.2 Hz, 1H), 1.82 – 1.72 (m, 2H), 1.67 
– 1.48 (m, 4H),1.37 (m, 1H); 13C NMR (101 MHz, CD2Cl2) δ 161.4, 149.0, 140.6, 129.0, 128.4, 
126.9, 105.7, 99.2, 69.9, 60.1, 55.7, 53.7, 37.2, 26.5, 25.6; IR (film): ν = 2933.2, 2852.2, 1607.4, 
1594.8, 1454.1, 1427.1, 1203.4, 1154.2, 1061.6 cm-1; HRMS (ESI+): m/z 312.19643 [M+H]+ 
(calcd. for C20H26NO2: 312.19581). Yield determined by GC: CP-Chirasil-Dex CB (25m x 
0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 170 °C (60 min), 20 
°C/min, 190 °C (10 min): t57d = 61.7 min. Enantiomeric excess determined by SFC: Lux 
Cellulose-3 (250 x 4.6 mm); 200 Bar; 254 nm; 40 °C; isocratic CO2/MeOH with 25 mM DEA = 
9:1, 4 mL/min: t(–) = 1.6 min., t(+) = 1.8 min. 
(+)-N-Benzyl-2-(4-(trifluoromethyl)phenyl)piperidine (57e): 1H NMR 
(400 MHz, CD2Cl2) δ 7.65 – 7.56 (m, 4H), 7.31 – 7.23 (m, 4H), 7.20 (m, 1H), 
3.67 (d, J = 13.6 Hz, 1H), 3.22 (dd, J = 11.0, 2.9 Hz, 1H), 2.95 (m, 1H), 2.84 
(d, J = 13.6 Hz, 1H), 1.97 (td, J = 11.6, 3.3 Hz, 1H), 1.85 – 1.71 (m, 2H), 1.67 – 1.50 (m, 3H), 
1.40 (m, 1H); 13C NMR (101 MHz, CD2Cl2) δ 150.8, 140.0, 129.0, 128.5, 128.3, 127.1, 125.9 (q, 
3J(C,F) = 3.7 Hz), 124.9 (q, 1J(C,F) = 273.9 Hz), 69.2, 60.3, 53.6, 37.5, 26.4, 25.5.; 19F NMR 
(282 MHz, CD2Cl2) δ -63.1; IR (film): ν = 2935.1, 2855.1, 2793.4, 1324.9, 1162.9, 1124.3, 
1067.4, 834.1 cm-1; HRMS (ESI+): m/z 320.16295 [M+H]+ (calcd. for C19H21NF3: 320.16206). 
Yield determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas 
flow: 2.7 bar; oven temperature: isotherm at 150 °C: t57e = 29.7 min. Enantiomeric excess 
determined by HPLC: Lux Cellulose-3 (250 x 4.6 mm); 254 nm; isocratic Hexane + 0.05% DEA, 
0.7 mL/min: t(+) = 8.7 min., t(–) = 8.9 min. 
(+)-N-Benzyl-2-(4-chlorophenyl)piperidine (57f): Known compound. 
Spectroscopic data are superimposable to those reported in the literature.17 Yield 
determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 150 °C (60 min), 20 °C/min, 190 °C (10 min): t57f = 
63.2 min. Enantiomeric excess determined by SFC: Lux Cellulose-3 (250 x 4.6 mm); 200 Bar; 
254 nm; 40 °C; isocratic CO2/MeOH with 25 mM DEA = 9:1, 4 mL/min: t(+)= 2.2 min., t(–) = 2.4 
min. 
(–)-N-Benzyl-2-(naphthalen-2-yl)piperidine (57g): Known compound. 
Spectroscopic data are superimposable to those reported in the literature.17 
Yield determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); 
carrier: helium; gas flow: 2.7 bar; oven temperature: isotherm at 190 °C: t57g = 36.7 min. 
Enantiomeric excess determined by SFC: Lux Cellulose-3 (250 x 4.6 mm); 200 Bar; 254 nm; 40 
°C; isocratic CO2/MeOH with 25 mM DEA = 9:1, 4 mL/min: t(+) = 5.1 min., t(–) = 5.8 min. 
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Monitoring of the reaction over time:  
A solution of [Ir(cod)Cl]2 (10.3 mg, 0.015 mmol), PA3 (14.0 mg, 0.034 mmol) and P(p-
CF3C6H4)3 (15.8 mg, 0.033 mmol) in DCM (15 mL) was stirred at 45 °C for 30 min. The 
preformed catalyst was added to a 50 mL vial containing a solution of the corresponding N-
benzyl-2-phenylpyridinium bromide 1a (503.38 mg, 1.53 mmol), dodecane (420.00 mg) and 
dimethyl terephthalate (145.98 mg) in DCM (15 mL). The autoclave was closed and taken out 
of the glovebox. After flushing it 5 times with N2, it was pressurized to 50 bar of H2 and stirred at 
50 °C for 10 h with sampling at different times. All samples were analyzed by chiral GC and NMR 
(results shown in Table 10). 
Table 10. Yield and ee of different species involved in the AH of 60a to 61a. 
Time (h) 
56a 
(%)[a] 
57a 
(%)[b] 
ee of 57a 
(%)[b] 
TH 
(%)[b] 
0 100 0 - 0 
0.5 90 3 68 2 
1 70 20 70 6 
2 42 46 72 5 
3.25 15 81 73 2 
6.25 1 99 74 0 
9.5 0 99 74 0 
[a] Determined by NMR with dimethyl terephthalate as internal standard. 
[b] Determined by GC analysis with CP-Chirasil-Dex CB column with 
dodecane as internal standard. Positive values of ee correspond to S 
configuration.  
Isotopic labeling experiments:  
With CD3OD. Inside a glovebox, a solution of [Ir(cod)Cl]2 (0.0015 mmol), PA3 (0.0033 
mmol) and P(p-CF3C6H4)3 (0.0033 mmol) in DCM (1 mL) was stirred at 45 °C for 30 min. The 
preformed catalyst was added to a 5 mL vial containing a solution of the corresponding N-benzyl-
2-arylpyridinium bromide (0.15 mmol) in DCM (2 mL) and CD3OD (0.3 mL). The vial was 
capped with a PTFE septum, removed from the glovebox and placed into a Premex 96er 
Multireaktor®. After flushing it 5 times with N2 and 5 times with H2, it was pressurized to 50 bar of 
H2 and stirred at 50 °C for 18 h. The crude mixture was washed with saturated aqueous solution 
of Na2CO3 and extracted with DCM. The organic extracts were dried, concentrated and purified 
by flash column chromatography Hexane/EtOAc (from 99:1 to 95:5). 
With D2. Inside a glovebox, a solution of [Ir(cod)Cl]2 (0.0015 mmol), PA3 (0.0033 mmol) 
and P(p-CF3C6H4)3 (0.0033 mmol) in DCM (1 mL) was stirred at 45 °C for 30 min. The 
preformed catalyst was added to a 5 mL vial containing a solution of the corresponding N-benzyl-
2-arylpyridinium bromide (0.15 mmol) in DCM (2 mL). The vial was capped with a PTFE 
septum, removed from the glovebox and placed into a Premex 96er Multireaktor®. After flushing 
it 5 times with N2 and 5 times with H2, it was pressurized to 40 bar of D2 and stirred at 50 °C for 
18 h. The crude mixture was washed with saturated aqueous solution of Na2CO3 and extracted 
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with DCM. The organic extracts were dried, concentrated and purified by flash column 
chromatography Hexane/EtOAc (from 99:1 to 95:5). 
- Quantitative 1H NMR spectra of 57a in CD3OD and toluene-d8 are shown below for a 
standard experiment and the two isotopic labeling experiments.  
Standard experiment: 
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Isotopic labeling experiment with CD3OD:  
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Isotopic labeling experiment with D2:  
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CHAPTER III. 
ASYMMETRIC HYDROGENATION OF  
3-SUBSTITUTED PYRIDINES 
 
III.1 INTRODUCTION 
Among chiral piperidines, the 3-substitued ones are particularly challenging to obtain in 
enantiomerically enriched form. Although several approaches have been developed for their 
preparation, there is still no efficient method for their synthesis. The most common ways to 
obtain these 3-substituted piperidines (Scheme 55) are the following: (a) hydrogenation of 3-
substituted pyridines and subsequent resolution, either by formation of diastereomeric salts63 or 
by chemoenzymatic resolution;64 (b) hydrogenation of 3-substituted pyridines bearing chiral 
auxiliaries with heterogeneous catalysts;5,7 (c) alkylation and reduction of oxazolopiperidones;65 
(d) ring expansion via an aziridinium salt;66 (e) ring closing-metathesis to form a prochiral 
tetrahydropyridine, which is subsequently hydrogenated enantioselectively.67 
 
Scheme 55. Methods to prepare chiral 3-substituted piperidines. 
All these methods require either a separation of the stereoisomers after the reaction or 
several steps for the synthesis of the piperidine precursor. In contrast, the asymmetric 
hydrogenation (AH) of 3-substituted pyridines would be of great importance, since the 
preparation of these substrates is much easier and many of them are commercially available. 
Unfortunately, no highly enantioselective hydrogenation has been reported yet.  
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Attempts to enantioselectively hydrogenate 3-substituted pyridines or related 6-membered 
N-heteroaromatics, such as 3-substituted quinolines or 4-substituted isoquinoline, led in all cases 
to very poor enantioselectivities, between 0-17% ee.8,40e,47c,68 All these substrates share a common 
mechanistic pathway, which involves a enamine-imine tautomerization before the hydride 
addition, generating a racemic stereocenter in the β-carbon of the nitrogen atom (Scheme 56). 
 
Scheme 56. Accepted mechanistic pathway responsible for the racemization of the β-carbon.  
However, Rueping and co-workers found a way to overcome this problem in the 
organocatalytic reduction of 3-substituted quinolines.52c The combination of Hantzsch esters as 
reductant with catalytic amounts of chiral phosphoric acids promoted an enantioselective 
enamine-iminium tautomerization. The chiral phosphate counterion induced the proton transfer 
preferentially from one of the faces of the dihydroquinoline ring, thus generating 3-substituted 
tetrahydroquinolines with ee’s up to 86% (Scheme 57). 
 
Scheme 57. Proposed mechanism for the enantioselective proton transfer in the AH of 3-substituted 
quinolines. 
Regarding pyridines, the most similar example is the AH of 2,3,6-trisubstituted pyridines, 
recently reported by Zhou and co-workers, where enantioselectivities up to 90% ee are obtained 
(see Chapter I, Scheme 9).19 In this particular example, the substituent in the 3-position is always 
a trifluoromethyl group, and the mechanism that allows to obtain high enantioselectivities is a 
dynamic kinetic resolution, which is the accepted path for all the reported cases of α,β-
disubstituted N-heteroarenes. Unfortunately, in the case of only 3-substituted pyridines, this 
mechanism is not observed or is less effective. 
III.2 RESULTS AND DISCUSSION 
After having gained some knowledge about the mechanism of hydrogenation of 2-
substituted pyridines (Chapter II), and taking in account all the mechanisms that have been 
proposed for N-heteroaromatic substrates, we decided to focus our efforts on the development of 
a highly enantioselective hydrogenation of 3-substituted pyridines.  
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Since the low enantioselectivity was most probably arising from the enaminium-iminium 
tautomerization, we wondered if it was possible to avoid this tautomerization by addition of a 
base, which would quench the generated HBr, and find a catalyst able to hydrogenate the 
resulting enamine (Scheme 58).  
 
Scheme 58. Proposed pathways for the AH of 3-substituted pyridines in presence or absence of a base. 
Unfortunately, the examples about AH of enamines are rather limited, and even more if we 
speak about β-substituted enamines.69 Much effort has been put on the AH of enamides, where a 
secondary coordination of the N-acyl moiety with the metal is crucial for achieving high 
enantioselectivities.70  
However, we decided to test if the base would affect somehow the outcome of the reaction. 
Rh has been widely used in the AH of enamines and enamides69a,70a-g and JosiPhos J002-2, a 
ferrocene derived ligand,71 has proved very effective in the AH of 2,4-disubstituted pyrimidines54 
and 3,4-disubstituted pyridinium salts.15 Thus, this combination of Rh-JosiPhos was selected 
together with diisopropylethylamine (DIPEA), a bulky base which might have difficulties to 
coordinate to the catalyst. Finally, a mixture of THF and MeOH was chosen to solubilize the 
catalyst and the N-benzyl-3-phenylpyridinium bromide (60a), which was selected as model 
substrate. The hydrogenation was carried out at 50 °C under 50 bar of H2 in the absence and in 
the presence of DIPEA, for comparison (Scheme 59). As expected, when no base was added, (S)-
N-benzyl-3-phenylpiperidine (61a) was obtained with only 9% ee. Instead, when DIPEA was 
used, the enantioselectivity rose to 73% ee, but TH-1 was observed as side product.  
 
Scheme 59. Initial attempt for the AH of N-benzyl-3-phenylpyridinium bromide. 
Encouraged by the dramatic effect of the base, we directed our efforts to optimize the 
reaction conditions. Initially, the solvent effect was investigated in order to increase the yield and 
ee of the piperidine 61a and lower the amount of TH-1 formed (Table 11). When the reaction 
was carried out in pure MeOH (entry 2), the final piperidine was obtained in high yield but low 
ee. Instead, in pure THF very low yield and the opposite enantiomer was obtained (entry 3). 
Testing different alcohols (entries 4-6) we observed that the more acidic the alcohol the higher 
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was the obtained ee (2,2,2-trifluoroethanol (TFE) > MeOH > EtOH > iPrOH) and the lower the 
amount of TH-1. Checking different ratios of THF/TFE (entries 6-8), the ratio 2:1 was a good 
compromise between yield and enantiomeric excess. Other solvent mixtures, such as DCM/TFE 
or toluene/TFE gave lower enantioselectivities (entries 10 and 11).  
Table 11. Solvent screening. 
 
# Solvent 
yield of 
61a (%) 
ee of  
61a (%) 
yield of  
TH-1 (%) 
1 THF/MeOH (2:1) 13 73 34 
2 MeOH  81 13 9 
3 THF 5 -59[a] 41 
4 THF/EtOH (2:1) 10 63 50 
5 THF/IPA (2:1) 6 34 48 
6 THF/TFE (2:1) 27 83 17 
7 THF/TFE (1:1) 40 68 2 
8 THF/TFE (1:2) 40 52 2 
9 DCM/TFE (2:1) 40 63 3 
10 Toluene/TFE (2:1) 35 67 10 
Reaction conditions: 60a (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos J002-2 (2.2 mol%), DIPEA (5 
equiv.), solvent (1.5 mL), 50 °C, 50 bar H2, 20 h. Yield and ee determined by chiral GC with dodecane as 
internal standard. [a] R configuration was obtained in this case.  
Next we focused on the optimization of the base (Table 12). As already observed before, the 
absence of base led to a poor yield and enantiomeric excess (entry 1). Screening different amines 
(entries 2-14) it was noticed that the more basic the amine the higher was the enantiomeric 
excess. While alkyl amines gave enantioselectivities ranging from 74 to 85% ee, less basic amines, 
such as p-ethylaniline or 2,6-lutidine, led only to 37% and 31% ee, respectively (see Figure 9 for a 
complete correlation). The correlation with the yields of 61a is not straightforward, and other 
factors apart from electronics might be involved. Other inorganic bases (entries 15 and 16) and 
phosphazene bases (entry 17) did not achieve as high enantioselectivities and produced 
important amounts of TH-1. It is noteworthy that non-bulky tertiary amines and even secondary 
amines were well tolerated. To check if the amines were coordinating to the catalyst, two 
enantiomers of a chiral secondary amine were tested (entries 18 and 19). In both cases the same 
enantiomeric excess was obtained, thus suggesting that there is no coordination of the ligand to 
the catalyst, at least during the enantiodetermining step. Finally, the equivalents of base were 
tested (entries 20-23). As long as more than one equivalent was used, the amount of base had 
little effect on the outcome of the reaction. 
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Table 12. Screening of bases. 
 
# Base pKBH
+ 
(in H2O) 
yield of 
61a (%) 
ee of  
61a (%) 
yield of  
TH-1 (%) 
1 - - 5 23 0 
2 DIPEA  11.07 27 83 17 
3 Et3N  10.75 57 85 20 
4 Proton Sponge®  12 39 84 21 
5 (nPr)3N  10.65 62 80 16 
6 (iPr)2NH  11.05 37 85 11 
7 DMAP  9.2 23 84 13 
8 2,6-lutidine  6.65 98 31 0 
9 p-ethylaniline 5.03 18 37 0 
10 DBU  12 23 60 49 
11 N-methylmorpholine  7.38 40 74 6 
12 Bn2NH  8.76 45 81 18 
13 N-methylpiperidine  10.08 51 83 15 
14 Quinuclidine  11 56 80 17 
15 Cs2CO3  10.32 40 48 32 
16 KOMe  15.54 54 48 23 
17 BEMP  16.2 27 72 28 
18[a] (R)-N-benzyl-1-phenylethanamine ≈ 9 97 59 4 
19[a] (S)-N-benzyl-1-phenylethanamine ≈ 9 94 60 4 
20 Et3N [0.5 equiv.]  40 76 9 
21 Et3N [1 equiv.]  54 85 16 
22 Et3N [3 equiv.]  60 81 17 
23 Et3N [10 equiv.]  58 78 16 
Reaction conditions: 60a (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos J002-2 (2.2 mol%), base (5 
equivalents, unless otherwise stated), THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Yield and ee 
determined by chiral GC with dodecane as internal standard. [a] Reaction performed at 70 °C.  
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Figure 9. Acidity of the protonated amines vs obtained ee. 
We then decided to investigate whether a different metal precursor or ligand could improve 
the results. The enantiomeric excesses were found to be highly dependent on the metal precursor 
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(Table 13). The best results were obtained with Rh(cod)2OTf, the RhI complex that we had been 
using for all prior optimizations (entry 1). Surprisingly, similar results were achieved with RhII-
carboxylate precursors (entries 2 and 3). Other Rh complexes did not show the same efficiency 
regardless of having coordinating or non-coordinating anions (entries 4-7). Interestingly, the 
same positive effect of the addition of base is observed when using iridium as metal – 5% ee in 
absence of base and 62% ee in presence of Et3N (entry 9 vs 8) –. 
Table 13. Screening of metal precursors. 
 
# Metal precursor 
yield of 
61a (%) 
ee of  
61a (%) 
yield of  
TH-1 (%) 
1 Rh(cod)2OTf 57 85 20 
2 [Rh(OAc)2]2 65 84 5 
3 [Rh(CF3CO2)2]2 50 77 7 
4 Rh(cod)2BF4 55 38 13 
5 Rh(cod)(acac) 51 16 9 
6 [Rh(cod)Cl]2 53 39 10 
7 [Rh(Cp*)Cl2]2 65 56 3 
8 [Ir(cod)Cl]2[a] 12 62 18 
9 [Ir(cod)Cl]2[b] 4 5 0 
Reaction conditions: 60a (0.025 mmol), metal precursor (2 mol% for monomers, 1 mol% for dimers), 
JosiPhos J002-2 (2.2 mol%), Et3N (5 equiv.), THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Yield and ee 
determined by chiral GC with dodecane as internal standard. [a] Performed in THF/MeOH (2:1). [b] 
Performed without base in THF/MeOH (2:1).  
Next, a ligand screening was carried out to try to identify a better performing ligand than 
JosiPhos SL-J002-2 (Table 14). Very diverse ligands were selected, such as aryl or alkyl bidentate 
phosphines with different kinds of stereogenic units (stereocenters at carbon and/or phosphorus, 
stereoaxis, stereogenic plane), phosphinooxazolines or even monodentate phosphoramidites. 
Unfortunately no ligand outperformed JosiPhos, being another ferrocene derivative, WalPhos, 
the best among the rest (38% ee, entry 12). Therefore, we decided to explore different JosiPhos 
derivatives available in house to compare other possible electronic or steric effects (Table 15). 
Again, the best performing ligand turned out to be JosiPhos SL-J002-2 (57% yield, 85% ee). 
Replacing its phenyl substituent for 4-methoxy-3,5-dimethylphenyl had minor effects on the 
enantioselectivities (entry 1 vs 4), but when exchanging it for other alkyl or aryl substituents the 
enantiomeric excess decreased dramatically (entries 3, 5 and 6). Much more sensitive to 
variations is the other phosphine of the ligand: replacing the tert-butyl substituents for cyclohexyl 
caused a drop of the enantioselectivity from 85% to 45% ee (entry 1 vs 2). Exchanging it for an 
aromatic ring was even more detrimental for the ee (entry 4 vs 7). 
Increasing the temperature from 50 to 70 °C led to higher yields (74%), but lower 
enantioselectivities (70% ee). Small variations of the substrate concentration did not affect either 
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the yield or the ee, but decreasing the catalyst loading led to lower yields, without affecting the 
enantiomeric excess (36% yield with 1 mol% catalyst and 25% yield with 0.5 mol% catalyst). 
Surprisingly, when the reaction time was decreased from 20 h to 16 h, the enantioselectivity 
increased in expenses of the yield (50% yield, 90% ee), suggesting an erosion of the ee with time.  
Table 14. Screening of ligands. 
 
# Ligand 
yield of 
61a (%) 
ee of  
61a (%) 
yield of  
TH-1 (%) 
1 Josiphos SL-J002-2 57 85 20 
2 (R)-MonoPhos 27 0 18 
3 (S)-Binap 15 -10 26 
4 (S)-Binaphane 50 -10 2 
5 (S)-Segphos 35 -6 19 
6 (R)-DTBM-MeOBiphep 42 2 33 
7 (R)-Phanephos  16 10 45 
8 (S)-SDP 72 14 1 
9 (1R,1′R,2S,2′S)-DuanPhos 25 -12 8 
10 (R,R)-QuinoxP* 57 2 13 
11 MandyPhos SL-M001-1 8 -5 47 
12 WalPhos SL-W008-1 21 38 33 
13 (S,S)-Me-DuPhos 26 0 6 
14 (R)-Phox 55 0 12 
15 (S,S)-Chiraphos 36 2 8 
16 (S)-DTBM-Segphos 63 3 19 
 
 
 
Reaction conditions: 60a (0.025 mmol), Rh(cod)2OTf (2 mol%), ligand (2.2 mol% for bidentate, 4.2 mol% 
for monodentate), Et3N (5 equiv.), THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Yield and ee 
determined by chiral GC with dodecane as internal standard.  
70 Asymmetric hydrogenation of 3-substituted pyridines  
Table 15. Screening of JosiPhos ligands. 
 
# JosiPhos R R’ 
yield of 
61a (%) 
ee of 
 61a (%) 
yield of  
TH-1 (%) 
1 J002-2[a] Ph tBu 57 85 20 
2 J001-1 Ph Cy 23 -45 15 
3 J009-1 Cy tBu 13 -37 15 
4 J013-1 4-MeO-3,5-diMeC6H2 tBu 60 -78 20 
5 J212-1 1-furyl tBu 25 -56 56 
6 J216-1 1-naphthyl tBu 60 -4 9 
7 J425-1 4-MeO-3,5-diMeC6H2 o-tolyl 12 -5 12 
8 J502-1 tBu Ph 21 41 60 
9 J505-1 tBu o-tolyl 97 21 0 
Reaction conditions: 60a (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos ligand (2.2 mol%), Et3N (5 
equiv.), THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Yield and ee determined by chiral GC with 
dodecane as internal standard. [a] JosiPhos SL-J002-2 is the enantiomer of SL-J002-1 
Before exploring the mechanism of the reaction, a substrate scope was performed with a 
variety of functional groups in the 3-position under the optimized conditions. The aim of it was 
to observe if the positive effect of the base was independent of the substituent (Table 16). While 
in absence of base only ee’s up to 40% were obtained, in presence of Et3N the enantioselectivities 
ranged from 32-90% ee. The yield did also increase in most of the cases. The best 
enantioselectivities were obtained with aromatic substituents, 75-90% ee (entries 1 and 4-7), but 
also considerable enantiomeric excesses were obtained with alkyl, esters and protected amines as 
substituents (entries 8-12). The best yields were obtained with electron donating groups, like 
para-methoxyphenyl (52% yield, entry 5). On the contrary, lower yields were obtained in the 
presence of electron withdrawing substituents (entries 4, 9 and 11). 
Gratifyingly, when the reaction was scaled up to 0.5 g, comparable results were obtained 
(entry 3). When the bromide counterion was exchanged for a non-coordinating anion like BArF-, 
the enantiomeric excess dropped from 90% to 50% ee (entry 1 vs 2), thus highlighting one more 
time the importance of the counterion in these systems.16 The best results were obtained with 
substrates bearing aromatic substituents: since the reaction optimization had been carried out 
using a phenyl-substituted model substrate. As it is well-known, every substrate requires a 
dedicate optimization, but as a matter of example, in the initial tests when the reaction was not 
yet optimized (DIPEA as base and 2:1 THF/MeOH as solvent), the hydrogenation of 60h 
afforded the corresponding piperidine with 70% ee, instead of the 50% ee obtained in this 
conditions (entry 10). 
Although this optimized protocol is not directly extrapolable to any kind of substituent in 
the pyridine, it demonstrated that the positive effect of the base is applicable to all of them. 
Moreover, in the cases where the absolute configuration could be determined, it was observed 
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that the substituent was always on the same face of the piperidine ring. These two facts suggest 
that all these substrates are hydrogenated via the same mechanism. 
Table 16. Asymmetric hydrogenation of 3-substituted pyridinium salts in presence 
or absence of base. 
 
# R = 
With Et3N Without Et3N 
yield of 61 (%) ee of 61 (%) yield of 61 (%) ee of 61 (%) 
1 Ph (60a) 50 90 (S) 5 23 (S) 
2 Ph (60a)[a] 66 50 (S) 3 2 (S) 
3 Ph (60a)[b] 57(52)[c] 84 (S)   
4 4-CF3C6H4 (60b) 20 83 (–) 12 14 (–) 
5 2-MeC6H4 (60c) 50 75 (–) 7 30 (–) 
6 4-MeOC6H4 (60d) 52 90 (–) 8 40 (–) 
7 2-naphthyl (60e) 42 86 (–) 21 20 (–) 
8 Me (60f) 36 57 (R) <1% nd 
9 CO2Et (60g) 2 33 3 -17[d] 
10 NHBoc (60h) 24 55 (R) 25 27 (R) 
11 CF3 (60i) 2 41 2 11 
12 nBu (60j) 43 32 (–) <1% nd 
Reaction conditions: 60 (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos J002-2 (2.2 mol%), Et3N (5 
equiv.), THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 16 h. Yield and ee determined by chiral GC with 
dodecane as internal standard. [a] Br- counterion was exchanged for BArF- using AgBArF (silver 
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate). [b] Reaction performed on 500 mg scale (1.53 mmol) for 
20 h. [c] In parenthesis, isolated yield. [d] The opposite enantiomer was obtained. 
As already done with 2-substituted pyridines (Chapter II), a mechanistic study was initiated 
monitoring the reaction over time (Figure 10). More than 90% of the pyridinium salt 60a was 
consumed within the first 4 hours. Simultaneously, the piperidine 61a was formed along with 
several N-benzylated tetrahydropyridines. Nevertheless, it should be noted that the sum of the 
products does not make up for the consumed starting material, suggesting that other 
intermediates or decomposition products are not observed by GC.  
TH-1 was formed at high rates during the first 3 hours of reaction an then its amount 
decreased very slowly. This side-product of the reaction could be isolated and fully characterized 
despite the reported instability of similar enamines.59 TH-2 was formed in very small amounts 
(less than 3%) and remained more or less constant during the course of the reaction. It was also 
identified as a tetrahydropyridine and was isolated at the end of the reaction. An alternative way 
to prepare this intermediate consists on reacting the pyridinium salt with an excess of NaBH4 in 
MeOH. A third compound, which is formed in appreciable amounts during the first 5 hours of 
reaction and then consumed during the next 10 hours, was also observed. This intermediate was 
identified also as an N-benzylated tetrahydropyridine by GC-MS (m/z = 249). Although it was 
not possible to isolate or synthesize by other methods, when injected in a chiral GC it split in two 
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peaks, suggesting that it contains a stereocenter and therefore it should correspond either to TH-
3 or TH-4. Furthermore, this tetrahydropyridine showed a very high and constant enantiomeric 
excess (93% ee) during all the reaction. Remarkably, the enantiomeric excess of piperidine 61a 
suffered important variations during the reaction course. It increased sharply during the first 10 
hours of reaction and then it slowly decreased.  
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Figure 10. Monitoring the reaction over time. Reaction conditions: 60a (1.53 mmol), Rh(cod)2OTf (2 
mol%), JosiPhos J002-2 (2.2 mol%), Et3N (5 equiv.), THF/TFE (2:1, 27 mL), 50 °C, 50 bar H2. 
Consumption of 60a determined by NMR with dimethyl terephthalate as internal standard. Yield and ee of 
61a and the different tetrahydropyridines monitored by chiral GC with dodecane as internal standard.  
While monitoring the disappearance of the starting material by NMR, it was noted that 
exactly one equivalent of triethylammonium salt was formed after the complete consumption of 
60a (Figure 11). This is in agreement with the postulated idea that the added base would quench 
the generated HBr.  
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Figure 11. Comparison between the consumption rate of 60a and the formation rate of triethylammonium.  
To gain more information about the reaction intermediates, especially of some possible 
dihydropyridines, a parallel reaction was monitored by in situ FTIR spectroscopy. To do so, an 
ATR Diamond probe inserted into the autoclave was used and a chromatogram was recorded 
every minute during a 22 h reaction. All the acquired chromatograms were analyzed by a software 
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performing multivariate data analysis, which consists in: (i) determining the absorbance variation 
at every wavelength; (ii) grouping all the wavelengths that increase or decrease simultaneously 
(which can correspond to a single compound or a linear combination of compounds); (iii) 
plotting the variation of each of these groups with the reaction time. To be able to detect 
variations in the IR spectra, the concentration of the substrate had to be increased 24 times (from 
0.017 M to 0.41 M), which affected the ratio of the different intermediates at the end of the 
reaction (Scheme 60). 
 
Scheme 60. Ratio of products at the end of the reaction with the optimized conditions (0.017 M) and with 
the concentration used for the in situ FTIR experiment (0.41 M). 
The superimposition of all the spectra acquired during the reaction can be seen in Figure 
12A. Although initially it seems difficult to determine the variations, when plotting the variation 
of some selected wavelengths with time, the picture becomes more clear (Figure 12B). Some 
wavelengths, such as 727 (maroon) and 762 cm-1 (purple), sharply decrease during the first hour. 
Others increase and then decrease, with a maximum at three hours, like 1032 (dark blue), 848 
(orange) and 803 cm-1 (yellow). The observed noise suggests that the technique is not sensitive 
enough for the concentration used, but when trying to perform the reaction at higher 
concentrations the obtained results were not comparable, probably because in those cases Et3N 
becomes the main solvent. An added difficulty for the IR interpretation can be attributed to the 
similarity of the spectra of the different tetrahydropyridines and final piperidine.  
 
Figure 12. A) Superimposed spectra recorded during 22 hours of reaction. B) Variation of the absorbance 
with time of selected wavelengths.  
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Analyzing all wavelength variations, the software is able to show the spectra of different 
compounds or linear combination of compounds (named from I-IV, Figure 13A and B). The first 
three (I - purple, II - yellow and III - orange) could be intermediates of the reaction, which we 
were not able to assign. However, it was impossible to assign them to a specific dihydropyridine 
without having a reference. With respect to IV (blue), it disappears during the first hour and it is 
not further observed. Initially, it was thought that this plot corresponded to the disappearance of 
60a, but comparing the graph with the experimental IR spectra (Figure 13A.IV vs 60a in Figure 
13C), it can be seen that it is not exactly the same. Actually, IV corresponds to the simultaneous 
disappearance of 60a and triethylamine, which forms triethylammonium bromide. 
 
Figure 13. A) Generated IR spectra of different compounds or group of compounds identified by the 
software during the first 9 h. B) Evolution of these species with time. C) Experimental IR spectra of 60a, 
Et3N and 60a + Et3N (all measured in THF/TFE).  
Thus, despite not being able to identify any dihydropyridine intermediate due to the 
complexity of the system, we were able to find more evidences proving the fast disappearance of 
60a with concomitant formation of ammonium salts.  
Identifying all these tetrahydropyridines and their evolution with time gave us a good 
perspective of what was going on, but it was still not clear which one of them was leading to the 
highly enantioenriched piperidine 61a. Since two of them could be isolated (TH-1 and TH-2), 
they were submitted to the optimized hydrogenation conditions. 
  Part A – Chapter III 75 
Under the exact conditions used to perform the hydrogenation of 60a (Table 17, entry 1), 
only 7% of TH-1 was converted into the racemic piperidine 61a. Increasing the acidity of the 
system (entries 2 and 3) also increased the conversion, but the hydrogenation always took place 
in a non-enantioselective way. This is in agreement with the proposed mechanism for this kind of 
enamines which, by catching a H+ from the medium, tautomerize to the iminium form and then 
are hydrogenated: since the tautomerization is not enantioselective, 61a is obtained as racemate. 
Table 17. Hydrogenation of TH-1 with different additives. 
 
# Additive 
Remaining 
TH-1 (%) 
yield of 
61a (%) 
ee of  
61a (%) 
1 Et3N [5 equiv.] 93 7 0 
2 - 57 43 0 
3 Et3N·HCl [5 equiv.] 12 88 0 
Reaction conditions: TH-1 (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos J002-2 (2.2 mol%), additive, 
THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Conversion and ee determined by chiral GC. 
Similar experiments were performed with TH-2 and, surprisingly, it was found that it could 
isomerize to TH-1 under the reaction conditions (Table 18). Actually, Rh-diphosphine 
complexes are known to promote allylamine-enamine isomerizations.72 Different amounts of base 
were tested (entries 1-3), even in the presence of pyridinium salt 60f to try to reproduce the 
reaction conditions (entry 4). Again, the more acidic the media, the higher was the conversion. 
The fact that 61a was obtained with some enantiomeric excess proves that TH-2 can be 
enantioselectively hydrogenated, without the need to isomerize to TH-1. Unfortunately, the 
obtained ee’s are far from those obtained in the direct hydrogenation of 60a.  
Table 18. Hydrogenation of TH-2 with different additives. 
 
# Additive 
Remaining 
TH-2 (%) 
yield of 
61a (%) 
ee of  
61a (%) 
yield of  
TH-1 (%) 
1 Et3N [5 equiv.] 80 7 15 13 
2 Et3N [5 equiv.]+ Et3N·HCl [5 equiv.] 53 17 21 30 
3 - 21 74 27 6 
4 60f [4 equiv.] + Et3N [20 equiv.] 78 9 31 13 
Reaction conditions: TH-2 (0.025 mmol), Rh(cod)2OTf (2 mol%), JosiPhos J002-2 (2.2 mol%), additive, 
THF/TFE (2:1, 1.5 mL), 50 °C, 50 bar H2, 20 h. Conversion and ee determined by chiral GC. 
The latter two experiments strongly indicate that neither TH-1 nor TH-2 are the 
intermediates leading to the highly enantioselective formation of 61a. Since those were the only 
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prochiral tetrahydropyridines, the enantioselective hydrogenation must occur on a 
dihydropyridine intermediate which leads to the unidentified tetrahydropyridine (TH-3 or TH-
4), whose ee had been found to be very high (see the monitoring of the reaction over time, Figure 
10). 
The plausible pathways for the hydrogenation of 60a to 61a are shown in Scheme 61. The 
first hydride addition could take place in any of the most electrophilic positions (C2, C4 and C6), 
to afford dihydropyridines DH-1, DH-2 and DH-3, respectively. Unfortunately, these 
dihydropyridines are not observed experimentally. Their enantioselective hydrogenation to 
afford TH-3 or TH-4 might go through the reduction of an enamine double bond (DH-3 → TH-
4 or DH-2 → TH-3) or by reduction of the C3-C4 double bond (DH-1 → TH-3). 
 
Scheme 61. Plausible pathways for the hydrogenation of 60a to 61a. 
To ascertain which of these pathways was occurring, an isotopic labeling experiment using 
D2 instead of H2 was performed. The deuteration pattern of 61a was not easy to determine, since 
all hydrogen atoms in the piperidine ring are diastereotopic. To be able to ascertain the extent of 
deuterium incorporation in all positions it was necessary to record the 1H NMR in three different 
solvents (CDCl3 – Figure 14, CD3OD – Figure 15 and toluene-d8 – Figure 16). In each of these 
solvents, different protons were separated from the rest, allowing for an accurate integration. 
Assignment of the chemical shift of each proton was done by multidimensional NMR 
analysis. Geminal protons were differentiated based on the anisotropy cone of C-C single bonds 
described in Chapter II.  
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Figure 14. 1H-NMR of 61a and deuterated 61a in CDCl3. 
 
 
Figure 15. 1H-NMR of 61a and deuterated 61a in CD3OD. 
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Figure 16. 1H-NMR of 61a and deuterated 61a in toluene-d8. 
Simple systems of equations with the integrals in the different solvents allowed for the 
calculation of the integral of overlapping signals in the deuterated sample: 
 CDCl3:   H2b + H6b + H3 = 1.30 
 CD3OD: H2b + H6b = 1.23  H3 = 0.06 
 Tol-d8:  H6b + H3 = 0.77  H2b = 0.51 H6b = 0.72 
 CDCl3:   H2a + H6a + H4b = 0.89 
 CD3OD: H2a + H6a = 0.84  H4b = 0.06 
 Tol-d8:  H6a + H4b = 0.26  H2a = 0.64 H6a = 0.20 
 CDCl3:   H5 + H5’ = 1.89 
 CD3OD: H5 + H5’ = 1.86   
 To-d8l:  H5 = 0.93  H5’ = 0.95 H4a = 0.86  
A summary of the chemical shifts of each proton in the different solvents can be found in 
Table 19, together with the integrals of the deuterated 61a. 
As expected, the deuteration pattern 61a turned out to be quite complex. It has to be 
considered that different pathways might be taking place simultaneously leading to a final linear 
combination of different deuteration distributions. Despite this complexity, the analysis of the 
deuteration pattern provided some useful information. First and most important, two syn-
arranged atoms of deuterium are incorporated at C3 and C4. According to the postulated 
pathways (Scheme 61), this can only originate from the hydrogenation of TH-2 → 2a or DH-1 → 
TH-3. Since we have already shown that the hydrogenation TH-2 is poorly enantioselective, the 
only reasonable pathway is a highly enantioselective hydrogenation of DH-1. This means that the 
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unidentified tetrahydropyridine is in fact TH-3. Second, the total number of deuterium atoms 
incorporated in 61a is four and not five, as it might have been expected if all protons were coming 
from hydrogen gas. This implies that one hydrogen from the solvent is also incorporated 
(probably at C5, which is the least deuterated position). This incorporation might arise from the 
tautomerization of enamine TH-3 to the corresponding iminium, prior to hydrogenation. 
Table 19. Chemical shift of each proton in different solvents and NMR integrals of the deuterated 61a. 
 
 
 
 
 
 
Third, it should be carefully analyzed the deuteration patterns in the two positions where the 
hydride addition is taking place, C2 and C6. While the deuterium incorporation in the two 
diastereotopic positions of C2 is quite similar (49% and 36%), in C6 that difference is much more 
remarkable (80% for the pro-S hydrogen and 28% for the pro-R). A possible explanation for it 
might be that, since the hydride addition to C2 takes places before the stereocenter is formed 
(60a → DH-1) it is only influenced by the chiral catalyst. Instead, when the hydride addition to 
C6 takes place the stereocenter is already formed (TH-3 → 61a), hence there is a remarkable 
substrate control also operating. Accordingly, the higher deuteration of the pro-S hydrogen in C6 
can be explained by the Fürst-Plattner rule (also known as the trans-diaxial effect),73 which 
predicts the stereoselective addition of nucleophiles to cyclohexenes (or similar) based on the 
stability of the transition state, i.e. a chair-like transition state will be more favored than the twist-
boat one. In our specific case, a chair-like transition state is involved when the deuterium addition 
takes place from the phenyl substituent side.  
 
Scheme 62. Fürst-Plattner effect governing the hydride addition to iminium TH-3’. 
Taking into account all this data regarding the pathway leading to 61a, a mechanism to 
explain the observed deuteration pattern was proposed (Scheme 63). The first hydride addition 
would take place in the C2 position leading to DH-1. The enantioselective hydrogenation of the 
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C3=C4 bond affords TH-3, which by catching a proton from the medium isomerizes to the 
iminium form TH-3’. In the last step, a hydride addition governed by the Fürst-Plattner effect 
furnishes piperidine 61a. 
 
Scheme 63. Proposed mechanism leading to the observed deuteration pattern in 61a. 
As previously discussed, the achievement of high enantioselectivities generally requires a 
secondary coordinating unit. A clear example of this is the Rh-catalyzed AH of enamides, where 
the carbonyl group chelates the rhodium center leading to an improved stereocontrol (Figure 
17A).74 In our case, the distance between the double bond that has to be enantioselectively 
hydrogenated and the nitrogen atom (the only possible coordinating group) is optimal for the 
formation of a 5-memebered ring intermediate after the first hydride addition (Figure 17B). The 
release of Rh from complex 62 might take place via protonation of C4 through a σ-bond 
metathesis with H2 or via an oxidative addition-reductive elimination sequence.  
 
Figure 17. A) Secondary coordination on the Rh-catalyzed enantioselective hydrogenation of enamides. B) 
Proposed secondary coordination for the enantioselective hydrogenation of dihydropyiridine DH-1. 
In the isotopic labeling experiment with D2, deuterated TH-1 and TH-2† were also isolated 
and analyzed (see III.3 Experimental section for the NMR spectra). In the case of TH-1 (Table 
20), the more deuterated positions are C4, C5 and C6. According to it, the postulated pathway 
for the formation of TH-1[d3] would proceed via an initial hydride addition to C6 to afford 
dihydropyridine DH-3, and subsequent C4-C5 double bond hydrogenation (Scheme 64A). 
Table 20. Chemical shift of each proton and NMR integrals of the deuterated TH-1. 
 
 
 
 
                                                                
† For clarity, the carbon numbering on the tetrahydropyridines follows the same numbering than the final piperidine 61a and not 
the IUPAC rules. 
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However, the theoretical deuteration shown in TH-1[d3] (Scheme 64) does not perfectly 
correlates with the observed deuteration in Table 20. On the one hand, the unexpected 
deuteration at C2 might be explained by H/D scrambling between C2 and C4 due to a Rh-
catalyzed allylamine-enamine isomerization.72 Indeed, the sum of deuterium at C2 and C4 is 
equal to one (0.73 + 0.27). On the other hand, the rather low deuteration at the C5 position 
(0.69 instead of 1) could also be explained by the same mechanism. The isomerization of TH-
2[d2], whose C4 position is not deuterated (vide infra), could afford TH-1[d2], which is also 
devoid of deuterium at C4 (Scheme 64B). Thus, a linear combination of TH-1[d3] and TH-
1[d2] would make up for the observed deuteration at C4. 
 
Scheme 64. A) Postulated formation of TH-1[d3] from 60a. B) Postulated formation of TH-1[d2] from 
TH-2[d2]. 
In the case of TH-2 the most deuterated positions were C2 and C6 (Table 21). An initial 
hydride addition to C2 would afford DH-1 that, after tautomerization to the iminium form (no 
deuteration in C5), would be reduced to TH-2[d2] (Scheme 65A).  
Table 21. Chemical shift of each proton and NMR integrals of the deuterated TH-2. 
 
 
 
 
Similarly to what was observed for TH-1, there is an unexpected deuteration in C4, 
ascribable to the allylamine-enamine isomerization, and a small amount of deuteration in C5 
which might arise from the isomerization of TH-1[d3] to TH-2[d3] (Scheme 65B).  
 
Scheme 65. A) Postulated formation of TH-2[d2] from 60a. B) Postulated formation of TH-2[d3] from 
TH-1[d3]. 
On the basis of this detailed study, a mechanism involving all different pathways investigated 
was proposed (Scheme 66). An initial hydride addition to C2 or C6 would afford 
dihydropyridines DH-1 or DH-3, respectively. An enantioselective hydrogenation of the C3-C4 
double bond in DH-1 would lead to the highly enantioenriched tetrahydropyridine TH-3, which 
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would be relatively fast hydrogenated to 61a via the corresponding iminium intermediate. 
Instead, the tautomerization of DH-1 to the more activated iminium form would trigger a fast 
hydrogenation to tetrahydropyridine TH-2. The latter can either undergo a Rh-catalyzed 
allylamine-enamine isomerization or be very slowly hydrogenated to 61a with a very low 
enantioselectivity. Simultaneously, the hydrogenation of the C4-C5 double bond of DH-3 
affords tetrahydropyridine TH-1, which can also undergo a Rh-catalyzed isomerization to TH-2 
or be non-enantioselectively hydrogenated to 61a. The proposed mechanism does not exclude 
other transformations or intermediates that might be involved in the process. 
 
Scheme 66. Proposed pathways involved in the AH of 60a to 61a. All represented steps involve Rh species. 
III.3 CONCLUSIONS 
To conclude, the first highly enantioselective hydrogenation of 3-substituted pyridines has 
been successfully developed. The addition of a simple base, like Et3N, remarkably improved the 
obtained yields and enantioselectivities with a Rh-Josiphos catalyst. Furthermore, an exhaustive 
mechanistic study shed some light on the main pathways governing the complex reaction 
network involved in the AH of these pyridinium salts. As initially postulated, the addition of a 
base retarded the enamine-iminium tautomerization on TH-1. However, the high 
enantioselectivities obtained did not arise from the enamine hydrogenation, but from an 
alternative pathway involving the AH of the dihydropyridine intermediate DH-1. The enamine 
intermediate TH-1 resulted to be a side-product of the reaction that, under non-basic conditions, 
is readily hydrogenated to the final piperidine in a non-enantioselective fashion, thus eroding the 
final enantiomeric excess.  
Although these results are still far from being amenable to industrial application, we hope 
that the better understanding of the system and its mechanism will contribute to the rational 
design of more efficient catalyst for the AH of 3-substituted pyridines.  
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III.4 EXPERIMENTAL SECTION 
Dry DCM and THF were obtained using an MBraun SPS system. Dry MeOH, EtOH, 
iPrOH and toluene (over molecular sieves in bottles with crown cap) were purchased from Sigma 
Aldrich and stored under nitrogen. 2,2,2-trifluoroethanol (TFE) was dried over molecular sieves. 
Commercially available reagents (from TCI Chemicals, ACROS, Sigma Aldrich, Strem) were 
used as received, without any further purification.  
Flash column chromatography was performed using Grace Reveleris® X2 Flash 
Chromatography System (silica gel cartridges with particle size 40 μm). Gas chromatography was 
performed on an Agilent Technologies 7890A and Hewlett Packard 6890 instruments, equipped 
with a flame ionization detector, using respectively a chiral and an achiral capillary column. 
HPLC analysis were performed using a Waters HPLC with a dual λ absorbance detector working 
at 210 and 254 nm.  
1H-NMR spectra were recorded using two different spectrometers operating at 400 or 500 
MHz. Proton chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard (CDCl3 δ = 7.26 ppm; CD2Cl2 δ = 
5.32 ppm, CD3OD δ = 3.31 ppm, toluene-d8 δ = 7.09, 7.01, 6.97 and 2.08). 13C-NMR spectra 
were recorded on a 400 MHz spectrometer operating at 101 MHz, with complete proton 
decoupling. Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective 
solvent resonance as the internal standard (CDCl3, δ = 77.16 ppm, CD2Cl2 δ = 53.84 ppm, 
CD3OD δ = 49.00 ppm). 19F-NMR spectra were recorded on a 300 MHz spectrometer operating 
at 282 MHz, with complete proton decoupling. Fluorine chemical shifts are reported in ppm (δ) 
relative to external CFCl3 at 0 ppm (positive values downfield). The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
dd = doublet-doublet, ddd = doublet-doublet-doublet, dt = doublet-triplet. Coupling constant 
values are given in Hz. 
Optical rotation signs were determined on an automatic polarimeter with a 1 dm cell at the 
sodium D line (λ = 589 nm). High resolution mass spectra (HRMS) were performed on a 
Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass 
software (Bruker Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI source. Infrared 
spectra were recorded on a standard FT/IR spectrometer. In situ FTIR spectroscopy was 
performed with a Mettler Toledo ReactIRTM 15 system connected with optical fibers to an ATR 
Diamond probe inserted in the reactor. Multivariance data analysis was performed with iC IR 
Software (Mettler Toledo). 
General procedure for the synthesis of 3-arylpyridines 
A mixture of 3-bromopyridine (1 ml, 9.9 mmol), the boronic acid (14.9 mmol, 1.5 equiv.), 
Pd(OAc)2 (22 mg, 0.1 mmol), K3PO4 (4.2 g, 19.8 mmol) and 75 mL of ethylene glycol were 
stirred at 80 °C for 5 h. Once the reaction was completed, the reaction mixture was poured into 
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150 mL of brine and extracted with 150 mL of Et2O. NaOH (7.5 g) was added to the ethereal 
phase and the mixture was stirred for 15 min. Then it was poured into 150 mL of brine, the 
ethereal phase was again separated and stirred in the presence of NaOH (7.5 g). After 15 min 
more, the mixture was poured one last time into 150 mL of brine and the ethereal phase was 
separated, dried over Na2SO4, filtered and concentrated several times in the presence of MeOH. 
The obtained 3-arylpyridine was used in the next step without any further purification. 
 
General procedure for the benzylation of pyridines  
Pyridinium salts 60 were prepared according to known literature methods.16,60 A mixture of 
3-substituted pyridine (6.5 mmol), benzyl bromide (7.7 mmol, 1.2 equiv.) and 2.5 mL acetone 
were stirred under reflux temperature for 18-48h. If the product precipitated, it was filtered, 
washed several times with acetone and dried under high vacuum. If the product did not 
precipitate, the solvent was removed and the resulting sticky oil was recrystallized from 
MeOH/AcOEt (9:1). If the desired product could not be recrystallized, it was purified from the 
reaction mixture by column chromatography on silica gel using CH2Cl2/MeOH (30:1) to give 
the desire products (25-95%). 
 
N-Benzyl-3-phenylpyridinium bromide (60a): White solid; m.p. = 91 °C; 1H 
NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 9.24 (d, 3J(H,H) = 6.0 Hz, 1H), 8.52 (d, 
3J(H,H) = 8.0 Hz, 1H), 8.06 (dd, 3J(H,H) = 8.0 Hz, 3J(H,H) = 6.0 Hz, 1H), 7.78 
(m, 2H), 7.63 (m, 2H), 7.59 – 7.46 (m, 3H), 7.46 – 7.38 (m, 3H), 6.27 (s, 2H); 13C 
NMR (101 MHz, CDCl3) δ 142.9, 142.9, 142.5, 141.3, 133.4, 132.7, 130.6, 129.9, 129.9, 129.8, 
129.6, 128.4, 127.8, 64.0; IR (film): ν = 3053.7, 2924.5, 1629.6, 1488.8, 1456.0, 1431.9, 1155.2 
cm-1; HRMS (ESI+): m/z 246.12790 [M]+ (calcd. for C18H16N1: 246.12773). 
N-Benzyl-3-(4-(trifluoromethyl)phenyl)pyridinium bromide (60b): White 
solid; m.p. = 170 °C; 1H NMR (400 MHz, CD3OD) δ 9.59 (s, 1H), 9.07 (d, 
3J(H,H) = 6.1 Hz, 1H), 8.95 (d, 3J(H,H) = 8.2 Hz, 1H), 8.22 (dd, 3J(H,H) = 8.2 
Hz, 3J(H,H) = 6.1 Hz, 1H), 8.06 (d, 3J(H,H) = 8.2 Hz, 2H), 7.92 (d, 3J(H,H) = 
8.2 Hz, 2H), 7.63 – 7.57 (m, 2H), 7.53 – 7.45 (m, 3H), 5.98 (s, 2H); 13C NMR (101 MHz, 
CD3OD) δ 145.3, 144.7, 144.5, 141.4, 138.4, 134.6, 133.1 (q, 2J(C,F) = 32.9 Hz), 131.1, 130.7, 
130.3, 129.9, 129.7, 127.5 (q, 3J(C,F) = 3.8 Hz), 124.0 (q, 1J(C,F) = 271.8 Hz), 65.9; 19F NMR 
(282 MHz, CD3OD) δ -64.7; IR (film): ν = 3042.2, 2956.3, 1629.6, 1497.5, 1456.0, 1406.8, 
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1326.8, 1170.6, 1123.3, 1075.1 cm-1; HRMS (ESI+): m/z 314.11468 [M]+ (calcd. for 
C19H15N1F3: 314.11511). 
N-Benzyl-3-(2-tolyl)pyridinium bromide (60c): White solid; m.p. = 151 °C; 1H 
NMR (400 MHz, CD3OD) δ 9.20 (t, 4J(H,H) = 1.7 Hz, 1H), 9.11 (dt, 3J(H,H) = 
6.1 Hz, 4J(H,H) = 1.3 Hz, 1H), 8.62 (ddd, 3J(H,H) = 8.0 Hz, 4J(H,H) = 1.8 Hz, 
4J(H,H) = 1.2 Hz, 1H), 8.20 (dd, 3J(H,H) = 7.8 Hz, 3J(H,H) = 6.3 Hz, 1H), 7.65 – 
7.58 (m, 2H), 7.53 – 7.35 (m, 7H), 5.97 (s, 2H), 2.28 (s, 3H); 13C NMR (101 MHz, CD3OD) δ 
147.5, 145.6, 144.1, 143.8, 137.0, 135.1, 134.8, 132.2, 131.2, 131.1, 131.1, 130.7, 130.2, 129.4, 
127.9, 65.8, 20.2; IR (film): ν = 3023.8, 2949.6, 1626.7, 1485.9, 1456.0, 1273.8, 1153.2 cm-1; 
HRMS (ESI+): m/z 260.14385 [M]+ (calcd. for C19H18N1: 260.14338). 
N-Benzyl-3-(4-methoxyphenyl)pyridinium bromide (60d): Yellowish 
solid; m.p. = 178 °C; 1H NMR (400 MHz, CD3OD) δ 9.46 (t, 4J(H,H) = 1.5 
Hz, 1H), 8.92 (dt, 3J(H,H) = 6.1 Hz, 4J(H,H) = 1.1 Hz, 1H), 8.80 (ddd, 
3J(H,H) = 8.2 Hz, 4J(H,H) = 1.9 Hz, 4J(H,H) = 1.1 Hz, 1H), 8.11 (dd, 3J(H,H) 
= 8.1 Hz, 3J(H,H) = 6.1 Hz, 1H), 7.84 – 7.79 (m, 2H), 7.63 – 7.58 (m, 2H), 7.50 – 7.43 (m, 3H), 
7.14 – 7.09 (m, 2H), 5.96 (s, 2H), 3.86 (s, 3H); 13C NMR (101 MHz, CD3OD) δ 163.2, 143.7, 
143.2, 142.9, 142.7, 134.8, 131.0, 130.7, 130.2, 130.1, 129.6, 126.5, 116.2, 65.7, 56.1; IR (film): ν 
= 3034.4, 2959.2, 2839.7, 1607.4, 1496.5, 1456.0, 1305.6, 1291.11, 1257.4, 1185.0, 1029.8, 
1017.3 cm-1; HRMS (ESI+): m/z 276.13858 [M]+ (calcd. for C19H18N1O1: 276.13829). 
N-Benzyl-3-(naphthalen-2-yl)pyridinium bromide (60e): White solid; m.p. 
= 207 °C; 1H NMR (400 MHz, CDCl3) δ 9.73 (s, 1H), 9.10 (d, 3J(H,H) = 5.8 
Hz, 1H), 8.61 (d, 3J(H,H) = 8.1 Hz, 1H), 8.38 (s, 1H), 8.05 – 8.00 (m, 2H), 
7.98 (d, 3J(H,H) = 8.8 Hz, 1H), 7.87 – 7.79 (m, 2H), 7.63 (m, 2H), 7.60 – 7.52 
(m, 2H), 7.45 – 7.38 (m, 3H), 6.26 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 143.0, 142.3, 142.2, 
141.0, 133.8, 133.4, 129.9, 129.8, 129.7, 129.6, 129.5, 129.2, 128.2, 128.1, 127.9, 127.7, 127.2, 
124.0, 64.0; IR (film): ν = 3035.4, 2949.6, 1626.7, 1501.3, 1456.0, 1155.2 cm-1; HRMS (ESI+): 
m/z 296.14378 [M]+ (calcd. for C22H18N1: 296.14338). 
N-Benzyl-3-methylpyridinium bromide (60f) 
Known compound. Spectroscopic data are superimposable to those reported in the 
literature.75 
N-Benzyl-3-(ethoxycarbonyl)pyridinium bromide (60g) 
Known compound. Spectroscopic data are superimposable to those reported in the 
literature.76 
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N-Benzyl-3-((tert-butoxycarbonyl)amino)pyridinium bromide (60h): White 
solid; m.p. = 186 °C; 1H NMR (400 MHz, CD3OD) δ 9.31 (s, 1H), 8.68 (d, 
3J(H,H) = 5.6 Hz, 1H), 8.33 (d, 3J(H,H) = 8.7 Hz, 1H), 7.97 (dd, 3J(H,H) = 8.6 Hz, 
3J(H,H) = 6.0 Hz, 1H), 7.56 – 7.43 (m, 5H), 5.82 (s, 2H), 1.53 (s, 9H); 13C NMR (101 MHz, 
CD3OD) δ 153.9, 142.5, 139.0, 134.6, 134.4, 134.3, 131.0, 130.7, 130.2, 129.4, 83.2, 66.2, 28.4; 
IR (film): ν = 3093.3, 2980.5, 1725.0, 1630.5, 1551.5, 1507.1, 1248.7, 1156.1 cm-1; HRMS 
(ESI+): m/z 285.16038 [M]+ (calcd. for C17H21N2O2: 285.15975). 
N-Benzyl-3-(trifluoromethyl)pyridinium bromide (60i): White solid; m.p. = 151 
°C; 1H NMR (400 MHz, CD3OD) δ 9.83 (s, 1H), 9.44 (d, 3J(H,H) = 6.2 Hz, 1H), 
9.05 (d, 3J(H,H) = 8.2 Hz, 1H), 8.43 (dd, 3J(H,H) = 7.6 Hz, 3J(H,H) = 6.8 Hz, 1H), 
7.74 – 7.65 (m, 2H), 7.54 – 7.43 (m, 3H), 6.13 (s, 2H); 13C NMR (101 MHz, CD3OD) δ 149.5, 
144.5 (q, 3J(C,F) = 3.3 Hz), 144.3, 133.8, 132.0 (q, 2J(C,F) = 36.4 Hz), 131.3, 130.8, 130.7, 
130.7, 122.8 (q, 1J(C,F) = 273.1 Hz), 66.3; 19F NMR (282 MHz, CD3OD) δ -64.4; IR (film): ν = 
3037.3, 2997.8, 2943.8, 1642.1, 1476.2, 1335.5, 1188.9, 1146.5, 1098.3 cm-1; HRMS (ESI+): m/z 
238.08431 [M]+ (calcd. for C13H11N1F3: 238.08381). 
N-Benzyl-3-butylpyridinium bromide (60j): Colorless and viscous oil; 1H 
NMR (400 MHz, CDCl3) δ 9.47 (s, 3J(H,H) = 11.2 Hz, 1H), 9.42 (d, 3J(H,H) = 
6.1 Hz, 1H), 8.15 (d, 3J(H,H) = 8.0 Hz, 1H), 7.92 (dd, 3J(H,H) = 7.9 Hz, 3J(H,H) 
= 6.2 Hz, 1H), 7.77 – 7.64 (m, 2H), 7.37 – 7.28 (m, 3H), 6.26 (s, 2H), 2.81 (d, 3J(H,H) = 15.8 
Hz, 2H), 1.62 (m, 2H), 1.31 (m, 2H), 0.87 (t, 3J(H,H) = 7.3 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 144.9, 144.4, 144.3, 142.5, 133.3, 129.9, 129.7, 129.6, 127.9, 63.8, 32.5, 32.3, 22.1, 
13.7.; IR (film): ν = 3031.6, 2957.3, 2930.3, 2869.6, 1629.6, 1498.4, 1456.0, 1205.3, 1149.4 cm-1; 
HRMS (ESI+): m/z 226.15875 [M]+ (calcd. for C16H20N1: 226.15903). 
General procedure for the asymmetric hydrogenation of pyridinium salts 
 
Inside a glovebox, Rh(cod)2OTf (0.23 mg, 2 mol%) and JosiPhos J002-2 (0.30 mg, 2.2 
mol%) were stirred for 1 h at 40 °C in 0.5 mL of THF. The solution was then transferred into a 
vial containing a mixture of 1 (0.025 mmol), Et3N (17.4 μL, 0.125 mmol, 5 equiv.) and dodecane 
(10 mg) in a solution of THF: TFE (1:1, 1 mL). The vial was capped and placed into a Premex 
96er Multireaktor®. After flushing it 5 times with N2 and 5 times with H2, it was pressurized to 50 
bar of H2 and stirred at 50 °C for 16 h. The yield and ee of the reaction were determined by GC or 
HPLC using dodecane as internal standard. 
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(S)-(–)-N-Benzyl-3-phenylpiperidine (2a): 1H NMR (400 MHz, CDCl3) δ 7.41 
– 7.18 (m, 10H), 3.59 (s, 2H), 3.05 (m, 1H), 3.01 – 2.86 (m, 2H), 2.14 – 2.00 (m, 
2H), 2.00 – 1.92 (m, 1H), 1.83 – 1.73 (m, 2H), 1.48 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 145.0, 138.4, 129.4, 128.5, 128.3, 127.4, 127.1, 126.4, 63.7, 61.2, 53.9, 
43.0, 31.8, 25.9.; IR (film): ν = 3026.7, 2931.3, 2796.3, 1661.37, 1600.6, 1493.6, 1452.1, 756.0 
cm-1; HRMS (ESI+): m/z 252.17515 [M+H]+ (calcd. for C18H22N1: 252.17468). Yield and 
enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 150 °C for 8 min., 5 °C/min., 170 °C for 60 min.: tR = 
23.6 min., tS = 24.0 min. Absolute configuration assigned by comparison of the sign of the optical 
rotation with literature data.77 
N-Benzyl-5-phenyl-1,2,3,4-tetrahydropyridine (TH-1): 1H NMR (400 MHz, 
CDCl3) δ 7.41 – 7.25 (m, 9H), 7.07 (m, 1H), 6.75 (s, 1H), 4.19 (s, 2H), 3.00 (t, 
3J(H,H) = 5.4 Hz, 2H), 2.45 (t, 3J(H,H) = 6.3 Hz, 2H), 2.02 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 141.9, 138.6, 134.2, 128.6, 128.4, 128.0, 127.4, 123.8, 122.5, 
106.2, 59.9, 46.4, 23.3, 22.6; IR (film): ν = 3026.7, 2924.5, 2838.7, 1673.9, 1631.5, 1593.9, 
1493.6, 1450.2, 1360.5, 1175.4 cm-1; HRMS (ESI+): m/z 250.15924 [M+H]+ (calcd. for 
C18H20N1: 250.15903). Yield determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); 
carrier: helium; gas flow: 2.7 bar; oven temperature: 150 °C for 8 min., 5 °C/min., 170 °C for 60 
min.: t = 46.8 min.  
TH-1 slowly decomposes to unknown products, even when stored at -20 °C.  
N-Benzyl-5-phenyl-1,2,3,6-tetrahydropyridine (TH-2): 1H NMR (400 MHz, 
CDCl3) δ 7.44 – 7.18 (m, 10H), 6.12 (m, 1H), 3.71 (s, 2H), 3.37 (dd, 3J(H,H) = 4.3 
Hz, 3J(H,H) = 2.4 Hz, 2H), 2.63 (t, 3J(H,H) = 5.7 Hz, 2H), 2.34 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 140.4, 138.4, 135.5, 129.3, 128.4, 127.2, 127.1, 125.1, 122.7, 
63.0, 54.9, 49.3, 26.6; IR (film): ν = 3026.7, 2908.1, 2799.2, 1947.8, 1868.7, 1807.9, 1741.4, 
1599.7, 1493.6, 1453.1, 1122.4, 1047.2, 853.3 cm-1; HRMS (ESI+): m/z 250.15943 [M+H]+ 
(calcd. for C18H20N1: 250.15903). Yield determined by GC: CP-Chirasil-Dex CB (25m x 
0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 150 °C for 8 min., 5 
°C/min., 170 °C for 60 min.: t = 32.2 min.  
TH-2 could be independently prepared by the following method: NaBH4 (2.5 mmol) was added 
to a solution of 60a (326 mg, 1 mmol) in EtOH (5 mL) and stirred for 18 h at 50 °C. The 
reaction was then quenched with 15 mL of H2O and extracted with DCM (3 x 15 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated. Flash column chromatography 
with hexane:EtOAc (95:5) afforded the pure product (212 mg, 85% yield). 
(S)-N-Benzyl-3-phenyl-1,2,3,4-tetrahydropyridine (TH-3): Not isolated. GC-
MS: found molecular peak – 250 (expected m/z = 250). Yield and enantiomeric 
excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 150 °C for 8 min., 5 °C/min., 170 °C 
for 60 min.: tR = 27.8 min., tS = 28.2 min. 
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(–)-N-Benzyl-3-(4-(trifluoromethyl)phenyl)piperidine (2b): 1H NMR 
(400 MHz, CDCl3) δ 7.54 (d, 3J(H,H) = 8.1 Hz, 2H), 7.39 – 7.27 (m, 5H), 3.65 
(s, 2H), 3.13 – 2.94 (m, 3H), 2.22 – 2.06 (m, 2H), 1.95 (m, 1H), 1.91 – 1.75 
(m, 2H), 1.48 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 148.2, 129.7, 128.9 (q, 
2J(C,F) = 32.6 Hz), 128.6, 127.7, 125.5 (q, 3J(C,F) = 3.7 Hz), 124.4 (q, 1J(C,F) = 271.9 Hz), 
63.3, 60.1, 53.5, 42.3, 31.3, 25.1; 19F NMR (282 MHz, CDCl3) δ –62.9; IR (film): ν = 2931.3, 
2852.2, 1639.2, 1619.9, 1326.8, 1164.8, 1122.4, 1069.3 cm-1; HRMS (ESI+): m/z 320.16290 
[M+H]+ (calcd. for C19H21N1F3: 320.16206). Yield and enantiomeric excess determined by GC: 
CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven 
temperature: 150 °C for 8 min., 5 °C/min., 170 °C for 60 min.: te1 = 24.8 min., te2 = 25.4 min. 
(–)-N-Benzyl-3-(2-tolyl)piperidine (2c): 1H NMR (400 MHz, CDCl3) δ 7.36 – 
7.04 (m, 10H), 3.59 (d, 2J(H,H) = 13.1 Hz, 1H), 3.52 (d, 2J(H,H) = 13.2 Hz, 1H), 
3.06 (m, 1H), 3.01 – 2.87 (m, 2H), 2.31 (s, 3H), 2.09 – 1.95 (m, 2H), 1.86 (m, 1H), 
1.81 – 1.68 (m, 2H), 1.46 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 142.9, 137.8, 
135.9, 130.5, 129.4, 128.3, 127.1, 126.1, 126.1, 125.8, 63.6, 60.2, 54.2, 38.6, 31.2, 26.1, 19.6.; IR 
(film): ν = 3024.8, 2930.3, 2853.2, 2795.3, 1641.1, 1492.6, 1454.1, 1099.2, 753.1 cm-1; HRMS 
(ESI+): m/z 266.19038 [M+H]+ (calcd. for C19H24N1: 266.19033). Yield and enantiomeric 
excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas 
flow: 2.7 bar; oven temperature: 150 °C for 8 min., 5 °C/min., 170 °C for 60 min.: te1 = 28.3 min., 
te2 = 28.9 min. 
(–)-N-Benzyl-3-(4-methoxyphenyl)piperidine (2d): 1H NMR (400 MHz, 
CDCl3) δ 7.36 – 7.20 (m, 6H), 7.13 (d, 3J(H,H) = 8.6 Hz, 2H), 6.82 (d, 
3J(H,H) = 8.6 Hz, 2H), 3.78 (s, 3H), 3.54 (s, 2H), 3.02 – 2.87 (m, 2H), 2.79 
(m, 1H), 2.05 – 1.93 (m, 2H), 1.90 (m, 1H), 1.79 – 1.68 (m, 2H), 1.41 (m, 
1H); 13C NMR (101 MHz, CDCl3) δ 158.1, 138.4, 137.2, 129.4, 128.3, 128.3, 127.1, 113.8, 63.7, 
61.5, 55.4, 53.9, 42.2, 32.0, 25.9; IR (film): ν = 2930.3, 1638.2, 1610.3, 1512.9, 1245.8, 1036.6 
cm-1; HRMS (ESI+): m/z 282.18518 [M+H]+ (calcd. for C19H24N1O1: 282.18524). Yield and 
enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: isotherm 170 °C for 60 min.: te1 = 52.5 min., te2 = 
53.4 min. 
(–)-N-Benzyl-3-(naphthalen-2-yl)piperidine (2e): 1H NMR (400 MHz, 
CDCl3) δ 7.82 – 7.71 (m, 3H), 7.66 (s, 1H), 7.48 – 7.20 (m, 8H), 3.58 (s, 2H), 
3.13 – 2.90 (m, 3H), 2.16 (t, 3J(H,H) = 10.8 Hz, 1H), 2.10 – 1.97 (m, 2H), 1.86 
– 1.71 (m, 2H), 1.58 (m, 1H).; 13C NMR (101 MHz, CDCl3) δ 142.5, 138.4, 
133.7, 132.4, 129.4, 128.3, 127.9, 127.7, 127.7, 127.1, 126.4, 126.0, 125.4, 125.4, 63.7, 61.1, 54.0, 
43.1, 31.8, 25.9; IR (film): ν = 3055.7, 2931.3, 2796.3, 1600.6, 1453.1, 1348.0, 1097.3, 816.7, 
738.6 cm-1; HRMS (ESI+): m/z 302.19056 [M+H]+ (calcd. for C22H24N1: 302.19033). Yield 
determined by GC: HP-1 (30m x 0.32mm, 0.25μm); carrier: helium; gas flow: 15.2 psi; oven 
temperature: 45 °C for 5 min., 20 °C/min., 245 °C for 2 min.: t = 9.5 min. Enantiomeric excess 
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determined by HPLC: Chiralcel OD-H (250 x 4.6 mm); hexane/iPrOH (98:2); 0.4 mL/min: te1 
= 19.6 min., te2 = 22.8 min. 
(R)-(–)-N-Benzyl-3-methylpiperidine (2f).78 Absolute configuration assigned by 
comparison of the optical rotation with literature data.79 Yield and enantiomeric excess 
determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: hydrogen; 
gas flow: 1.0 bar; oven temperature: isotherm 105 °C for 40 min.: tR = 29.8 min., tS = 30.7 min.  
Ethyl N-Benzylpiperidine-3-carboxylate (2g).80 Yield and enantiomeric excess 
determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
hydrogen; gas flow: 1.0 bar; oven temperature: isotherm 140 °C for 50 min.: te1 = 
36.7 min., te2 = 37.3 min. Determination of the optical rotation was not possible due 
to the low conversion. 
tert-Butyl (R)-(+)-(N-benzylpiperidin-3-yl)carbamate (2h).20  Yield and 
enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 
0.25μm); carrier: hydrogen; gas flow: 1.0 bar; oven temperature: isotherm 170 °C 
for 40 min.: tS = 26.4 min., tR = 27.7 min. Absolute configuration assigned by comparison of the 
sign of the optical rotation with literature data.81 
N-Benzyl-3-(trifluoromethyl)piperidine (2i): 1H NMR (400 MHz, CDCl3) δ 7.35 
– 7.25 (m, 5H), 3.55 (d, 2J(H,H) = 13.2 Hz, 1H), 3.51 (d, 2J(H,H) = 13.2 Hz, 1H), 
3.04 (m, 1H), 2.85 (m, 1H), 2.35 (m, 1H), 2.00 – 1.86 (m, 3H), 1.78 – 1.67 (m, 2H), 
1.57 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 138.1, 129.1, 128.4, 127.3, 127.1 (q, 1J(C,F) = 
278.7 Hz), 63.4, 53.3, 52.4 (q, 3J(C,F) = 3.0 Hz), 41.2 (q, 2J(C,F) = 26.1 Hz), 24.3, 23.4 (q, 
2J(C,F) = 2.5 Hz); 19F NMR (282 MHz, CDCl3) δ –73.5; IR (film): ν = 2947.7, 2925.5, 2855.1, 
1455.0, 1335.5, 1258.3, 1185.0, 1118.5, 1090.6 cm-1; HRMS (ESI+): m/z 244.13059 [M+H]+ 
(calcd. for C13H17N1F3: 244.13076). Yield and enantiomeric excess determined by GC: CP-
Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: hydrogen; gas flow: 1.0 bar; oven 
temperature: isotherm 105 °C for 40 min.: te1 = 27.0 min., te2 = 27.8 min. Determination of the 
optical rotation was not possible due to the low conversion. 
(–)-N-Benzyl-3-butylpiperidine (2j): 1H NMR (400 MHz, CD2Cl2) δ 7.35 – 
7.26 (m, 4H), 7.22 (m, 1H), 3.47 (d, 2J(H,H) = 13.2 Hz, 1H), 3.41 (d, 2J(H,H) = 
13.2 Hz, 1H), 2.85 – 2.69 (m, 2H), 1.92 – 1.84 (m, 2H), 1.78 (m, 1H), 1.68 – 1.57 
(m, 2H), 1.57 – 1.43 (m, 2H), 1.35 – 1.09 (m, 6H), 0.94 – 0.82 (m, 3H); 13C NMR (101 MHz, 
CD2Cl2) δ 139.6, 129.5, 128.5, 127.2, 63.9, 61.1, 54.7, 36.6, 34.7, 312.5, 29.6, 26.0, 23.4, 14.3; IR 
(film): ν = 2954.4, 2928.4, 2855.1, 2755.8, 1644.0, 1465.6, 1454.1, 1121.4, 736.7, 698.1 cm-1; 
HRMS (ESI+): m/z 232.20661 [M+H]+ (calcd. for C16H26N1: 232.20598). Yield and 
enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25 m x 0.25mm, 0.25μm); carrier: 
hydrogen; gas flow: 1.0 bar; oven temperature: isotherm 125 °C for 55 min.: te1 = 44.3 min., te2 = 
45.1 min. 
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Monitoring of the reaction over time by GC and NMR 
Inside a glovebox, Rh(cod)2OTf (14.3 mg, 2 mol%) and JosiPhos J002-2 (18.2 mg, 2.2 
mol%) were stirred for 1 h at 40 °C in 9 mL of THF. The solution was then transferred into a 50 
mL EasyMaxTM high pressure autoclave (Mettler Toledo) containing a mixture of 60a (503.52 
mg, 1.53 mmol), Et3N (1.068 mL, 7.65 mmol, 5 equiv.), dodecane (351.4 mg – as GC internal 
standard) and dimethyl terephthalate (151.24 mg – as NMR internal standard) in a solution of 
THF/TFE (1:1, 18 mL). The autoclave was closed and taken out of the glovebox. After flushing 
it 5 times with N2, it was pressurized to 50 bar of H2 and stirred at 50 °C for 47 h with sampling at 
different times. All samples were analyzed by GC analysis with CP-Chirasil-Dex CB column and 
some by NMR (results shown in Table 22). 
Table 22. Yield and ee of different species involved in the AH of 60a to 61a. 
Time (h) 60a 
(%)[a] 
61a 
(%)[b] 
ee of 61a 
(%)[b] 
TH-1 
(%)[b] 
TH-2 
(%)[b] 
TH-3 
(%)[b] 
ee of TH-3 
(%)[b] 
Et3NH+ 
(mmol)[a] 
0 100 0 - 0 0 0 - 0 
0,5 71 6 53 10 1 1 93 0,42 
1 50 9 53 18 1 4 93 0,61 
2 24 9 61 21 2 9 93 0,97 
3,5 6 12 76 25 2 11 93 1,18 
6,9 1 24 83 26 2 10 93 1,35 
10 0 31 85 26 2 7 93 1,44 
13,25  38 87 26 2 4 93  
17,1 0 43 86 25 2 2 93 1,53 
23,1  48 85 25 2 1 93  
30  51 83 25 2 1 93  
47  55 79 24 1 1 93  
[a] Determined by NMR with dimethyl terephthalate as internal standard. [b] Determined by GC 
analysis with CP-Chirasil-Dex CB column with dodecane as internal standard. Positive values of ee 
correspond to S configuration.  
Monitoring of the reaction over time by in situ FTIR spectroscopy  
Inside a glovebox, Rh(cod)2OTf (140.5 mg, 2 mol%) and JosiPhos J002-2 (179.0 mg, 2.2 
mol%) were stirred for 1 h at 40 °C in 9 mL of THF. The solution was then transferred into a 50 
mL EasyMaxTM high pressure autoclave (Mettler Toledo) containing a mixture of 60a (4.9 g, 15 
mmol) and Et3N (9 mL, 64.5 mmol, 4.3 equiv.) in a solution of THF/TFE (1:1, 18 mL). The 
autoclave was closed and taken out of the glovebox and the IR probe was assembled. After 
flushing it 5 times with N2, it was pressurized to 40 bar of H2 and stirred at 50 °C for 20 h. The 
spectral resolution for the FTIR adquisition was set to 4 cm-1, the number of scans to 256 and the 
measurement interval to one minute. 
General procedure for the hydrogenation of TH-1 and TH-2  
Inside a glovebox, Rh(cod)2OTf (0.23 mg, 2 mol%) and JosiPhos J002-2 (0.30 mg, 2.2 
mol%) were stirred for 1 h at 40 °C in 0.5 mL of THF. The solution was then transferred into a 
vial containing a mixture of TH-1 or TH-2 (0.025 mmol) and the selected additive in a solution 
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of THF/TFE (1:1, 1 mL). The vial was capped and placed into a Premex 96er Multireaktor®. 
After flushing it 5 times with N2 and 5 times with H2, it was pressurized to 50 bar of H2 and stirred 
at 50 °C for 20 h. The conversion and ee of the reaction were determined by GC analysis with CP-
Chirasil-Dex CB column. 
Isotopic labeling experiment  
Inside a glovebox, Rh(cod)2OTf (14.3 mg, 2 mol%) and JosiPhos J002-2 (18.2 mg, 2.2 
mol%) were stirred for 1 h at 40 °C in 9 mL of THF. The catalyst solution was transferred into a 
50 mL autoclave containing a mixture of 60a (500 mg, 1.53 mmol), Et3N (1.07 mL, 7.65 mmol) 
in 9 mL of THF and 9 mL of TFE. The autoclave was closed and taken out of the glovebox. After 
flushing it 5 times with N2, it was pressurized to 40 bar of D2 and stirred at 50 °C for 20 h. After 
that time, the crude mixture was concentrated, the product was redissolved in DCM (30 mL) and 
washed with a saturated aqueous solution of Na2CO3 (30 mL) and H2O (30 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated under vacuum. Purification by column 
chromatography with hexane/EtOAc (99:1 to 95:5) afforded TH-1 (76 mg, 0.31 mmol, 20% 
yield), TH-2 (8 mg, 0.03 mmol, 2% yield) and 61a (200 mg, 0.8 mmol, 52% yield). 
- NMR spectra of deuterated 61a can be found in section 3.2 Results and discussion (Figure 14, 
Figure 15, Figure 16). 
- Deuterated NMR spectra of tetrahydropyridines TH-1 and TH-2 are shown below in Figure 
18 and Figure 19. 
 
Figure 18. 1H-NMR of TH-1 and deuterated TH-1 in CDCl3. 
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Figure 19. 1H-NMR of TH-2 and deuterated TH-2 in CDCl3. 
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Part B. 
Tandem Olefin Metathesis – 
Asymmetric (Transfer) 
Hydrogenation 
 
 
 
 
 
 
 
Abstract: 
An overview on the state of the art of tandem olefin metathesis followed by hydrogenation or 
transfer hydrogenation is presented in Chapter IV. The disclosed mechanistic studies on the 
transformation of Ru complexes involved in olefin metathesis into Ru hydride species active in 
hydrogenation are also summarized. In Chapters V and VI, the asymmetric version of these 
tandem protocols is investigated and the successful development of a tandem olefin metathesis–
asymmetric hydrogenation and a tandem olefin metathesis-asymmetric transfer hydrogenation 
are described, respectively. 
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CHAPTER IV. 
OVERVIEW ON THE  
TANDEM OLEFIN METATHESIS – 
(TRANSFER) HYDROGENATION 
 
 
Over the last few decades, plenty of synthetic methodologies have been developed which 
allowed for more selective, efficient and green transformations. However, pharmaceutical drug 
molecules are of great complexity and long multi-step syntheses are required for their 
preparation. Practically, this means that large amounts of reagents, solvents and energy are 
required, which then produce big quantities of waste.1 For this reason, the research in synthetic 
methodologies has been focusing more and more into developing one-pot processes, trying to 
mimic the efficiency of biological systems.2 These processes do not require the isolation of the 
intermediates, thus considerably reducing the large amount of solvent used to perform the 
reactions and the purification steps. When metal-catalyzed processes are involved, one-pot 
sequential processes may also allow reusing the same metal for more than one reaction. 
Furthermore, there is no loss of yield arising from the purification of intermediates. Overall, one-
pot methodologies save time, money, energy and considerably reduce the amount of waste when 
compared to their stepwise counterparts.  
Due to the rapid progress of this field, the term to define a reaction like cascade, domino, 
tandem and sequential catalysis has been used interchangeably to describe different processes.3 
Fogg et al., in their review on the taxonomy of tandem catalysis, proposed a clear classification for 
all the one-pot processes involving multiple catalytic events. According to it, tandem catalysis 
describes “coupled catalyses in which sequential transformation of the substrate occurs via two 
(or more) mechanistically distinct processes”.3 This definition rules out similar concepts like 
domino or cascade catalysis, where the sequential transformations are effected via the same 
mechanism. Tandem catalysis can be divided in three subcategories: orthogonal, auto-tandem 
and assisted catalysis. Orthogonal catalysis implies the use of two catalysts, both present at the 
beginning of the reaction, which catalyze two consecutive transformations on the initial substrate 
(Figure 1A). In auto-tandem catalysis processes, instead, only one catalyst precursor is used, 
which is able to catalyze two consecutive reactions via different mechanisms, interacting 
differently with the various species present (Figure 1B). Finally, in assisted tandem catalysis 
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processes, the initial catalyst, which performs the first reaction, is converted into new species able 
to catalyze the second transformation upon addition of a reagent or a change in the reaction 
conditions (Figure 1C). 
Apart from the workup efficiency, inherent in all one-pot reactions, assisted tandem catalysis 
processes have several advantages: (i) efficiency in catalyst utilization, (ii) no interaction between 
the two catalysts –as they do not coexist– and (iii) possibility to optimize the conditions for the 
two catalytic cycles independently. Although the development of this technology is still in early 
stages, it has already been widely explored in tandem catalytic processes involving olefin 
metathesis. Some of the reactions that have been used in tandem with Ru-carbene-catalyzed 
olefin metathesis catalysts include: Kharasch additions, oxidations, hydrogenations, 
cyclopropanations, isomerizations, cycloadditions, Wittig olefinations and intramolecular 
hydroarylations.4 
 
Figure 1. Classification of tandem catalysis processes. 
This introduction will focus on assisted tandem olefin metathesis–hydrogenation and olefin 
metathesis–transfer hydrogenation, as those are the subject of investigation in the second part of 
this thesis.  
IV.1 TANDEM OLEFIN METATHESIS–HYDROGENATION  
The first uses of tandem olefin metathesis–hydrogenation were in the production of 
saturated polymers (Scheme 1).5 After the metathesis step, upon treatment with H2 the Ru 
present in the reaction mixture was able to catalyze the double bond hydrogenation. Grubbs and 
co-workers proposed that the addition of H2 to 1st generation Grubbs catalyst (G-I) was leading 
to the formation of the [RuHCl(H2)(PCy3)2] complex,5c which was already known to be an 
effective hydrogenation pre-catalyst.6  
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Scheme 1. Tandem olefin metathesis–hydrogenation applied in the field of polymers. 
Soon after, Grubbs and co-workers extended this process to the synthesis of small molecules 
(Scheme 2).7 Using either 1st generation (G-I) or 2nd generation (G-II) Grubbs catalysts, they 
demonstrated with several examples the viability of this tandem process and expanded it to 
transfer hydrogenation and transfer dehydrogenation of alcohols (see Section IV.2). 
 
Scheme 2. Examples of tandem olefin metathesis–hydrogenation. 
In this same publication, there is an interesting example where the selectivity of the Ru 
hydrogenation catalyst is modulated by addition of ethylenediamine, which might be acting as a 
ligand (Scheme 3). After the cross metathesis of styrene with methyl vinyl ketone, if the system is 
pressurized with hydrogen and warmed up to 70 °C, the double bond is selectively hydrogenated. 
Instead, if ethylenediamine is added, also in presence of iPrOH, NaOH and H2, the carbonyl 
group is hydrogenated selectively. This was the only example in the literature where a ligand was 
used to modulate the hydrogenation step of this tandem protocol, and it became the inspiration 
for our investigations in this second part of my thesis. 
 
Scheme 3. Catalyst selectivity modulated by addition of ethylenediamine.  
Since then, tandem olefin metathesis–hydrogenation processes have found plenty of 
applications in chemical synthesis. Schmidt and Pohler disclosed a milder protocol for the 
conversion of G-II into an effective hydrogenation catalyst.8 To avoid the use of elevated 
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pressures and temperature, Ru hydride species were formed in situ by addition of an inorganic 
hydride (NaH) and the hydrogenation was run at 20 °C and under 1 bar of H2. Applying this 
methodology, they carried out the ring-closing metathesis (RCM)–hydrogenation of different 
diallyl carabinols (Scheme 4). 
 
Scheme 4. RCM–hydrogenation of different diallyl carabinols. 
In the effort to expand this technology to other Grubbs catalysts, Fogg and co-workers 
reported the tandem ring-opening metathesis polymerization–hydrogenation with 3rd generation 
Grubbs catalyst (G-III).9 This catalyst, one of the fastest-initiating ruthenium catalyst known 
(measured to be >4000 faster to initiate than G-II), is commonly used in ROMP as it provides 
narrow polydispersity.10 Initially, the hydrogenation step led to very poor yields. Fogg proposed 
that the lack of stabilizing phosphines in this catalyst might make it very unstable under 
hydrogenation conditions. Thus, the addition of PCy3 (1.2 equivalents/Ru) prior to the 
hydrogenation step proved very effective, achieving full hydrogenation in all examples (Scheme 
5). 
 
Scheme 5. Tandem ROMP–hydrogenation with G-III. 
Miao et al. employed the same protocol to synthesize different saturated linear diols11 and 
aminoesters12 –important polymer monomers– via cross-metathesis (CM)–hydrogenation, using 
2nd generation Hoveyda-Grubbs catalyst (HG-II). It is remarkable the observed difference in 
selectivity when employing G-II or HG-II since the former, unlike the latter, is able to 
hydrogenate the double bond without reducing the nitrile to amine (Scheme 6).  
 
Scheme 6. CM–hydrogenation for the synthesis of saturated linear diols and aminoesters. 
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This technology has also been applied as intermediate step for the synthesis of other relevant 
molecules, such as cyclic dinucleotides (Scheme 7),13 peptidomimetics14 and biologically active 
compounds (Scheme 8).15  
 
Scheme 7. Example of RCM–hydrogenation for the synthesis of a cyclic nucleotide. 
 
Scheme 8. Example of RCM–hydrogenation for the synthesis of an intermediate in the total synthesis of 
(+)-Licoflexine. 
IV.2 TANDEM OLEFIN METATHESIS–TRANSFER 
HYDROGENATION  
Transfer hydrogenation (TH) is defined as the process of addition of hydrogen to a 
molecule from a source different than H2. Grubbs and co-workers were the first to show that Ru 
olefin metathesis catalysts G-I and G-II could be also transformed into efficient transfer 
hydrogenation catalysts.7 After an initial RCM step, the addition of a base (K2CO3 or NaOH) and 
iPrOH selectively afforded the reduction of the carbonyl group without affecting the C=C double 
bond (Scheme 9). Analogously, the dehydrogenation of alcohols could be performed using 3-
pentanone as solvent. Employing the latter methodology, and with a subsequent hydrogenation 
of the C-C double bond, they achieved the one-pot synthesis of (R)-(–)-Muscone (Scheme 10). 
 
Scheme 9. Example of a tandem olefin metathesis–TH. 
This report had been so far the only one describing a tandem olefin metathesis–TH of 
ketones. Surprisingly, although it has been reported that ruthenium complexes are not 
particularly efficient in promoting the hydrogen transfer towards olefins and alkynes,16 all later 
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publications have been focused in the TH of C=C bonds. The published methodologies differ in 
the hydrogen source and in the mode of generating the Ru hydride species. 
 
Scheme 10. Example of three Ru-catalyzed steps in tandem. 
The first report on the TH of alkenes using a Ru olefin metathesis catalysts was disclosed by 
Menozzi et al.17 They initially demonstrated that the combination of triethylsilane and G-I was 
able to effect the reduction of C=C bonds. The proposed mechanism consisted of a Ru-catalyzed 
stepwise addition of two hydrides, originating from the triethylsilane, to the double bond, 
generating disilane as by-product. When trying to establish the tandem protocol for the olefin 
metathesis–TH, they realized that the presence of triethylsilane was not affecting the metathethic 
activity of the Ru complex. Thus, it was possible to perform the tandem reaction with all the 
reagents present from the outset. However, when performing the same reaction with sequential 
additions of the carbene catalyst followed by the alkylsilane, the yield was slightly improved 
(Scheme 11).  
 
Scheme 11. Tandem RCM–TH of olefins using Et3SiH as hydrogen source. 
Schmidt et al. disclosed the use of G-I for the RCM–TH of 2-(allyloxy)styrenes to give 
different chromane derivatives.18 Employing similar conditions to those used by Grubbs and co-
workers for the TH of ketones (NaOH and iPrOH),7 they were able to hydrogenate C-C double 
bonds (Scheme 12). However, when this methodology was applied to non-benzofused 
substrates, the hydrogenation proceeded much slower and isomerization took place preferentially 
(Scheme 13).19  
 
Scheme 12. Synthesis of chromanes by tandem RCM–TH. 
 
Scheme 13. Attempt to synthesize tetrahydropyran derivatives by tandem RCM–TH. 
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Connolly et al. recently found that the addition NaBH4 and an alcohol to a Ru olefin 
metathesis catalyst was inducing the reduction of C=C bonds.20 In this case, the use of MeOH as 
co-solvent was crucial for the formation of Ru species able to efficiently transfer hydrogen from 
NaBH4 to the substrate. From these findings they developed a tandem protocol for the RCM–
TH (Scheme 14). Obviously, under these conditions, any group susceptible to be reduced by 
NaBH4 was also hydrogenated (e.g. ketones, aldehydes).  
 
Scheme 14. Tandem RCM–TH of alkenes using borohydrides as hydrogen source. 
The most recent report of a tandem RCM–TH of alkenes was disclosed by Grela and co-
workers.21 In this approach, G-II is converted into Ru hydride species by addition of sodium 
formate and formic acid, which also serves as a source of hydrogen (Scheme 15). During a 
substrate scope investigation, it was observed that trisubstituted alkenes were hydrogenated 
slower than disubstituted. Moreover, differently sized unsaturated rings were hydrogenated with 
different rates. While cyclopentene and cycloheptene derivatives were smoothly hydrogenated, 
the hydrogenation of cyclohexene rings was about two orders of magnitude slower. Taking 
advantage of this situation, they showed the possibility of a selective hydrogenation, although an 
additional amount of G-II had to be added before the hydrogenation step (Scheme 16). 
 
 
Scheme 15. Tandem RCM–TH of alkenes using formic acid as hydrogen source. 
 
Scheme 16. Selective TH of cycloalkenes after RCM. 
IV.3 MECHANISTIC STUDIES 
During these years of development of the tandem olefin metathesis–(transfer) 
hydrogenation protocols, many efforts have also been put into understanding the mechanism of 
formation of the active species and the role of the different additives used (e.g. bases or alcohols). 
The first study on the reaction of G-I with H2 in different conditions was performed by Fogg 
and co-workers (Scheme 17).22 Hydrogenolysis of the ruthenium carbene in chlorinated solvents 
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affords the Ru(IV) dihydride species 1. Instead, with non-chlorinated solvents, complex 2 is 
formed preferentially, although it is in equilibrium with its tautomeric form 1. Addition of a base 
abstracts HCl leading to the Ru(II) hydride species 3, which is assumed to be the one entering 
into the catalytic cycle. Coordination of a second molecule of H2 can lead to the formation of 
complexes 4 and 5. 
 
Scheme 17. Different Ru species formed by hydrogenolysis of G-I under different conditions. 
In a later publication, Fogg and co-workers demonstrated the great influence of solvents and 
additives to form different Ru hydride species featuring various levels of efficiency in 
hydrogenation.23 After ROMP of octene with G-I in DCM, the subsequent hydrogenation was 
performed in different conditions (Table 1). The Ru species 1, formed exclusively in DCM, gave 
very low conversions even at high pressures of H2 (Table 1, entry 1). When THF was used as co-
solvent, the equilibrium was displaced to the formation of 2, which proved to be much more 
active in hydrogenation, but only at high pressures (entries 2 and 3). In presence of a base (entry 
4), the Ru species 3 was formed, which showed high efficiency in the reduction step. Surprisingly, 
the addition of MeOH as co-solvent strongly accelerated the hydrogenation rate (entry 5) and 
with addition of Et3N full conversion was achieved under only 1 bar of H2 at 60 °C (entry 6). In 
the latter case, the already known hydrogenation catalyst [RuHCl(CO)(PCy3)2] (6), which 
might have been formed by decarbonylation of methanol, was identified as the active species. 
However, although decarbonylation cannot occur with iPrOH, its use also increased the reaction 
rate (entry 7), thus suggesting an additional role of the alcohol.  
Table 1. ROMP-hydrogenation of cyclooctene in DCM. 
 
# co-solvent additive pH2 (bar) time (h) conv. (%) 
1 - - 69 24 32
2 75% THF - 69 24 >99
3 75% THF - 7 24 9
4 - Et3N 7 24 85
5 20% MeOH - 7 4 83
6 20% MeOH Et3N 1 24 >99a
7 20% iPrOH - 7 4 54
a) Hydrogenation at 60 °C.
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Complementary conclusions were drawn by Dinger and Mol when investigating the 
conversion of G-I to the Ru species 6 in absence of H2.24 When G-I was reacted with an excess of 
a primary alcohol in toluene at 70 °C for 2 days, compound 6 was obtained. These findings were 
also reported by Grubbs and co-workers.25 However, when secondary alcohols or water were 
used, no reaction was observed. Addition of a base (organic or inorganic) greatly increased the 
rate of formation and the yield of 6 in presence of primary alcohols (Scheme 18). Although a 
general mechanism could not be proposed, it was shown that the base was facilitating the 
abstraction of HCl (triethylamine hydrochloride was isolated) and that the carbonyl ligand was 
originating by decarbonylation of the primary alcohol (1-13C-labeled ethanol was used to prove 
it). In this case, toluene, the product of hydrogenation of the benzylidene moiety, and the 
decarbonylated primary alcohol were also detected. Nolan and co-workers later proved that the 
reaction of G-I with secondary alcohols and Et3N did not lead to the hydridocarbonyl species 6, 
but to the Ru-dihydrogen complex 3 (Scheme 19). 26 
 
Scheme 18. Conversion of G-I to Ru species 6 and observed by-products. 
 
Scheme 19. Reaction of G-I with secondary alcohols and base to give Ru species 3. 
Simultaneously, Dinger and Mol also studied the reaction of G-II with primary alcohols and 
bases (Scheme 20).27 The resulting reaction mixture turned out to be more complicated than 
when G-I had been used. The expected hydridocarbonyl Ru complex 7 was indeed formed along 
with decarbonylated alcohol and toluene. In addition, complex 6 was also formed by exchange of 
the NHC ligand (IMes) for PCy3, but unfortunately the possibly formed bis-carbene complex 
arising from the PCy3/IMes scrambling could not be unambiguously identified. Comparable 
results were obtained by Banti and Mol28 when reacting a complex analogous of G-II bearing SIPr 
instead of SIMes as the NHC ligand.  
 
Scheme 20. Conversion of G-II to Ru species 7 and 6 and observed by-products. 
As observed in all these reports, Ru hydridocarbonyl complexes, highly active in 
hydrogenation, can be formed by reaction of G-I or G-II with a primary alcohol and a base, in the 
presence or in the absence of H2. The increasing number of applications of these complexes in 
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tandem olefin metathesis–hydrogenation required a better understanding of which is the most 
efficient path for the formation of the active hydrogenation species. For this reason, Fogg and co-
workers undertook investigations on both hydrogenolysis and methanolysis processes of G-I and 
G-II.29 The competition studies were based on the two different paths already described to obtain 
the Ru hydridocarbonyl complexes 6 and 7 (Scheme 21). A first path involves an initial 
hydrogenolysis, in presence of hydrogen to give the dihydrogen complexes 3 and 8, followed by 
decarbonylation of methanol. The second path is a direct methanolysis of the Ru benzylidene 
complexes to afford the final hydridocarbonyl complexes in one step. Analyzing the rate of 
reaction of the different paths and the speciation, it was concluded that for G-I the most efficient 
route is the two-steps hydrogenolysis–carbonylation. Direct methanolysis of G-I is much slower 
and decomposition therefore competes. Instead, for G-II the one-step protocol is much more 
efficient. This is due to the susceptibility of dihydrogen complex 8 to disproportionate into bis-
phosphine and bis-carbene complexes –[RuHCl(H2)(PCy3)2] and [RuHCl(H2)(IMes)2], 
respectively. 
 
Scheme 21. Possible paths for the conversion of G-I and G-II to the corresponding hydridocarbonyl 
species. 
Mechanisms for the formation of this type of hydridocarbonyl species have been proposed 
by Dinger and Mol,24 when using MeOH and Et3N, and by Fogg and co-workers,30 using NaOMe 
in MeOH. At room temperature, the PCy3 ligand in G-I is labile enough to allow the insertion of 
MeOH or NaOMe. This dissociative pathway had been demonstrated when the hydrogenation 
of G-I and G-II was inhibited by addition of PCy3 and enhanced by HBF4 (a phosphine 
scavenger).29 Then, a proton transfer from the methoxide to the benzylidene leads to the Ru-
formaldehyde complex. By dehydrogenation of formaldehyde, the carbonyl group is formed with 
liberation of the benzyl group as toluene. Final re-coordination of PCy3 renders the 
hydridocarbonyl species. The facile β-elimination from methoxide makes the proposed 
mechanism possible, in contrast to what is observed when using tert-butoxide31 or phenoxides,32 
which form stable Ru-bis(alkoxides).  
 
Scheme 22. Proposed mechanism for the formation of Ru-hydridocarbonyl species from G-I. 
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An analogous mechanistic study for similar Ru-carbene catalysts was reported by Nolan and 
co-wokers, which reinforces the one previously described.26 The same mechanism is also 
proposed for G-II, but without the initial decoordination of the phosphine, since it has been 
observed that it is much slower than in 1st generation catalysts.  
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CHAPTER V. 
TANDEM OLEFIN METATHESIS – 
ASYMMETRIC HYDROGENATION 
 
V.1 INTRODUCTION 
Inspired by the findings of Grubbs and co-workers,7 where the hydrogenation selectivity of 
Grubbs 2nd generation catalyst (G-II) after a metathesis step was modulated by addition of 
ethylenediamine (probably acting as ligand), we wondered if it would be possible to use a chiral 
ligand instead. In this way, it might be possible to convert a Grubbs catalyst into an asymmetric 
hydrogenation (AH) catalyst. 
As shown in the reported mechanistic studies, under hydrogenolysis conditions the 
benzylidene moiety attached to the Ru center is hydrogenated out leaving free coordination sites, 
where eventually a chiral ligand could coordinate.  
 
Scheme 23. Simplified concept for the formation of a chiral hydrogenation Ru catalyst from a Grubbs 
catalyst. 
This concept could be later applied to a tandem protocol, in which the chiral ligand would be 
added after the metathesis step and before the addition of H2. However, this approach could be 
risky considering that at the end of a metathesis step the original Grubbs catalyst is no longer 
present. Instead, new Ru species originating from the metathesis of the Ru-benzylidene with 
other alkenes and from the decomposition of the metathesis catalyst are coexisting in solution.33,34 
The addition of a chiral ligand to that mixture, under hydrogen pressure, might lead to different 
complexes containing or not containing the chiral ligand and showing diverse efficiencies in AH. 
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V.2 RESULTS AND DISCUSSION 
Among the different commercially available Ru olefin metathesis catalysts (Figure 2), we 
selected Hoveyda-Grubbs 2nd generation catalyst (HG-II), since it does not contain any 
phosphine which could compete with the added ligand leading to the formation of achiral 
hydrogenation catalysts. 
 
Figure 2. Commercially available Ru olefin metathesis catalysts. 
For the initial attempts, the enantioselective hydrogenation of methyl 2-acetamidoacrylate 
(9) was attempted using HG-II in combination with (S)-BINAP as chiral ligand. In THF or 
DCM, the conversion of 9 to methyl 2-acetamidopropanoate (10) was almost zero, either in the 
presence or in the absence of ligand (Table 2, entries 1-4). As reported by Fogg and co-
workers,9,23, 35  the presence of alcohols can enhance the activity of Grubbs catalysts in 
hydrogenation. Indeed, the same experiments carried out with (S)-BINAP in DCM/MeOH 1:4 
or THF/MeOH 1:4 led to full conversion (entries 5-6). Even more gratifying was the significant 
enantioselectivity obtained in both cases, suggesting that a Ru-BINAP complex active in 
hydrogenation had formed.  
Table 2. AH with HG-II and (S)-BINAP. 
 
# Ligand Solvent Conv. (%) ee (%) 
1 none DCM 2 0 
2 none THF 0 0 
3 (S)-BINAP DCM 2 0 
4 (S)-BINAP THF 0 0 
5 (S)-BINAP DCM/MeOH 1:4 100 59 
6 (S)-BINAP THF/MeOH 1:4 100 61 
7 none DCM/MeOH 1:4 15 0 
8 none THF/MeOH 1:4 16 0 
9[a] none DCM/MeOH 1:4 29 0 
10[a] (S)-BINAP DCM/MeOH 1:4 35 4 
Reaction conditions: 9 (1 mmol), HG-II (1 mol %), (S)-BINAP 
(1.1 mol %), H2 (25 bar), solvent (5 mL), 16 h, rt. Conversion 
and ee determined by chiral GC. [a] 3 equiv. Et3N relative to Ru.  
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In the absence of ligand (entries 7-8) the activity of the catalyst was significantly reduced, 
which indicates that the hydrogenation was ligand-accelerated. In fact, this is the most desirable 
situation, since the enantioselective catalyst is much more active than the non-enantioselective 
one, and thus the erosion of the ee due to the activity of the non-enantioselective catalyst is 
minimized. Fogg already observed this effect9 when, by adding PCy3 after the metathesis step, the 
activity in hydrogenation of the G-III precursor was substantially improved, most probably by 
stabilizing the resting state of the catalyst. Et3N was also reported to be beneficial for the 
formation of active hydrogenation species.9,23,35 However, this additive did not give any positive 
effect in our case (entries 9-10). 
To ascertain whether the ligand-acceleration observed for HG-II was also acting when using 
other catalyst precursors, the hydrogenation of 9 was carried out with different commercially 
available ruthenium olefin metathesis catalysts in DCM/MeOH 1:4 (Table 3, entries 1-6). The 
same trend was observed with G-III, but not with G-II, which led to full conversion but no ee, 
either in presence or absence of BINAP.  
Table 3. Ligand-acceleration effect in the hydrogenation of methyl 
acetamidoacrylate with different ruthenium catalysts. 
 
# Ru cat. Ligand Solvent Conv. (%) ee (%) 
1 G-II none DCM/MeOH 1:4 100 0 
2 G-II (S)-BINAP DCM/MeOH 1:4 100 0 
3 HG-II none DCM/MeOH 1:4 15 0 
4 HG-II (S)-BINAP DCM/MeOH 1:4 100 58 
5 G-III none DCM/MeOH 1:4 39 0 
6 G-III (S)-BINAP DCM/MeOH 1:4 72 26 
7 G-I none THF/iPrOH 1:4 13 0 
8 G-I (S)-BINAP THF/iPrOH 1:4 100 82 
9 HG-I none THF/iPrOH 1:4 99 0 
10 HG-I (S)-BINAP THF/iPrOH 1:4 100 72 
11 G-II none THF/iPrOH 1:4 59 0 
12 G-II (S)-BINAP THF/iPrOH 1:4 93 40 
13 HG-II none THF/iPrOH 1:4 7 0 
14 HG-II (S)-BINAP THF/iPrOH 1:4 65 83 
15 G-III none THF/iPrOH 1:4 4 0 
16 G-III (S)-BINAP THF/iPrOH 1:4 17 70 
Reaction conditions: 9 (1 mmol), Ru catalyst (1 mol %), (S)-BINAP (1.1 
mol %), H2 (25 bar), solvent (5 mL), 16 h, rt. Conversion and ee 
determined by chiral GC. 
When the solvent mixture THF/iPrOH was used (entries 7-16), the same effect was 
observed for all tested catalyst precursors. Even in the case where the reaction is completed in 
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absence of ligand (entry 9), the kinetic profile (Figure 3) shows a much faster reaction rate in 
presence of the ligand. While without ligand the reaction takes 16 h to be completed, in the 
presence of (S)-BINAP the reaction is finished in about 6 h. 
 
Figure 3. Kinetic profiles (conv. vs time) of entries 9 and 10 from Table 3, derived from hydrogen 
consumption measurements. 
The reactions proved much faster when MeOH was used as alcoholic solvent, but more 
enantioselective in the presence of iPrOH. These differences might be attributed to the 
formation of different active species. Actually, carbonyl complexes (such as 6 and 7, Scheme 24), 
which are formed by dehydrogenation of methanol, proved to be much more robust and active in 
hydrogenation than 3 or 8,36 which would be formed in presence of a secondary alcohol like 
iPrOH.23-28 However, the presence of a strongly coordinating CO ligand would prevent the 
coordination of a bisphosphine ligand, thus leading to lower ee’s.  
 
Scheme 24. Formation of Ru-hydride species upon addition of hydrogen to G-I and G-II. 
Analyzing the reaction rate profiles, derived from hydrogen consumption measurements, 
with different Ru olefin metathesis catalysts and (S)-BINAP in THF/iPrOH 1:4, some 
observations can be made (Figure 4). First of all, induction times (ranging from a few minutes to 
almost 4 h) follow the trend G-III < G-I ≈ HG-I < G-II ≈ HG-II. This is the same trend 
followed by the initiation rates of these complexes in the metathesis reaction.33 The phosphines of 
the 1st generation catalysts are quite labile, being the dissociation rate slightly faster in the case of 
G-I as it contains two equivalent phosphines which can be dissociated. With respect to G-II, 
although one might expect a fast dissociation of the phosphine due to the large trans-effect of the 
NHC ligand, it was demonstrated by Grubbs et al. that the dissociation of the phosphine is 
extremely slow compared to G-I.37 Actually, mechanistic studies have shown that, while the 
activation of 1st generation catalysts goes via the dissociation of the phosphine, with 2nd 
generation catalysts this dissociation does not take place, making the whole process slower.26,30,33 
For HG-II an initiation rate similar to that of G-II is reported.38 Finally, G-III is known to be one 
of the fastest-initiating catalysts,10a thus being the catalyst with the shortest induction time. The 
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similar trend on the activation of the catalysts suggests that the hydrogenation of the benzylidene 
moiety and the initiation of the metathesis reaction might follow a similar mechanism. 
 
Figure 4. Kinetic profiles (conv. vs time) derived from hydrogen consumption measurements in the 
hydrogenation of methyl acetamidoacrylate with different ruthenium catalysts (corresponding to entries 8, 
10, 12, 14 and 16 from Table 3). Reaction conditions: 9 (1 mmol), Ru catalyst (1 mol %), (S)-BINAP (1.1 
mol %), H2 (25 bar), THF/iPrOH 1:4 (5 ml), 16 h, rt.  
Additional relevant information that can be extracted from Figure 4 is the reaction rates 
(slope of the curves). The 1st generation catalysts have parallel slopes, this denoting the same 
reaction rate and hence, with high probability, the same active species involved in hydrogenation. 
In the case of the 2nd generation catalysts, although the slope of HG-II increases with time, 
indicating that more active species are being generated as the reaction proceeds, it eventually gets 
constant and parallel to that of G-II, again suggesting that most likely the same active species are 
involved. The case of G-III is a bit more surprising, because from an NHC-containing catalyst we 
would expect similar active species and similar reaction rates to those of the 2nd generation 
catalysts, but instead it is remarkably lower. The explanation for this observation might be in the 
study from Fogg et al. where they found out that G-III, although it is very fast hydrogenated, 
decomposes under hydrogenation conditions, thus generating negligible amounts of hydride 
species.9  
It is well known that the solvent plays a crucial role in AH.39 As we have already observed, it 
is even more so in our case, where the solvent can determine the nature of the active 
hydrogenation species and their rate of formation. Therefore, employing the most 
enantioselective catalyst found so far (HG-II), we continued the study by carrying out a solvent 
screening with mixtures of THF or DCM with different amounts of MeOH or iPrOH (Figure 5).  
For all solvent mixtures, the addition of an alcoholic solvent led to higher activities and, 
almost in all cases, higher enantioselectivities. The induction periods, ranging from 1 to 10 hours, 
and the reaction rates appeared to be also highly dependent on the solvent system. In 
DCM/MeOH 4:1 (Figure 5A), poor activity and no enantioselectivity was observed. Instead, 
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when the alcoholic solvent was increased all the way up to pure MeOH, full conversion was 
obtained without important differences in the reaction rates and enantioselectivities. The same 
was true in mixtures DCM/iPrOH (Figure 5B), even when using only 20% alcohol. However, in 
these cases the activity was overall lower, with longer induction times and lower rates, but with 
higher enantiomeric excesses (82% in DCM/iPrOH vs 60% in DCM/MeOH). A very different 
behavior was observed in THF (Figure 5C and D). The reaction rates increased considerably 
with the amount of alcohol and the enantiomeric excesses varied significantly with the different 
solvent ratios, but in an opposite manner depending on the alcohol employed. Thus, the highest 
enantioselectivities were obtained in THF/MeOH 4:1 (89% ee) and in DCM/iPrOH 1:4 (83% 
ee). 
 
Figure 5. AH of 9 with HG-II/(S)-BINAP in different solvent mixtures. The kinetic profiles (conv. vs time) 
are derived from hydrogen consumption measurement (in parenthesis, the conversion and ee at the end of 
the reaction are reported). Reaction conditions: 9 (1 mmol), Ru-catalyst (1 mol %), (S)-BINAP (1.1 mol %), 
H2 (25 bar), solvent (5 mL), rt. Conversion and ee determined by chiral GC. 
A detailed understanding of the molecular processes that take place in the different solvent 
combinations is difficult. The nature of the solvent influences the formation of the active 
hydrogenation species, its activity and its enantioselectivity. Although the effects governing the 
overall catalytic performance are difficult to deconvolute, several observations can be made. First, 
the induction periods observed are dependent on the rate of alcoholysis and/or hydrogenolysis 
towards active hydrogenation species. This transformation seems to occur more readily when 
using MeOH as alcoholic solvent than with iPrOH, indicating that the former is more efficient in 
the alcoholysis of HG-II. Second, for the slower reactions (generally the ones with a lesser 
amount of alcohol), the rate of hydrogenation increases with time, indicating that some 
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additional active species are being formed during the course of the reaction. In contrast, at higher 
ratios of alcohol, the reaction profiles resemble zero order kinetics, which suggests that HG-II 
undergoes a rapid and complete transformation to the active hydrogenation species before 
significant hydrogenation takes place. Third, the remarkable variation of the enantiomeric excess 
with different amounts of THF, compared to the little influence that DCM has on it, might be 
ascribed to the known ability of THF to bind ruthenium, thus modulating its performance. 
A screening with a variety of monodentate and bidentate ligands showed that actually (S)-
BINAP is the best performing in both solvent mixtures (Table 4). The ferrocene derivative 
MandyPhos SL-M001-1 also showed promising enantioselectivities.  
Table 4. Ligand screening for the AH of 9 with HG-II. 
 
# Ligand 
DCM/iPrOH 1:4 THF/MeOH 4:1 
Conv. (%) ee (%) Conv. (%) ee (%) 
1 (S)-BINAP 100 82 100 89 
2 (R)-DTBM-MeOBiphep 40 60 28 21 
3 Josiphos SL-J002-2 100 66 100 66 
4 WalPhos SL-W008-1 21 8 27 9 
5 MandyPhos SL-M001-1 100 72 100 81 
6 (R,R)-BICP 11 0 11 0 
7 (S)-Binaphane 15 5 27 0 
8 (S)-PhanePhos 12 8 18 7 
9 (R)-MonoPhos 4 58 2 22 
10 (R,R)-QuinoxP* 45 0 70 0 
11 (R)-DM-SegPhos 100 58 73 59 
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O
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Reaction conditions: 9 (1 mmol), HG-II (1 mol %), ligand (1.1 mol % for bidentate, 2.2. mol% for 
monodentate), H2 (50 bar), solvent (5 mL), 16 h, rt. Conversion and ee determined by chiral GC.  
In an effort to determine the nature of the active hydrogenation catalyst, the alcoholysis of 
HG-II with (S)-BINAP in THF-d8:CD3OD (4:1) or CD2Cl2:iPrOH-d8 (1:1) was followed by 1H 
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NMR, but no changes were observed after 2 days stirring at room temperature. When the same 
mixture was submitted to 50 bar of H2 at room temperature for 18 h, again no change was 
appreciable (Figure 6B). The latter experiments were repeated in presence of 2 equivalents of 
methyl 2-acetamidoacrylate 9 (Figure 6C). Product 10 was obtained with full conversion and 
different enantioselectivities (85% and 77% ee respectively) depending on the solvent mixture. 
Surprisingly, the only observed change by NMR was the quantitative disappearance of 9 and the 
appearance of 10. All signals corresponding to HG-II and (S)-BINAP were still present in the 
same amount than at the beginning of the reaction. No signal of a possible coordination of (S)-
BINAP with Ru was observed by 31P NMR either.  
 
 
Figure 6. 1H NMR in CD2Cl2/iPrOH-d8 of: A) HG-II + (S)-BINAP; B) HG-II + (S)-BINAP stirred for 18 
h at room temperature under 50 bar of H2; C) HG-II + (S)-BINAP + 9 stirred for 18 h at room temperature 
under 50 bar of H2 
Although most mechanistic studies use a base for the activation of the catalyst – which in our 
case proved detrimental for the reaction – Fogg and co-workers reported that G-I could be 
converted into Ru-hydride species by hydrogenation of its benzylidene moiety in the absence of a 
base.22,23 Hence, we decided to try the same experiments with another NHC-containing catalyst, 
in this case G-II (Figure 7). After stirring it in presence of one equivalent of (S)-BINAP under 50 
bar of H2 we could observe that the integral of the benzylidene proton (δ = 19.44 ppm) decreased 
ca. 35% compared to the NHC or PCy3 protons. Moreover, a hydride peak appeared as a singlet 
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at δ = -6.13 ppm, which could be correlated with other small peaks that appeared in the aromatic 
region. The multiplicity of this peak indicates that no phosphorus is attached to the Ru center 
(also confirmed by 31P NMR), thus suggesting that, although these species might be involved in 
the overall process, they are not the enantioselective ones. The slow conversion to Ru-hydride 
species had been already reported by Fogg, when the hydrogenolysis of G-II in presence of Et3N 
at 69 bar of H2 was not completed after 24 hours.29 Thus, we could expect HG-II to be even less 
reactive, due to the chelation of the isopropoxy group attached to the benzylidene moiety. 
 
Figure 7. 1H NMR in CD2Cl2/iPrOH-d8 of: A) G-II; B) G-II + (S)-BINAP stirred for 18 h at room 
temperature under 50 bar of H2. 
The experiments performed with HG-II were also injected in the GC-MS, but no extra 
information could be obtained. Furthermore, ESI-MS analysis of the crude mixtures, before and 
after hydrogenation, showed several peaks corresponding to Ru species, but none of them could 
be identified as a Ru-BINAP complex. 
Besides all these inconclusive experiments, the hydrogenation of 9 in the optimized 
conditions proceeds with up to 89% ee. Thus, only two explanations can be given for the lack of 
evidences in the mechanistic studies: (i) not observable traces of HG-II are hydrogenated to 
afford highly active Ru-BINAP hydride species or (ii) the hydrogenation proceeds via an 
unknown mechanism that does not involve the hydrogenation of the benzylidene moiety and 
where HG-II regenerates when the catalytic cycle is finished, as it is observed at the end of the 
reaction without any change.  
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Two other prochiral substrates, methyl 2-acetamidocinnamate (11) and dimethyl itaconate 
(13), were tested under the optimized conditions in the two solvent mixtures. Using 11 as 
substrate led to almost no conversion and no enantiomeric excess (Table 5, entries 1 and 2). 
Even trying to optimize the conditions on a ligand screening, no good results were achieved, 
being the best ligands those shown in Table 5, entries 3 and 4. Instead for substrate 13, 
acceptable results were obtained in DCM/iPrOH but not in THF/MeOH (Table 6, entries 1 and 
2). A Ru precursor and ligand screening allowed improving the results, achieving up to 86% ee 
with full conversion (Table 6, entry 3). Since we had observed that different combinations of Ru 
precursors and ligands can form more efficient catalysts, a large screening was also performed 
with 9. Gratifyingly, it was found that the combination of HG-I, G-I or G-III with MandyPhos 
SL-M001-1 achieved enantioselectivities up to 93% ee (Table 7, entries 3-5). These results just 
demonstrated something that is well-known in the AH field, i.e. that every substrate requires its 
own optimization. 
Table 5. Selected results from a large screening on the AH of 11.  
 
# Ru cat. Ligand Solvent Conv. (%) ee (%) 
1 HG-II (S)-BINAP DCM:iPrOH 1:4 7 0 
2 HG-II (S)-BINAP THF/MeOH 4:1 3 0 
3 HG-II (R)-DM-SegPhos THF/MeOH 4:1 31 62 
4 HG-II Josiphos SL-J002-2 DCM/iPrOH 1:4 99 26 
Table 6. Selected results from a large screening on the AH of 13. 
 
# Ru cat. Ligand Solvent Conv. (%) ee (%) 
1 HG-II (S)-BINAP DCM/iPrOH 1:4 66 85 
2 HG-II (S)-BINAP THF/MeOH 4:1 83 20 
3 HG-I (R)-DM-SegPhos THF/iPrOH 1:4 100 86 
4 G-II (R)-DM-SegPhos THF/iPrOH 1:4 100 70 
Table 7. Selected results from a large screening on the AH of 9. 
 
# Ru cat. Ligand Solvent Conv. (%) ee (%) 
1 HG-II (S)-BINAP DCM/iPrOH 1:4 100 82 
2 HG-II (S)-BINAP THF/MeOH 4:1 100 89 
3 G-I MandyPhos SL-M001-1 THF/iPrOH 1:4 100 92 
4 HG-I MandyPhos SL-M001-1 THF/iPrOH 1:4 100 92 
5 G-III MandyPhos SL-M001-1 THF/iPrOH 1:4 100 93 
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Having demonstrated that Ru olefin metathesis catalysts can be converted into efficient 
asymmetric hydrogenation catalysts, we decided to test whether the same transformation could 
be effectively performed after a metathesis step. As commented before, this might be challenging 
due to the different Ru species present in solution after a metathesis step, but also because the 
different Ru-carbene species, originating from the reaction with different alkenes, are known to 
greatly differ in the initiation rate of the metathesis reaction.33  
To this purpose, diethyl diallylmalonate (15) was selected as metathesis substrate. After 
performing the ring-closing metathesis (RCM) of 15 with HG-II in DCM, we added the 
prochiral substrate 9, (S)-BINAP and the alcohol to the reaction mixture and pressurized it to 25 
bar of H2 (Scheme 25). Gratifyingly, product 10 was formed with the same conversion and 
enantiomeric excess (99% conv. and 85% ee) that had been obtained without the previous 
metathesis step. Besides that, diethyl cyclopent-3-ene-1,1-dicarboxylate (16) was also fully 
hydrogenated to the corresponding saturated cyclopentane 17. 
 
Scheme 25. Proof of concept for the tandem metathesis–AH. Reaction conditions: metathesis: 15 (1 mmol), 
HG-II (1 mol%), DCM (1 mL), 15 min, rt; hydrogenation: 9 (1 mmol), (S)-BINAP (1.1 mol %), H2 (25 
bar), iPrOH (4 mL), 16 h, rt. Conversion and ee determined by chiral GC. 
Since methyl 2-acetamidoacrylate (9) is not active in cross-metathesis with the known Ru 
catalysts, a modified version had to be synthesized to be able to carry out the metathesis reaction 
and the asymmetric hydrogenation on the same molecule. With this aim, allyl 2-
acetamidoacrylate (18) was engineered by reaction of 2-acetamidoacrylic acid and allyl bromide. 
This substrate was submitted to cross-metathesis (CM) with an excess of 1-octene (19). Despite 
not having completely optimized the CM, the subsequent AH of 20 led quantitatively to the fully 
hydrogenated nonyl 2-acetamidoacrylate (21) with 80% ee (Scheme 26), thus demonstrating the 
concept. The non-metathesized 18 was also completely hydrogenated to propyl acetylalaninate 
(22) with 71% ee. 
 
Scheme 26. Tandem metathesis–AH of 18. Reaction conditions: metathesis: 18 (0.15 mmol), 19 (100 
equivalents), HG-II (5 mol%), DCM (1.5 mL), 40 °C, 5.5 h; hydrogenation: (S)-BINAP (5.5 mol %), H2 
(50 bar), THF/MeOH 4:1(2 mL), 16 h, rt. Conversion and ee determined by chiral GC. 
Considering that the highest enantioselectivities for the AH of 9 had been obtained with G-
III and MandyPhos SL-M001-1 (Table 7, entry 5) we tried those conditions in the described 
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tandem reaction, but very low conversions were obtained in the cross-metathesis step. Thus, 
since the main difference between G-III and HG-II is the presence of 3-bromopyridine ligands in 
the former (Figure 2), we attempted the AH with HG-II and 3-bromopyridine derivative as 
additive. Indeed, after the CM with HG-II and subsequent AH with MandyPhos SL-M001-1 as 
ligand and 3-bromopyridine as additive, product 21 was obtained with an overall 68% conversion 
and 90% ee (Scheme 27). 
 
Scheme 27. Optimized tandem metathesis–AH of 18. Reaction conditions: metathesis: 18 (0.05 mmol), 19 
(100 equivalents), HG-II (5 mol%), DCM (1.5 mL), 40 °C, 5.5 h; hydrogenation: MandyPhos SL-M001-1 
(5.5 mol %), 3-bromopyridine (30 mol%), H2 (50 bar), DCM/iPrOH 1:4 (2 mL), 16 h, rt. Conversion and 
ee determined by chiral GC. 
During the cross-metathesis of 18 a side product was always formed with ca. 18% 
conversion. After isolation and characterization by NMR it was identified as the RCM product 
23. Surprisingly, this compound was not hydrogenated in the following hydrogenation step. 
 
Scheme 28. RCM product of 18. 
Finally, we decided to focus on an example where the prochiral olefin was the one formed by 
metathesis. To do so, we took inspiration on a recent publication by Andersson and co-workers.40 
There, the synthesis of 3-substituted piperidines 26 via RCM of 24, isolation of the 
tetrahydropyridine intermediate 25 and AH of the formed alkene with an Ir chiral complex is 
reported (Scheme 29).  
 
Scheme 29. Synthesis of 3-substituted piperidines by RCM and subsequent Ir-catalyzed enantioselective 
hydrogenated, reported by Andersson and co-workers. 
Substrate 24a (R = Me) was selected to apply our one-pot tandem protocol. Large 
screenings of different solvent mixtures, Ru olefin metathesis catalysts and ligands led to the final 
optimized conditions. As a matter of example, one of the screenings is shown in Figure 8. (R)-
DTBM-MeOBiphep gave good conversions in almost all solvents but very poor 
enantioselectivities. The contrary was observed with MandyPhos SL-M001-1, which gave high 
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enantioselectivities but poor activities. Gratifyingly, the combination of G-II with (S)-PhanePhos 
in DCM/iPrOH 1:1 gave the best combination of conversion and enantioselectivity (87% conv. 
and 86% ee), demonstrating once more that each substrate requires a particular optimization. 
 
Figure 8. Screening of solvents, ligands and Ru catalysts for the AH of 25 to 26. 
Thus, the optimized AH protocol together with the RCM step, already optimized by 
Andersson and co-workers, led to N-tosyl-3-methylpiperidine (26a) in an overall 87% conversion 
and 86% ee from 24a (Scheme 30).  
 
Scheme 30. Tandem RCM–AH of 24a. Reaction conditions: metathesis: 24a (0.07 mmol), G-II (5 mol%), 
DCM (0.2 mL), 40 °C, 15 min; hydrogenation: (S)-PhanePhos (5.5 mol %), DCM (0.3 mL), iPrOH (0.5 
mL), H2 (50 bar), 16 h, rt. Conversion and ee determined by chiral GC. 
V.3 CONCLUSIONS 
Our goal to demonstrate that the reactivity of a Ru olefin metathesis catalyst can be 
modulated under hydrogenation conditions by addition of a ligand has been reached: different 
Ru catalysts have been transformed into efficient AH catalysts, achieving ee’s up to 93% in the 
hydrogenation of methyl 2-acetamidoacrylate. Recent experiments also showed that, in some 
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cases, the enantioselectivity can be improved by reducing the H2 pressure, leaving place for 
further improvements. Efforts have also been put in determining the active species responsible for 
the hydrogenation, but unfortunately no conclusive results could be obtained, leaving the door 
open for deeper investigations in this area.  
The possibility to perform a tandem metathesis–AH has also been demonstrated for the first 
time. This allows an expensive metal like Ru to efficiently catalyze two consecutive reactions. 
Remarkably, high enantioselectivities were obtained from the mixture of Ru species present at the 
end of the metathesis reaction. In fact, practitioners in the field of AH usually take care of using 
very pure metal precursors, due to the high sensitivity of these reactions. However, this is not 
essential as long as the enantioselective species are much more active than the non-
enantioselective ones. Considering the latest developments in the Ru-based metathesis to form 
tri- and tetrasubstituted prochiral olefins,41 we hope that this methodology could be applied to a 
great number of substrates. Furthermore, we have demonstrated that this technology can be used 
for an alternative synthesis of 3-substitued piperidines, thus complementing the one presented in 
Chapter III, by tandem RCM–AH. 
V.4 EXPERIMENTAL SECTION 
Dry DCM and THF were obtained from MBraun SPS system. Dry MeOH, iPrOH, DMF 
and acetonitrile (over molecular sieves in bottles with crown cap) were purchased from Sigma 
Aldrich and stored under nitrogen. Commercially available reagents (from TCI Chemicals, 
ACROS, Sigma Aldrich, Strem) were used as received, without any further purification. (Z)-
methyl 2-acetamido-3-phenylacrylate (11) was synthesized according to the procedure described 
by Merlic et al.42 N-(but-3-en-1-yl)-4-methyl-N-(2-methylallyl)benzenesulfonamide (24a) and 5-
methyl-1-tosyl-1,2,3,6-tetrahydropyridine (25a) were synthesized according to the procedure 
described by Andersson et al.40 
The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution. 
Flash column chromatography was performed using Grace Reveleris® X2 Flash Chromatography 
System (silica gel cartridges with particle size 40 μm). Gas chromatography was performed on an 
Agilent Technologies 7890A and Hewlett Packard 6890 instruments, equipped with a flame 
ionization detector, using respectively a chiral and an achiral capillary column. Mass analysis was 
performed using a Hewlett Packard 6890 instrument coupled with a mass spectrometer. 
1H-NMR spectra were recorded on a spectrometer operating at 300 MHz. Proton chemical 
shifts are reported in ppm (δ) with the solvent reference relative to tetramethylsilane (TMS) 
employed as the internal standard (CDCl3 δ = 7.26 ppm; CD2Cl2 δ = 5.32 ppm, iPrOH-d8 δ = 
1.10, 3.89, 5.27[H2O] ppm). 13C-NMR spectra were recorded on a 300 MHz spectrometer 
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operating at 75 MHz, with complete proton decoupling. Carbon chemical shifts are reported in 
ppm (δ) relative to TMS with the respective solvent resonance as the internal standard (CDCl3, δ 
= 77.2 ppm; CD2Cl2 δ = 54.0 ppm). The following abbreviations are used to describe spin 
multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad signal, dd = 
doublet-doublet, td = triplet-doublet, ddd = doublet-doublet-doublet. Coupling constant values 
are given in Hz. 
Synthesis of new compounds 
Allyl 2-acetamidoacrylate (18): Allyl bromide (2.6 mL, 30 mmol) was added to 
a solution of 2-acetamidoacrylic acid (2.6 g, 20 mmol) and K2CO3 (3.3 g, 24 
mmol) in 200 mL of DMF. The reaction mixture was stirred overnight at room 
temperature. After that, it was diluted with EtOAc (400 mL) and extracted with water (2 x 400 
mL), 2 M HCl (1 x 400 mL) and brine (2 x 400 mL). The collected organic extracts were dried 
over anhydrous MgSO4 and concentrated under reduced pressure. After purification by column 
chromatography with heptane/EtOAc (95:5 to 85:15), allyl 2-acetamidoacrylate (3.2 g, 95 %) 
was obtained as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.73 (bs, 1H), 6.61 (s, 1H), 5.95 
(m, 1H), 5.93 (s, 1H), 5.37 (ddd, 3J(H,H) = 17.1 Hz, 2J(H,H) = 2.5 Hz, 4J(H,H) = 1.2 Hz, 1H), 
5.30 (ddd, 3J(H,H) = 10.2 Hz, 2J(H,H) = 2.5 Hz, 4J(H,H) = 1.2 Hz, 1H), 4.73 (dt, 3J(H,H) = 5.7 
Hz, 4J(H,H) = 1.2 Hz, 2H), 2.13 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.9, 164.0, 131.4, 
131.0, 119.2, 108.9, 66.8, 24.8; GC-MS: found molecular peak – 169 (expected 169). 
Non-2-en-1-yl 2-acetamidoacrylate (20): In a nitrogen filled mBraun 
glovebox, to a solution of Hoveyda-Grubbs 2nd Generation catalyst (19 mg, 
0.03 mmol, 5 mol%) in DCM (0.3 mL), a mixture of allyl 2-acetamidoacrylate 
(102 mg, 0.6 mmol) and 1-octene (60 mmol, 100 equiv.) in DCM (0.5 mL) was added. The vial 
was capped with a PTFE septum, pierced with a needle and stirred at 40°C for 5.5 hours. After 
purification by column chromatography with heptane/EtOAc (100:0 to 95:5), non-2-en-1-yl 2-
acetamidoacrylate (99 mg, 0.39 mmol, 65% yield, 9:1 of E/Z ratio) was obtained. 1H NMR (300 
MHz, CD2Cl2) δ 7.68 (bs, 1H), 6.43 (s, 1H), 5,76 (m, 1H), 5.75 (s, 1H), 5.52 (m, 1H), 4.69 (dd, 
3J(H,H) = 6.8 Hz, 4J(H,H) = 1.2 Hz, 0.2H (Z)-isomer), 4.57 (dd, 3J(H,H) = 6.5 Hz, 4J(H,H) = 
1.1 Hz, 1.8H (E)-isomer), 2.00 (s, 3H), 1.98 (m, 2H), 1.23 (m, 8H), 0.79 (t, J = 6.7 Hz, 3H); 13C 
NMR for E-isomer (75 MHz, CD2Cl2) δ 169.2, 164.4, 138.1, 132.1, 123.5, 108.0, 67.4, 32.8, 32.2, 
29.4, 29.3, 25.0, 23.2, 14.4; 13C NMR for Z-isomer (75 MHz, CD2Cl2) δ 169.2, 164.5, 137.0, 
132.1, 123.0, 108.1, 62.4, 32.3, 30.0, 29.4, 28.2, 25.0, 23.2, 14.4; GC-MS: found molecular peak – 
253 (expected 253). 
N-(2-Oxo-2,5-dihydrofuran-3-yl)acetamide (23): obtained as a by-product of the 
previously described cross-metathesis (18% yield). 1H NMR (300 MHz, CD2Cl2) δ 
7.73 (bs, 1H), 7.40 (t, J = 2.1 Hz, 1H), 4.80 (d, J = 2.1 Hz, 2H), 2.07 (s, 3H); 13C 
NMR (75 MHz, CD2Cl2) δ 171.0, 169.6, 126.4, 126.2, 71.3, 24.2; GC-MS: found molecular peak 
– 141 (expected 141). 
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General procedure for the asymmetric hydrogenation  
Using Biotage® Endeavor™ - equipped with eight parallel autoclaves and allowing monitoring 
hydrogen consumption in real time. The substrate (1 mmol), metal complex (1 mol%) and ligand 
(1.1 mol%) were weighed in glass vials and placed in the reactor under a flow of N2. THF or 
DCM were added, followed by the selected alcohol (iPrOH or MeOH), to a total volume of 
5 mL. The system was purged five times with 3 bar of N2 and five times with 10 bar of H2. The 
reactions were stirred for 16 hours under 25 bar of H2 at room temperature and then analyzed by 
GC for conversion and ee determination. This procedure was used for all the hydrogenations of 2-
acetamido-acrylic acid methyl ester (9), methyl 2-acetamidocinnamate (11) and dimethyl 
itaconate (13). 
Using Premex 96er Multireaktor® - autoclave allowing performing up to 96 reactions in 
parallel. In a N2 filled mBraun glovebox, the ligand in solution (0.825 μmol in 200 μL of DCM, 
1.1 mol%) were dispensed into 5 mL vials using Zinsser LISSY® Automated Liquid Handling 
Platform. The solvent was left for evaporation during 4h. A solution of the substrate (75 μmol in 
100 μL in DCM or THF) and the metal complex (0. 75 μmol in 150 μL in DCM or THF, 1 
mol%) were added. The the selected alcohol was added to the vials in the selected amount. After 
capping with a PTFE septum, the vials were removed from the glovebox and placed in the 
Premex A96 Multireaktor®. The system was purged three times with 10 bar of N2 and three times 
with 10 bar of H2. The reactions were stirred overnight under 50 bar of H2 at room temperature. 
The reactions mixtures were analyzed by GC for conversion and ee determination. This 
procedure was used for large screenings. 
Preparation of the racemates. The substrate (0.15 mmol) in DCM (1 mL) was added to a 
vial with palladium on carbon (0.015 mmol) and placed into Premex 96er Multireaktor®. The 
system was purged five times with 10 bar of N2 and five times with 10 bar of H2. The reactions 
were stirred for 16 hours under 50 bar of H2 at room temperature. After filtration through a short 
pad of Celite®, the samples were analyzed by GC.  
Methyl acetylalaninate (10):43 Conversion and enantiomeric excess determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; 
oven temperature: 115 °C for 7 min.: t9 = 2.8 min.; te1 = 3.3 min.; te2 = 3.4 min.  
Methyl 2-acetamido-3-phenylpropanoate (12):44 Conversion and enantiomeric 
excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 150 °C for 14 min., 15 °C/min. to 190 
°C: te1 = 13.0 min.; te2 = 13.4 min.; t11 = 18.2 min. 
Dimethyl 2-methylsuccinate (14): 45  Conversion and enantiomeric excess 
determined by GC: Astec® Chiraldex® G-TA (30m x 0.25mm, 0.12 μm); carrier: 
helium; gas flow: 1.0 bar; oven temperature: 85 °C for 22 min., 10 °C/min. to 165 
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°C: te1 = 20.4 min.; te2 = 21.1 min.; t13 = 25.4 min. 
Propyl acetylalaninate (22): 1H NMR (300 MHz, CDCl3) δ 6.11 (bs, 1H), 4.58 
(m, 1H), 4.10 (t, 3J(H,H) = 6.5 Hz, 2H), 2.01 (s, 3H), 1.67 (m, 2H), 1.40 (d, 
3J(H,H) = 7.1 Hz, 3H), 0.94 (t, 3J(H,H) = 7.4 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 173.7, 169.9, 67.4, 48.5, 23.6, 22.3, 19.1, 10.7; GC-MS: found molecular peak – 173 
(expected 173). Conversion and enantiomeric excess determined by GC: CP-Chirasil-Dex CB 
(25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 
min.: t18 = 6.0 min., te1 = 6.6 min., te2 = 6.8 min.  
Nonyl 2-acetamidopropanoate (21): 1H NMR (300 MHz, CDCl3) 
δ 6.15 (bs, 1H), 4.56 (m, 1H), 4.10 (m, 2H), 2.01 (s, 3H), 1.63 (m, 
2H), 1.39 (d, 3J(H,H) = 7.2 Hz, 3H), 1.36 – 1.21 (m, 12H), 0.87 (t, 
3J(H,H) = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 173.4, 169.8, 77.2, 65.8, 48.3, 32.0, 29.6, 
29.3, 29.3, 28.6, 25.9, 23.3, 22.8, 18.8, 14.2; GC-MS: found molecular peak – 257 (expected 257). 
Conversion and enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 
0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 140 °C for 50 min., 20 °C/min to 
190 °C: t(Z)-20 = 46.6 min.; te1 = 48.1 min.; te2 = 49.1 min.; t(E)-20 = 51.1min. 
3-methyl-1-tosylpiperidine (26a):40 Conversion and enantiomeric excess determined 
by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 
bar; oven temperature: 160 °C for 30.5 min, gradient 20 °C/min, 180 °C for 3 min.: te1 = 
29.3 min.; te2 = 30.0 min.; t25a = 32.8 min. 
Procedure for the proof of concept of the tandem metathesis–AH 
 
In a N2 filled mBraun glovebox, a solution of HG-II (6.27 mg, 0.01 mmol) in DCM (1 mL) 
was added to diethyl diallylmalonate (1 mmol, 240 mg). The reaction mixture was stirred in an 
open glass vial for 15 min. Analysis by GC confirmed that the RCM of the substrate was 
complete. The vial was placed in the Biotage® Endeavor™ under flow of N2. 9 (143 mg, 1 mmol), 
(S)-BINAP (6.9 mg, 0.011 mmol) and iPrOH (4 mL) were added. The system was purged five 
times with 3 bar of N2 and five times with 10 bar of H2. The reactions mixture was stirred for 16 h 
under 25 bar of H2 at room temperature. 
Conversion and enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 
0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 105 °C for 10 min., 5 
°C/min. to 125 °C: t9 = 4.9 min.; t10 = 6.2 and 6.7 min.; t17 = 12.3 min. 
N
Ts
*
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Procedure for tandem metathesis–AH of 18 
 
Step I: Cross-metathesis 
In a N2 filled mBraun glovebox, in a 5 mL vial, HG-II (0.0075 mmol, 5 mol%) was dissolved 
in DCM (1.0 mL). A mixture of 18 (0.15 mmol) and 1-octene 19 (15 mmol, 100 eq) in DCM 
(0.5 mL) was added. The vial was capped with a PTFE septum, pierced with a needle and stirred 
at 40°C for 5.5 hours (until full solvent evaporation).  
Conversion determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 min., 30 °C/min., 150 °C for 10 min, 
30 °C/min, 180 °C for 5 min: t18 = 6.0 min; t(Z)-tetradec-7-ene = 7.1 min.; t(E)-tetradec-7-ene = 7.4 min.; 
t23 = 12.3 min.; t(Z)-20 = 24.7 min., t(E)-20 = 25.2 min. 
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Step II: Asymmetric hydrogenation  
To the vial from step I, a solution of (S)-BINAP (0.083 mmol, 5.5 mol%) in THF (1.6 mL) 
was added followed by MeOH (0.4 mL). After recapping with a PTFE septum, the vial was 
removed from the glovebox and placed in the Premex 96er Multireaktor®. The system was purged 
three times with 10 bar of N2 and three times with 10 bar of H2. The reactions were stirred 
overnight under 50 bar of H2 at room temperature. 
Conversion and enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 
0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 min., 30 
°C/min., 150 °C for 10 min, 30 °C/min, 180 °C for 5 min: t22 = 6.6 and 6.8 min.; t(E)-tetradec-7-ene = 
7.4 min.; ttetradecane = 7.6 min.; t23 = 12.3 min.; t21 = 24.6 min. (no separation of the enantiomers) 
Enantiomeric excess of 21: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; 
gas flow: 2.7 bar; oven temperature: 140 °C for 50 min., 20 °C/min to 190 °C: t21 = 48.1 and 49.1 
min. 
 
High-throughput screening for the tandem metathesis–AH of 24a 
 
Step I: RCM  
In a N2 filled mBraun glovebox, to a 20 mL vial with 24a (2.87 mmol) a solution of Grubbs 
catalyst (0.144 mmol - 5 mol %) in 6.5 mL of solvent (DCM or THF) was added. The vial was 
capped with a PTFE septum, pierced with a needle and stirred for 15 min at 26 °C. A sample was 
analyzed by GC, confirming that the reaction was complete:  
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Conversion determined by GC: Agilent J&W HP-1 (30m x 0.32mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 150°C, 10 °C/min. to 250°C: t24a = 6.9 min.; t25a = 
7.4 min. 
Step II: Asymmetric hydrogenation  
Using Zinsser LISSY® Automated Liquid Handling Platform, the solution of 25a with the Ru 
catalyst (170 μL containing 0.07 mmol of 25a and 0.0035 mmol of Ru) was dispensed to 5 mL 
vials containing a chiral ligand solution (330 μL, 0.0039 mmol, 5.5 mol %). Alcohols (0.5 mL of 
methanol or propan-2-ol) were added. After capping with a PTFE septum, the vials were 
removed from the glovebox and placed in the Premex 96er Multireaktor®. The system was purged 
three times with 10 bar of N2 and three times with 10 bar of H2. The reactions were stirred 
overnight under 50 bar of H2 at room temperature.  
Conversion and enantiomeric excess determined by GC: CP-Chirasil-Dex CB (25m x 
0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 160 °C for 30.5 min, 
gradient 20 °C/min, 180 °C for 3 min.: t24a = 29.3 and 30.0 min.; t25a = 32.8 min. 
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CHAPTER VI. 
TANDEM OLEFIN METATHESIS – 
ASYMMETRIC TRANSFER HYDROGENATION 
 
VI.1 INTRODUCTION 
Having demonstrated that Ru olefin metathesis catalyst can be converted into efficient 
asymmetric hydrogenation catalyst by addition of a chiral ligand (Chapter V), we decided to 
expand this concept to transfer hydrogenation reactions.  
Transfer hydrogenation refers to reactions where the hydrogen added to a molecule 
originates from a non-H2 source. This methodology is a good alternative to direct hydrogenation 
for a series of reasons: (i) it does not require the use of hazardous pressurized H2 and specific 
experimental setups; (ii) the hydrogen donors are readily available, inexpensive and easy to 
handle; (iii) the dehydrogenated compound can be recycled.46 
As discussed in Chapter IV, Grubbs and co-workers already demonstrated the possibility of a 
tandem metathesis–transfer hydrogenation of carbonyl groups,7 but later publications have been 
mainly focused in the transfer hydrogenation of C=C bonds.17-21 In our case, we decided to focus 
on the enantioselective reduction of prochiral ketones. A tandem protocol of this kind would 
allow for an olefin metathesis followed by the asymmetric transfer hydrogenation (ATH) of a 
carbonyl group present in the molecule, employing only one Ru source. 
VI.2 RESULTS AND DISCUSSION 
Initially we explored the viability of converting a Ru olefin metathesis catalyst into an ATH 
catalyst. To do so, we took inspiration from the seminal work of Noyori and co-workers in the 
ATH of ketones with Ru catalysts.47 We selected acetophenone (27a) as model substrate, HG-I 
as Ru precursor, (R,R)-TsDPEN (L1) as chiral ligand, tBuOK as base to activate the catalyst and 
iPrOH as the hydrogen donor. Since the final goal was to apply this methodology after a 
metathesis step, two co-solvents suitable for this reaction were chosen, THF and DCM. 
Gratifyingly, the initial tests already achieved good conversions and moderate 
enantioselectivities. Similar enantiomeric excesses were obtained, 67% and 72% respectively, 
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suggesting that the same active species are present in solution, but higher activities were observed 
in THF (Scheme 31). When the same experiment was performed with HG-II, only poor 
activities (less than 15% conversion) and low enantioselectivities (less than 9% ee) were 
obtained.  
 
Scheme 31. Initial tests on the ATH of acetophenone (27a) with HG-I. 
 
Figure 9. Conversion and ee vs time for the ATH of 27a. 27a and HG-I were mixed in THF and the other 
components were subsequently added in the order shown on top of each graph (stirring 5 min between each 
addition unless otherwise stated). Reaction conditions: 27a (0.1 mmol), HG-I (1 mol%), THF (1 mL), L1 
(1.1 mol%), base (20 mol%), iPrOH (1 mL), 30 °C, 18 h. Conversion and ee determined by chiral GC. 
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When the reaction was monitored over time, we found out that the enantiomeric excess was 
increasing during the first 18 h (Figure 9A, order of addition used in the initial tests). This 
observation led us to think that probably a more enantioselective species than the initial one(s) 
was being formed during the course of the reaction. Thus, we first tried to stir the catalyst for 
longer in presence of the base before the addition of iPrOH (Figure 9B), but this was only 
detrimental for the activity. Furthermore, when adding the base before the ligand, both the 
activity and the enantioselectivity were negatively affected (Figure 9C). From these experiments 
we concluded that addition of iPrOH was the responsible of the formation of highly 
enantioselective species, most probably by reaction with tert-butoxide to give isopropoxide. 
Hence, when tBuOK was added the latest (Figure 9D), 1-phenylethanol (28a) was obtained with 
96% conversion and 90% ee and, importantly, the enantiomeric excess remained constant during 
all the reaction course. Surprisingly, no erosion of the ee was observed even after 40 h of reaction, 
in contrast to what is observed with these types of reactions as a result of the reversibility of this 
transformation.47a,48 When KOMe was employed instead of tBuOK, the same behavior was 
observed regarding the order of addition of base and iPrOH (Figure 9E and F). In contrast, when 
iPrONa was employed, a high ee was observed from the beginning of the reaction independently 
of the order of addition (Figure 9G and H). Remarkably, the latter reactions showed a slow 
erosion of the ee with time, possibly due to a cation effect (Na vs K) already reported in previous 
studies.49 All these experiments together point towards a Ru-isopropoxide species as the 
responsible for the high enantiomeric excesses obtained or as the intermediate towards it. 
Actually, the remarkably stable 14-electron species [(PCy3)(tBuO)2Ru=CHPh] has been 
isolated and characterized by Grubbs and co-workers by reaction of G-I with an excess of 
tBuOK.31 An analogue of this compound is what we might be forming when we add the tBuOK 
before the iPrOH. 
To try to get further insight into the active species responsible for the obtained 
enantioselectivity we undertook some NMR and GC-MS studies under the optimized reaction 
conditions (Figure 9D). HG-I and TsDPEN were dissolved in THF-d8:iPrOH-d8 (1:1), and 
NMR spectra were recorded before adding the tBuOK and after stirring the mixture with the base 
for 5 h. In the 31P NMR (Figure 10), the singlet at δ = 56.1 ppm, corresponding to the Ru(PCy3), 
disappeared after addition of the base. Besides, some new species formed: two singlets at δ = 47.3 
and 6.2 ppm corresponding to O=PCy3 and free PCy3, respectively, and more interesting, two 
1:1:1 triplets at δ = 56.8 and 56.2 ppm, in a ratio 3:1. These triplets correspond to RuD(PCy3) 
species, both with a 2JP,D = 7.7 Hz. Consistently with the latter signals, the 1H NMR (Figure 11) 
showed two doublets at δ = -7.4 and -7.5 ppm (with a 2JH,P = 52 Hz) in a ratio 3:1, corresponding 
to the same species but with hydrogen instead of deuterium, RuH(PCy3). In this case the 
intensity is very low, since these species are formed with the residual undeuterated iPrOH. 
Knowing that 2JH,P coupling constants follow a Karplus-like equation,50 the value of 52 Hz 
suggests a disposition of the hydride in between cis (10-25 Hz) and trans (>100 Hz) with respect 
to the phosphine. Two more singlets, corresponding to RuH species without any phosphine 
coordinated, are also observed at δ = -5.0 and -6.2 ppm. It is remarkable the high ee obtained with 
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this system if we consider the mixture of hydride species observed by NMR. This suggests that 
one enantioselective Ru species bearing the TsDPEN ligand is much more active than the other 
species present in solution. 
 
Figure 10. Comparison of the 31P NMR before and after the addition of tBuOK (15 equiv.) to a solution of 
HG-I (5 mg) and TsDPEN (1.1 equiv.) in THF-d8:iPrOH-d8 (1:1, 1 mL).  
 
Figure 11. Comparison of the 1H NMR before and after the addition of tBuOK (15 equiv.) to a solution of 
HG-I (5 mg) and TsDPEN (1.1 equiv.) in THF-d8:iPrOH-d8 (1:1, 1 mL).  
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Furthermore, the benzylidene proton at δ = 17.2 ppm completely disappeared after the 
addition of tBuOK. All these data are consistent with the alcoholysis of Grubbs catalysts and the 
concomitant formation of Ru hydrides, which has been previously reported.24,27,29,30 When the 
same sample was injected in the GC-MS, a peak corresponding to o-isopropoxytoluene-d2 (m/z = 
152) was detected and, as expected, when the experiment was performed with non-deuterated 
solvents, undeuterated o-isopropoxytoluene (m/z = 150) was detected instead. This confirms 
that the benzylidene moiety is hydrogenated out after dehydrogenation of iPrOH, as shown in 
Scheme 32. Initially the chlorides would be exchanged by isopropoxide30 and subsequent partial 
hydrogenation of the benzylidene moiety with concomitant release of acetone would afford 
complex 30. Then, dehydrogenation of another molecule of iPrOH would complete the 
hydrogenation of the benzylidene moiety releasing o-isopropoxytoluene and forming hydride 
species 31, which might be able to accommodate the TsDPEN ligand. 
 
Scheme 32. Proposed mechanism for the hydrogenation of the benzylidene moiety and for chelation of the 
TsDPEN ligand. 
Interesting was also the deuteration pattern observed on PCy3. When non-deuterated PCy3 
was injected in the GC-MS, the mass spectra showed three main fragments with m/z = 280, 198 
and 117 corresponding to PCy3·+, PHCy2·+ and PH3Cy+, respectively (see Figure 12). However, 
when the reaction was performed in deuterated solvents PCy3-d9 was found instead and, 
according to the fragmentation peaks (m/z = 289, 204 and 120) each cyclohexyl contained 
exactly three deuterium atoms (Figure 12). Indeed, the same trend is observed for O=PCy3 and 
O=PCy3-d9 
 
Figure 12. Main peaks observed in the GC-MS fragmentation for PCy3 and PCy3-d9 
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The deuterium incorporation on the cyclohexyl ring presumably takes place in the 3-, 4- and 
5-positions, otherwise the deuterium would be transferred to the phosphorus atom during the 
fragmentation process, according to the proposed fragmentation pathway (Scheme 33).51 
 
Scheme 33. Proposed fragmentation pathway for PCy3-d9. 
We propose that this deuteration takes place via a C-H activation forming stable 5- and 6-
membered metallacycles with the 3-, 4- and 5-positions of the cyclohexyl ring, as shown in 
Scheme 34. In fact, a chelation like the one of complex 34, have been reported also by Cheung et 
al with similar complexes.52  
 
Scheme 34. Proposed pathway for the deuteration of the cyclohexyl rings. 
Simultaneously to this mechanistic study, the ATH of 27a was further optimized (Table 8). 
As expected, when no base was added, no conversion was obtained (Table 8, entry 1), and at least 
20 equivalents of base compared to Ru had to be used to achieve some conversion (entries 2-5). 
Different ratios of THF/iPrOH were also explored, finding that a higher amount of iPrOH 
increased the activity (entry 6) and a higher amount of THF slightly increased the ee but 
decreased the activity (entry 7). The most common commercially available Ru olefin metathesis 
catalyst were also tested and, surprisingly, only the 1st generation catalyst achieved good results 
(entries 6 and 8), while NHC-containing catalysts led to conversions under 10% (entries 9-11). 
Finally, a ligand screening was performed (entries 12-17), making evident the great dependence 
of both activity and enantioselectivity from small variations on the ligand structure. The only 
ligand with a performance comparable to that one of (R,R)-TsDPEN (L1) was the (R,R)-
camphorsulfonyl-DPEN (L4). 
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Table 8. Optimization of the reaction conditions on the ATH of 27a. 
 
# Ru cat. Ligand tBuOK THF/iPrOH Conv. (%) ee (%) 
1 HG-I L1 - 1:1 0 - 
2 HG-I L1 5 1:1 0 - 
3 HG-I L1 10 1:1 0 - 
4 HG-I L1 20 1:1 86 93 
5 HG-I L1 40 1:1 95 92 
6 HG-I L1 20 1:3 97 93 
7 HG-I L1 20 3:1 56 96 
8 G-I L1 20 1:3 96 95 
9 HG-II L1 20 1:3 4 10 
10 G-II L1 20 1:3 8 86 
11 G-III L1 20 1:3 4 30 
12 HG-I L2 20 1:3 53 62 
13 HG-I L3 20 1:3 96 88 
14 HG-I L4 20 1:3 92 94 
15 HG-I L5 20 1:3 97 78 
16 HG-I L6 20 1:3 67 64 
17 HG-I L7 20 1:3 34 -5 
 
Reaction conditions: 27a (0.1 mmol), Ru catalyst (1 mol%), ligand (1.1 mol%), THF/iPrOH (2 mL), 
tBuOK, 30 °C, 18 h. Conversion and ee determined by chiral GC. 
Surprised by the negative results obtained with 2nd generation catalysts, we performed a 
series of experiments to try to form active an enantioselective species from G-II (Table 9). The 
highest enantioselectivities were obtained with isopropoxide (entries 1 and 3), but with very low 
activities. When pre-stirring the catalyst with tBuOK (entry 2), again a very ineffective catalyst 
was obtained. Instead, when using methoxide the activity increased substantially, probably due to 
the formation of active Ru carbonyl species, but unfortunately the obtained enantioselectivities 
were very low (entries 4 and 5). Finally, to assess whether the lack of activity in the standard 
conditions was due to a lack of stability of the formed complex, as Fogg had reported for G-III,9 
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we added one equivalent of PCy3, and in fact the activity increased, but the enantioselectivity 
dropped considerably.  
Table 9. Attempts to convert G-II into a highly active and enantioselective ATH catalyst. 
 
# 
Penultimate 
reagent added[a] 
Last reagent 
 added[a] 
Conv. (%) ee (%) 
1 iPrOH tBuOK 8 86 
2 tBuOK iPrOH 30 24 
3 iPrOK[b] iPrOH 16 77 
4 NaOMe iPrOH 57 20 
5 KOMe iPrOH 33 10 
6 iPrOH + PCy3[c] tBuOK 47 37 
Reaction conditions: 27a (0.1 mmol), Ru catalyst (1 mol%), ligand (1.1 mol%), THF/iPrOH (2 mL), 
tBuOK, 30 °C, 18 h. Conversion and ee determined by chiral GC. [a] Between the penultimate reagent 
added and the last one, the solution was stirred for 3 h at 30 °C. [b] A 0.5 M solution of tBuOK in iPrOH 
was used. [c] 1 equivalent of PCy3 compared to Ru. 
With the optimized conditions and, unfortunately, without being able to effectively convert 
NHC-containing Ru precursors in ATH catalysts, we set to validate the system with a substrate 
screening employing HG-I and (R,R)-TsDPEN (Table 10). Very bulky alkyl groups were not 
well tolerated, decreasing substantially the activity and the enantioselectivity (entries 2-4). The 
presence of orto-substituents in the aromatic ring produced the same effect (entry 8). The best 
conversions were achieved with electron-deficient acetophenones (entries 5 and 6), while the 
electron-rich ones only led to good conversions (entry 7). 2-Acetonaphtone as well as aromatic 
cyclic ketones (entries 9-11) were reduced with ee’s up to 97%. Unfortunately, more challenging 
substrates such as 3-acetylpyridine (entry 14) or alkyl ketones (entries 12 and 13) led to poor or 
no conversion and low ee. In general, the obtained results are quite close to those reported with 
the Noyori catalyst.47 
Table 10. Substrate scope for the ATH with HG-I and (R,R)-TsDPEN. 
# Substrate 
Conv. (%)
ee (%) 
# Substrate 
Conv. (%) 
ee (%) 
1 
 
97 
93, R 
8 
0 
n.d. 
2 
 
84 
90, R 
9 
96 
95, R 
3 
 
27 
33, R 
10 
60 
97, R 
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4 
 
36 
17, R 
11 
43 
93, R 
5 
99 
80, R 
12 
4 
n.d. 
6 
100 
73, R 
13 
45 
30, R 
7 
73 
85, R 14 
0 
n.d. 
Reaction conditions: 27 (0.1 mmol), HG-I (1 mol%), (R,R)-L1 (1.1 mol%), THF/iPrOH (1:3, 2 mL), 
tBuOK (20 mol%), 30 °C, 20 h. Conversion and ee determined by chiral GC. n.d.= not determined. [a] 40 
equivalents of base compared to the catalyst. [b] Reaction run for 44 h. [c] Reaction run for 90 h.  
The reduction of the imine 27o was also attempted, but unfortunately no conversion was 
obtained under the optimized conditions (Scheme 35). 
 
Scheme 35. Attempt for the ATH of imine 27o. 
We then tested the possibility to hydrogenate α,β-unsaturated ketones. When trans-chalcone 
(27p) was submitted to the optimized ATH conditions, three different products were obtained 
(Scheme 36), the main product being the fully reduced alcohol 28p with 80% ee. To assess which 
of the two partially hydrogenated products was the intermediate towards 28p, the commercially 
available alcohol 28’’p was submitted to ATH conditions, but almost no conversion was 
observed. This suggests that, while simple double bonds are unreactive under these conditions, 
double bonds conjugated with ketones are readily hydrogenated. Thus, the formation of 28p 
goes via intermediate 28’p. 
 
Scheme 36. ATH of trans-chalcone 27p. 
The last substrate tested was the β,γ-unsaturated ketone 27q, and also in this case the double 
bond was hydrogenated faster than the ketone. Since we have observed that isolated double 
bonds are not hydrogenated with this system, we proposed that a base-catalyzed isomerization of 
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the double bond would produce the α,β-unsaturated ketone53 which would be then readily 
hydrogenated to 28’q, and a subsequent ketone reduction would render alcohol 28q. 
 
Scheme 37. ATH of 1-phenylbut-3-en-1-one (27q). 
Once demonstrated that 1st generation Ru olefin metathesis catalyst can be converted into 
efficient ATH catalysts by addition of a chiral ligand, iPrOH and a base, we undertook 
investigations towards a tandem olefin metathesis–ATH protocol. The first thing to test was 
whether the Ru complex could be converted into an ATH catalyst after having performed a 
metathesis step. To this purpose, we carried out in parallel the ring-closing metathesis (RCM) of 
diethyl 2,2-diallylmalonate (15) and the homo-metathesis of 1-octene (19) in presence of 
acetophenone (27a). After checking by GC that the metathesis reaction had been completed, the 
ligand, iPrOH and tBuOK were added in this order. After 20 h of reaction, (R)-1-phenylethanol 
was obtained with moderate conversions and excellent enantioselectivities, 93% and 89% ee 
respectively (Scheme 38). It is also remarkable that the double bonds generated by metathesis 
remained unchanged after the ATH step. 
 
Scheme 38. Proof of concept for the tandem olefin metathesis–ATH. 
Encouraged by the obtained results, we undertook the search of a substrate that could 
undergo both the metathesis reaction and the ATH. The β,γ-unsaturated ketone 27q was the first 
choice, but when the metathesis reaction was attempted no conversion was obtained, 
independently of the cross-metathesis partner. This was probably due to the stable chelating 
alkylidene complex formed with these kinds of substrates after the first metathesis cycle (Scheme 
39).54  
 
Scheme 39. Chelating alkylidene Ru-complex formed by reaction of β,γ-unsaturated ketones and HG-I. 
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The second substrate synthesized was the diallyl ketone 37. In this case the RCM proceeded 
smoothly, but when the ATH was attempted no carbonyl reduction was observed (Scheme 40).  
 
Scheme 40. Attempt of tandem RCM–ATH of 37. 
Surprised by this lack of activity we tried to find a possible cause. The metathesis reaction 
was repeated and, before starting the ATH step, acetophenone (27a) was added to the reaction 
mixture. After 4 h of hydrogenation, (R)-1-phenylethanol was observed with 10% conversion and 
77% ee, proving that the catalyst was still active, although less than usual. To check if the problem 
was arising from the substrate, ketones 38 and 40 were synthesized and isolated (Scheme 41). 
When these two were submitted to the standard ATH conditions, results comparable to those 
obtained with 2-methyl-1-phenylpropan-1-one (27c) were observed. Then, the only possible 
explanation for the lack of activity might be the conjunction of a not very active catalyst, formed 
after the RCM step, with a sterically hindered substrate, challenging for this system. 
 
Scheme 41. Attempts to hydrogenate ketones 38 and 40 with the optimized ATH conditions. 
After trying different substrates with olefins in the alkyl part of the ketone without much 
success, it was decided to attach the olefin to the aromatic moiety, thus 4-vinylacetophenone 
(42) was selected as substrate. Although electron-poor styrenes are known to be sluggish in 
metathesis with 1st generation Grubbs catalysts (type II olefin in Chatterjee/Grubbs 
nomenclature),55 we expected that the distance between the double bond and the ketone would 
make the ATH step easier. 1-octene was selected as a cross-metathesis partner and the tandem 
metathesis–ATH was carried out in different solvents and with G-I or HG-I as catalysts (Table 
11, entries 1-6). HG-I performed much better than G-I and, while the best ee was obtained in 
toluene (entry 4), the best overall conversion was achieved in DCM (entry 5). Performing the 
metathesis reaction in toluene at 50 °C, instead of 40 °C, led to a higher overall yield but a lower 
enantioselectivity (entry 7). When 2,2-dichloroethane was used instead of DCM, the 
temperature of the metathesis step could be risen to 50 °C, which proved beneficial for the 
conversion (entry 8). Moreover, in the ATH step a good conversion (60%) and the highest 
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enantiomeric excess (87% ee) were obtained. The remaining 4-vinylacetophenone (42) was 
hydrogenated to 1-(4-vinylphenyl)ethan-1-ol (45) with 79% conversion and 90% ee. 
Table 11. Tandem cross metathesis–ATH of 4-vinylacetophenone (37) with 1-octene. 
 
# Solvent 
Metathesis ATH 
Conditions Conv. (%) Conv. (%) ee (%) 
1 toluene G-I, 40 °C, 4h 39 12 24 
2 DCM G-I, 40 °C, 4h 18 10 35 
3 THF G-I, 40 °C, 4h 38 50 19 
4 toluene HG-I, 40 °C, 4h 30 26 73 
5 DCM HG-I, 40 °C, 4h 38 74 54 
6 THF HG-I, 40 °C, 4h 18 23 64 
7 toluene HG-I, 50 °C, 5h 42 54 48 
8 2,2-dichloroethane HG-I, 50 °C, 5h 46 60 87 
Reaction conditions: Metathesis: 42 (0.05 mmol), 19 (0.15 mmol), Ru cat. (10 
mol%), solvent (0.3 mL); ATH: (R,R)-L1 (11 mol%), solvent (0.3 mL), iPrOH 
(1.5 mL), tBuOK (20 mol%), 30 °C, 18 h. Conversion and ee determined by chiral 
GC.  
VI.3 CONCLUSIONS 
In this chapter, it has been demonstrated that 1st generation Ru olefin metathesis catalyst can 
be converted into efficient and highly enantioselective asymmetric transfer hydrogenation 
catalysts, achieving enantioselectivities up to 97% ee. However, NHC-containing complexes did 
not prove suitable for this transformation. It has also been shown that a tandem olefin 
metathesis–ATH protocol is possible and a selective carbonyl hydrogenation can be obtained in 
some cases. We believe that the orthogonal reactivity shown by this system might be of interest 
for the synthetic community, especially in the field of high-throughput synthesis. Furthermore, 
the multiple uses of a precious metal such as ruthenium discloses new prospects towards a more 
efficient and sustainable use of this expensive and scarce metal. 
VI.4 EXPERIMENTAL SECTION 
Dry DCM and THF were obtained from MBraun SPS system. Dry MeOH, iPrOH and 1,2-
dichloroethane (over molecular sieves in bottles with crown cap) were purchased from Sigma 
Aldrich and stored under nitrogen. Commercially available reagents (from TCI Chemicals, 
ACROS, Sigma Aldrich, Strem) were used as received, without any further purification. 1-(4-
vinylphenyl)ethanone (42) was synthesized according to the procedure described by Littke et 
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al.56 2-allyl-1-phenylpent-4-en-1-one (37) was synthesized according to the procedure described 
by Pandey et al.57 
The reactions were monitored by analytical thin-layer chromatography (TLC) using silica 
gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with a potassium permanganate alkaline solution. 
Flash column chromatography was performed using Grace Reveleris® X2 Flash Chromatography 
System (silica gel cartridges with particle size 40 μm). Gas chromatography was performed on an 
Agilent Technologies 7890A and Hewlett Packard 6890 instruments, equipped with a flame 
ionization detector, using respectively a chiral and an achiral capillary column. Infrared spectra 
were recorded on a standard FT/IR spectrometer. High resolution mass spectra (HRMS) were 
performed on a Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometer 
APEX II & Xmass software (Bruker Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI 
source, available at CIGA (Centro Interdipartimentale Grandi Apparecchiature) c/o Università 
degli Studi di Milano.  
1H-NMR spectra were recorded in two different a spectrometer operating at 400 or 500 
MHz. Proton chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard (CDCl3 δ = 7.26 ppm; THF-d8, δ = 
1.72 and 3.58 ppm). 13C-NMR spectra were recorded on a 400 MHz spectrometer operating at 
100 MHz, with complete proton decoupling. Carbon chemical shifts are reported in ppm (δ) 
relative to TMS with the respective solvent resonance as the internal standard (CDCl3, δ = 77.2 
ppm). 31P-NMR spectra were recorded on a 500 MHz spectrometer operating at 202.5 MHz, 
with complete proton decoupling. 31P-NMR chemical shifts are reported in ppm (δ) relative to 
external H3PO4 (85% in H2O) at 0 ppm (positive values downfield). The following abbreviations 
are used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, bs = broad signal, td = triplet-doublet. Coupling constant values are given in Hz. 
Synthesis of substrates and characterization of new compounds 
1-phenylbut-3-en-1-one (27q): 1-phenylbut-3-en-1-ol (0.75 g, 5 mmol) was 
dissolved in DCM (25 mL) and cooled down to 0 °C. Dess-Martin periodinane (2.5 
g, 6 mmol) was added and the mixture was stirred for 2 h at room temperature. After that time, a 
saturated aqueous solution of NaHCO3/Na2S2O3 (1:1, 20 mL) was added and the resulting 
mixture stirred for 30 min. The organic layer was separated and washed once more with the same 
saturated solution (20 mL) and then with brine (20 mL). The organic extracts were dried with 
MgSO4, filtered and concentrated. The reaction was purified by column chromatography 
(Heptane:EtOAc 20:1). Known compound. Spectroscopic data are superimposable to those 
reported in the literature.58  
Cyclopent-3-en-1-yl(phenyl)methanone (38): 2-allyl-1-phenylpent-4-en-1-one 
37 (150 mg, 0.75 mmol), HG-I (1 mol%) and DCM (2 mL) were stirred for 2 h at 
30 °C. After this time, 38 was quantitatively obtained as observed by NMR.59 Half of 
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it was used for the synthesis of 40 and the other half was purified by filtration through a short pad 
of silica. 
Cyclopentyl(phenyl)methanone (40): the reaction crude from the synthesis of 38, 
with the Ru catalyst still inside, was submitted to hydrogenation at 70 °C and 50 bar 
of H2 for 16 h. The product was purified by filtration through a short pad of silica 
and identified as 40.21 
 (E)-1-(4-(oct-1-en-1-yl)phenyl)ethanone (43): In a 5 ml vial, 
Grubbs-Hoveyda 1st generation (30 mg, 0.05 mmol) was added to 
a mixture of 1-(4-vinylphenyl)ethanone (150 mg, 1.02 mmol) and 
1-octene (482 μl, 3.07 mmol) in 1,2-dichloroethane (2 ml). The reaction was stirred at 50 °C for 
18 h. The reaction was concentrated and purified by column chromatography (Hexane:EtOAc 
50:1) to obtain 138 mg (0.6 mmol, 59% yield) of 7-CM as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.89 (d, 3J(H,H) = 8.3 Hz, 2H), 7.41 (d, 3J(H,H) = 8.3 Hz, 2H), 6.45 – 6.36 (m, 2H), 
2.58 (s, 3H), 2.24 (m, 2H), 1.48 (m, 2H), 1.40 – 1.24 (m, 6H), 0.90 (t, 3J(H,H) = 6.8 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 197.70, 142.81, 135.49, 134.71, 129.02, 128.86, 126.02, 33.31, 
31.83, 29.23, 29.04, 26.65, 22.73, 14.21; IR (film): ν = 3027.7, 3001.7, 2956.3, 2925.5, 2854.1, 
1681.6, 1601.6, 1357.6, 1267.0, 1180.2, 965.2, 854.3 cm-1; HRMS (ESI+): m/z 253.15694 [M + 
Na]+ (calcd. for C16H22O1Na: 253.15629). 
(±,E)-1-(4-(oct-1-en-1-yl)phenyl)ethanol (44): NaBH4 (68 mg, 
1.8 mmol) was added to a solution of 7-CM (138 mg, 0.60 mmol) 
and CeCl3·7H2O (313 mg, 0.84 mmol) in MeOH (5 ml) at 0 °C 
and the solution was stirred for 3 h at room temperature. After this time, the reaction was 
quenched with a saturated aqueous solution of NH4Cl (5 ml) and extracted with DCM (3 x 
10ml). The organic phases were dried over Na2SO4, filtered and concentrated, to render 132 mg 
(0.57mmol, 95% yield) of 8 as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.27 (m, 4H), 
6.37 (d, 3J(H,H) = 15.8 Hz, 1H), 6.22 (dt, 3J(H,H) = 15.8, 6.8 Hz, 1H), 4.87 (q, 3J(H,H) = 6.4 
Hz, 1H), 2.21 (q, 3J(H,H) = 6.8 Hz, 2H), 1.81 (bs, 1H), 1.49 (d, 3J(H,H) = 6.5 Hz, 3H), 1.47 (m, 
2H), 1.40 – 1.28 (m, 6H), 0.90 (t, 3J(H,H) = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
144.44, 137.52, 131.45, 129.46, 126.18, 125.70, 70.37, 33.19, 31.90, 29.50, 29.04, 25.17, 22.77, 
14.22; IR (film): ν = 3352.6, 3022.9, 2957.3, 2924.5, 2853.2, 1453.1, 1086.7, 964.2 cm-1; HRMS 
(ESI+): m/z 255.17260 [M + Na]+ (calcd. for C16H24O1Na: 255.17194).  
General procedure for the ATH 
Substrate (0.1 mmol), metal complex (0.001 mmol, 1 mol%) and ligand (0.0011 mmol, 1.1 
mol%) were dissolved in THF (0.5 ml) and iPrOH (1.5 ml) inside a nitrogen filled mBraun 
glovebox. After stirring the solution for 5 min, tBuOK (0.02 mmol, 20 mol%) was added and the 
reaction was stirred for 20 h at 30 °C. After this time, the reaction was analyzed by GC or HPLC 
for conversion and ee determination.  
  Part B – Chapter VI 147 
Products' absolute configurations were assigned by comparison of the sign of the optical 
rotation with literature data. 
(R)-1-Phenylethanol (28a):60 Conversion and ee determined by GC: CP-Chirasil-Dex 
CB, 0.25 μm; diameter = 0.25 mm; length = 25 m; carrier: helium; gas flow: 2.7 bar; 
oven temperature: 120 °C for 10 min: tsubstrate = 3.5 min; tR = 6.9 min; tS = 7.5 min.  
(R)-1-Phenylpropan-1-ol (28b):60 Conversion and ee determined by GC: CP-
Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven 
temperature: 120 °C for 10 min: tsubstrate = 3.7 min; tR = 8.2 min; tS = 8.7 min.  
(R)-2-Methyl-1-phenylpropan-1-ol (28c):61 Conversion and ee determined by GC: 
CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; 
oven temperature: 120 °C for 15 min: tsubstrate = 4.0 min; tR = 11.7 min; tS = 12 min.  
(R)-2,2-Dimethyl-1-phenylpropan-1-ol (28d):60 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; 
oven temperature: 120 °C for 20 min: tsubstrate = 4.5 min; tS = 15.6 min; tR = 16.0 min.  
(R)-1-(4-Chlorophenyl)ethanol (28e):62 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 
bar; oven temperature: 120 °C for 25 min: tsubstrate = 6.3 min; tR = 17.3 min; tS = 
20.6 min.  
(R)-1-(4-(Trifluoromethyl)phenyl)ethanol (28f):60 Conversion and ee 
determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 min: tsubstrate = 2.7 min; 
tR = 7.7 min; tS = 9.3 min.  
(R)-1-(4-Methoxyphenyl)ethanol (28g):60 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 
2.7 bar; oven temperature: 120 °C for 20 min: tsubstrate = 10.8 min; tR = 16.7 min; 
tS = 18.3 min. 
1-(2-Chlorophenyl)ethanol (28h):63 Conversion determined by GC: CP-Chirasil-
Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven 
temperature: 120 °C for 15 min: tsubstrate = 6.6 min; tR+S = 11.7 min. 
(R)-1-(Naphthalen-1-yl)ethanol (28i):61 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 
2.7 bar; oven temperature: 140 °C for 30 min: tsubstrate = 13.9 min; tR = 25.8 min; tS 
= 28.0 min.  
(R)-1,2,3,4-Tetrahydronaphthalen-1-ol (28j):60 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 
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bar; oven temperature: 130 °C for 17 min: tsubstrate = 8.1 min; tS = 13.6 min; tR = 14.3 min.  
(R)-2,3-Dihydro-1H-inden-1-ol (28k):64 Conversion and ee determined by GC: 
CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; 
oven temperature: 130 °C for 10 min: tsubstrate = 5.1 min; tS = 7 min; tR = 7.2 min.  
1,2,3,4-Tetrahydronaphthalen-2-ol (28l):65 The product was derivatized as 
acetate before conversion and ee determination by GC: MEGADEX DACTBS, 
diacetyl-tert-butylsilyl--cyclodextrin (25m x 0.25mm, 0.25 μm); carrier: hydrogen; inlet 
pressure: 1 bar; oven temperature: 110 °C for 40 min: te1 = 29.3 min; te2 = 30.3 min; tsubstrate = 35.1 
min. 
(R)-2-Octanol (28m):66 Conversion and ee determined by GC: CP-Chirasil-Dex CB 
(25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven temperature: 80 °C 
for 25 min: tsubstrate = 9.4 min; tS = 21.1 min; tR = 21.4 min.  
1-(Pyridin-3-yl)ethanol (28n):67  Conversion determined by GC: MEGADEX 
DACTBS, diacetyl-tert-butylsilyl--cyclodextrin (25m x 0.25mm, 0.25 μm); carrier: 
hydrogen; inlet pressure: 1 bar; oven temperature: 130 °C for 15 min: tsubstrate = 3.4 
min; tR+S = 12.0 min.  
6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (28o): 68  Conv. 
and ee determined by HPLC: CHIRALPAK IB-3 (150 x 4.6 mm, 3 μm), 254 
nm, 40 °C, isocratic Heptane/iPrOH/DEA 95:5:0.05, 1.3 mL/min: tsubstrate = 
14.3 min; tS = 22.0 min; tR = 24.3 min. 
1,3-Diphenylpropan-1-ol (28p):69 Conversion and ee determined by HPLC: 
CHIRALCEL OD-H (150 x 4.6 mm, 3 μm), 215 nm, isocratic Heptane/iPrOH 
90:10, 1 mL/min: tsubstrate = 13.3 min; te1 = 20.1 min; te2 = 23.3 min. 
1-Phenylbutan-1-ol (28q):70 Conversion and ee determined by GC: CP-Chirasil-
Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven 
temperature: 130 °C for 10 min: tsubstrate = 3.5 min; te1 = 7.0 min; te2 = 7.1 min.A77  
Cyclopent-3-en-1-yl(phenyl)methanol (39):59 Conversion and ee determined by 
GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 
bar; oven temperature: 130 °C for 10 min: tsubstrate = 12.6 min; te1 = 26.5 min; te2 = 
27.0 min. 
Cyclopentyl(phenyl)methanol (41):71 Conversion and ee determined by GC: CP-
Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; oven 
temperature: 130 °C for 10 min: tsubstrate = 12.3 min; te1 = 28.0 min; te2 = 28.5 min. 
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1-(4-vinylphenyl)ethan-1-ol (45):72 Conversion and ee determined by GC: 
CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: helium; gas flow: 2.7 bar; 
oven temperature: 120 °C for 10 min, gradient 30 °C/min, 150 °C for 1 min: te1 = 
11.7 min, te2 = 12.1 min. 
Procedure for the tandem metathesis-ATH 
 
Step I: RCM  
In a nitrogen filled mBraun glovebox, a solution of HG-I (3.0 mg, 0.005 mmol) in 2,2-
dichloroethane (0.3 mL) was added to 1-octene (16.8 mg, 0.15 mmol) and 1-(4-
vinylphenyl)ethanone (7.3 mg, 0.05 mmol). The reaction mixture was stirred in an open glass 
vial for 5 h at 50 °C. The conversion to the cross-metathesis product was analyzed by GC.  
Conversion determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); carrier: 
helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 min, gradient 30 °C/min, 150 °C for 
10 min, gradient 30°C/min, 180 °C for 15 min: t(Z)-tetradec-7-ene = 7.3 min.; t(E)-tetradec-7-ene = 7.6 min.; 
t42 = 8.1 min.; t43 = 28.1 min. 
 
 
Step II: Asymmetric hydrogenation  
(R,R)-TsDPEN (2.0 mg, 0.0055 mmol), 2,2-dichloroethane (0.2 ml), iPrOH (1.5 mL) and 
tBuOK (5.6 mg, 0.05 mmol) were added in this order. The vial was closed and stirred for 18 h at 
30 °C. 
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Conversion and ee determined by GC: CP-Chirasil-Dex CB (25m x 0.25mm, 0.25μm); 
carrier: helium; gas flow: 2.7 bar; oven temperature: 120 °C for 10 min, gradient 30 °C/min, 150 
°C for 10 min, gradient 30°C/min, 180 °C for 15 min: t(Z)-tetradec-7-ene = 7.3 min.; t(E)-tetradec-7-ene = 7.6 
min.; t42 = 8.1 min.; t1-(4-vinylphenyl)ethan-1-ol = 11.7/12.1 min.; t43 = 28.1 min.; t44 = 30.9/31.4 min.; 
 
 
 
 
  Part B 151 
 
REFERENCES 
 
 
1. R. A. Sheldon, Chem. Commun. 2008, 44, 3352–3365.  
2. K. C. Nicolaou, D. J. Edmonds, P. G. Bulger, Angew. Chem. Int. Ed. 2006, 45, 7134–7186.  
3. D. E. Fogg, E. N. dos Santos, Coord. Chem. Rev. 2004, 248, 2365–2379. 
4. a) B. Schmidt, Pure Appl. Chem. 2006, 78, 469–476. b) V. Dragutan, I. Dragutan, J. Organomet. Chem. 2006, 691, 
5129–5147. c) S. Kotha, S. Misra, G. Sreevani, B. V. Babu, Curr. Org. Chem. 2013, 17, 2776–2795. d) B. Alcaide, 
P. Almendros, A. Luna, Chem. Rev. 2009, 109, 3817–3858. 
5. a) J. McLain, S. D. Arthur, E. Hauptman, J. Feldman, W. A. Nugent, L. K. Johnson, S. Mecking, M. Brookhart, 
Polym. Mater. Sci. Eng. 1997, 76, 246–247. b) M. D. Watson, K. B. Wagener, Macromolecules 2000, 33, 3196–
3201. c) C. W. Bielawski, J. Louie, R. H. Grubbs, J. Am. Chem. Soc. 2000, 122, 12872–12873. 
6. R. P. Beatty, R. A. Paciello (E. I. Du Pont de Nemours and Company), U.S. Patent 5554778, 1996. 
7. J. Louie, C. W. Bielawski, R. H. Grubbs, J. Am. Chem. Soc. 2001, 123, 11312–11313. 
8. B. Schmidt, M. Pohler, Org.Biomol. Chem. 2003 , 1, 2512–2517. 
9. K. D. Camm, N. M. Castro, Y. Liu, P. Czechura, J. L. Snelgrove, D. E. Fogg, J. Am. Chem. Soc. 2007, 129, 4168–
4169. 
10. a) J. A. Love, J. P. Morgan, T. M. Trnka, R. H. Grubbs, Angew. Chem. Int. Ed. 2002, 41, 4035–4037. b) T.-L. 
Choi, R. H. Grubbs, Angew. Chem. Int. Ed. 2003, 42, 1743–1746. 
11. X. Miao, C. Fischmeister, C. Bruneau, P. H. Dixneuf, ChemSusChem 2009, 2, 542 – 545. 
12. X. Miao, C. Fischmeister, C. Bruneau, P. H. Dixneuf, J.-L. Dubois, J.-L. Couturier, ChemSusChem 2012, 5, 1410–
1414. b) X. Miao, C. Fischmeister, P. H. Dixneuf, C. Bruneau, J.-L. Dubois, J.-L. Couturier, Green Chem. 2012, 
14, 2179–2183. 
13. a) P. Børsting, K. E. Nielsen, P. Nielsen, Org. Biomol. Chem. 2005, 3 , 2183–2190. b) P. Børsting, P. Nielsen, 
Chem. Commun. 2002, 2140–2141. P. Børsting, M. Freitag, P. Nielsen, Tetrahedron 2004, 60, 10955–10966. 
14. A. N. Whelan, J. Elaridi, R. J. Mulder, A. J. Robinson, W. R. Jackson, Can. J. Chem. 2005, 83, 875–881.  
15. a) A. Fürstner, A. Leitner, Angew. Chem. Int. Ed. 2003, 42, 308–311. b) A. V. Statsuk, D. Liu, S. A. Kozmin, J. Am. 
Chem. Soc. 2004, 126, 9546–9547. c) P. A. Evans, D. K. Leahy, W. J. Andrews, D. Uraguchi, Angew. Chem. Int. Ed. 
2004, 43, 4788–4791. d) J. Ramharter, H. Weinstabl, J. Mulzer J. Am. Chem. Soc. 2010, 132, 14338–14339. e) T. 
E. La Cruz, S. D. Rychnovsky, J. Org. Chem. 2007, 72, 2602–2611. f) L. J. Van Orden, B. D. Patterson, S. D. 
Rychnovsky, J. Org. Chem. 2007, 72, 5784–5793. 
16. a) R. H. Morris, Ruthenium and Osmium. In The Handbook of Homogenous Hydrogenation (Eds.: J. G. De Vries, 
C. J. Elsevier ) Wiley-VCH, Weinheim 2007, 1, 45. b) S. Horn, M. Albrecht, Chem. Commun. 2011, 47, 8802–
8804. c) A. A. Poeylaut-Palena, S. A. Testero, E. G. Mata, Chem. Commun. 2011, 47, 1565–1567. d) T. D. Nixon, 
M. K. Whittlesey, J. M. J. Williams, Tetrahedron Lett. 2011, 52, 6652–6654. 
17. C. Menozzi, P. I. Dalko, J. Cossy, Synlett 2005, 2449–2452. 
 
152 References  
 
18. B. Schmidt, S. Krehl, V. Sotelo-Meza, Synthesis 2012, 1603–1613. 
19. B. Schmidt, J. Org. Chem. 2004, 69, 7672–7687. 
20. T. Connolly, Z. Wang, M. A. Walker, I. M. McDonald, K. M. Peese, Org. Lett. 2014, 16, 4444–4447. 
21. G. K. Zieliński, C. Samojłowicz, T. Wdowik, K. Grela, Org. Biomol. Chem. 2015, 13, 2684–2688. 
22. S. D. Drouin, G. P. Yap, D. E. Fogg, Inorg. Chem. 2000, 39, 5412–5414. 
23. S. D. Drouin, F. Zamanian, D. E. Fogg, Organometallics 2001, 20, 5495–5497. 
24. M. B. Dinger, J. C. Mol, Organometallics 2003, 22, 1089–1095. 
25. T. M. Trnka, J. P. Morgan, M. S. Sanford, T. E. Wilhelm, M. Scholl, T.-L. Choi, S. Ding, M. W. Day, R. H. 
Grubbs, J. Am. Chem. Soc. 2003, 125, 2546–2558. 
26. S. Manzini, A. Poater, D. J. Nelson, L. Cavallo, A. M. Z. Slawin, S. P. Nolan, Angew. Chem. Int. Ed. 2014, 53, 
8995–8999. 
27. M. B. Dinger, J. C. Mol, Eur. J. Inorg. Chem. 2003, 2003, 2827–2833. 
28. D. Banti, J. C. Mol, J. Organomet. Chem. 2004, 689, 3113–3116. 
29. N. J. Beach, K. D. Camm, D. E. Fogg, Organometallics 2010, 29, 5450–5455. 
30. N. J. Beach, J. A. Lummiss, J. M. Bates, D. E. Fogg, Organometallics 2012, 31, 2349–2356. 
31. M. S. Sanford, L. M. Henling, M. W. Day, R. H. Grubbs, Angew. Chem. Int. Ed. 2000, 39, 3451−3453. 
32. a) J. C. Conrad, D. Amoroso, P. Czechura, G. P. A. Yap, D. E. Fogg, Organometallics 2003, 22, 3634−3636. b) J. 
N. Coalter, J. C. Bollinger, O. Eisenstein, K. G. Caulton, New J. Chem. 2000, 24, 925−927. c) S. R. Caskey, M. H. 
Stewart, Y. J. Ahn, M. J. A. Johnson, J. W. Kampf, Organometallics 2005, 24, 6074−6076. 
33. M. S. Sanford, J. A. Love, R. H. Grubbs, J. Am. Chem. Soc. 2001, 123, 6543−6554. 
34. a) S. H. Hong, A. G. Wenzel, T. T. Salguero, M. W. Day, R. H. Grubbs, J. Am. Chem. Soc. 2007, 129, 7961–7968. 
b) M. Ulman, R. H. Grubbs, J. Org. Chem. 1999, 64, 7202–7207. c) W. J. van Rensburg, P. J. Steynberg, W. H. 
Meyer, M. M. Kirk, G. S. Forman, J. Am. Chem. Soc. 2004, 126, 14332–14333. d) D. Amoroso, G. P. A. Yap, D. E. 
Fogg, Organometallics 2002, 21, 3335–3343. e) D. Amoroso, G. P. A. Yap, D. E. Fogg, Can. J. Chem. 2001, 79, 
958–963. f) D. Bourgeois, A. Pancrazi, S. P. Nolan, J. Prunet, J. Organomet. Chem. 2002, 643-644, 247–252. g) S. 
H. Hong, M. W. Day, R. H. Grubbs, J. Am. Chem. Soc. 2004, 126, 7414–7415. h) G. C. Vougioukalakis, R. H. 
Grubbs, Chem. Rev. 2010, 110, 1746–1787. i) M. B. Herbert, Y. Lan, B. K. Keitz, P. Liu, K. Endo, M. W. Day, K. 
N. Houk, R. H. Grubbs, J. Am. Chem. Soc. 2012, 134, 7861–7866. 
35. D. E. Fogg, D. Amoroso, S. D. Drouin, J. Snelgrove, J. Conrad, F. Zamanian, J. Mol. Catal. A: Chem. 2002, 190, 
177-184.  
36. a) Rowley, C. N.; Foucault, H. M.; Woo, T. K.; Fogg, D. E. Organometallics 2008, 27, 1661–1663. b) Beach, N. 
J.; Blacquiere, J. M.; Drouin, S. D.; Fogg, D. E. Organometallics 2009, 28, 441–447. 
37. Sanford, M. S.; Ulman, M.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 749–750. 
38. Handbook of Metathesis: Catalyst Development and Mechanism, Volume 1 (Eds.: R. H. Grubbs, A. G. Wenzel) John 
Wiley & Sons, 2015.  
39. a) N. Haddad, B. Qu, S. Rodriguez, L. van der Veen, D. C. Reeves, N. C. Gonnella, H. Lee, N. Grinberg, S. Ma, D. 
Krishnamurthy, T. Wunberg, C. H. Senanayake, Tetrahedron Lett. 2011, 52, 3718–3722. b) U. Berens, C. 
 
  Part B 153 
 
Fischer, R. Selke, Tetrahedron Asymmetry 1995, 6, 1105–1108. c) A. Wolfson, I. F. J. Vankelecoma, D. Geresh, P. 
A. Jacobs, J. Mol. Catal. A-Chem. 2003, 198, 39–45. d) E. V. Starodubtseva, O. V. Turova, M. G. Vinogradov, L. S. 
Gorshkova, V. A. Ferapontov, Russ. Chem. Bull., Int. Ed., 2007, 56, 552–554. 
40. J. J. Verendel, T. Zhou, J. Li, A. Paptchikhine, O. Lebedev, P. G. Andersson, J. Am. Chem. Soc. 2010, 132, 8880–
8881. 
41. a) T. Vorfalt, S. Leuthäußer, H. Plenio, Angew. Chem. Int. Ed. 2009, 48, 5191–5194. b) I. C. Stewart, T. Ung, A. 
A. Pletnev, J. M. Berlin, R. H. Grubbs, Y. Schrodi, Org. Lett. 2007, 9, 1589–1592. c) Y. Liang, R. Raju, T. Le, C. D. 
Taylor, A. R. Howell, Tetrahedron Lett. 2009, 50, 1020–1022. d) D. Rost, M. Porta, S. Gessler, S. Blechert, 
Tetrahedron Lett. 2008, 49, 5968–5971. e) X. Elias, R. Pleixats, M. W. C. Man, J. J. E. Moreau, Adv. Synth. Catal. 
2007, 349, 1701–1713. f) A. Fürstner, O. R. Thiel, L. Ackermann, H.-J. Schanz, S. P. Nolan, J. Org. Chem. 2000, 
65, 2204-2207. g) S.-M. Paek, Molecules 2012, 17, 3348–3358. 
42. C. A. Merlic; M. F. Semmelhack, J. Organomet. Chem. 1990, 391, C23–C27. 
43. C. Stueckler, C. K. Winkler, M. Hall, B. Hauer, M. Bonnekessel, K. Zangger, K. Faber, Adv. Synth. Catal. 2011, 
353, 1169–1173. 
44. N. Khiar, R. Navas, B. Suárez, E. Álvarez, I. Fernández, Org. Lett. 2008, 10, 3697–3700. 
45. L. Yu, Z. Wang, J. Wu, S. Tu, K. Ding, Angew. Chem. Int. Ed. 2010, 49, 3627–3630.  
46. D. Wang, D. Astruc, Chem. Rev. 2015, 115, 6621–6686. 
47. a) S. Hashiguchi, A. Fujii, J. Takehara, T. Ikariya, R. Noyori, J. Am. Chem. Soc., 1995, 117, 7562–7563. b) R. 
Noyori, S. Hashiguchi, Acc. Chem. Res., 1997, 30, 97–102. 
48. Y. Jiang, Q. Jiang, X. Zhang, J. Am. Chem. Soc., 1998, 120, 3817–3818. 
49. a) R. Hartmann, P. Chen, Angew. Chem. Int. Ed., 2001, 40, 3581–3585. b) J-H. Xie, S. Liu, X-H. Huo, X. Cheng, 
H-F. Duan, B-M. Fan, L-X. Wang, Q-L. Zhou, J. Org. Chem., 2005, 70, 2967–2973. c) P. Västilä, A. B. Zaitsev, J. 
Wettergren, T. Privalov, H. Adolfsson, Chem. Eur. J., 2006, 12, 3218–3225. 
50. Phosphorus-31 NMR Spectroscopy. (Ed. Olaf Kühl), Springer-Verlag Berlin Heidelberg, 2008. 
51. R. G. Kostyanovsky , V. G. Plekhano, Org. Mass Spectrom. 1972, 6, 1183–1198. 
52. W-M. Cheung, W-H. Chiu, X.-Y. Yi, Q.-F. Zhang, I. D. Williams, W.-H. Leun, Organometallics 2010, 29, 1981–
1984. 
53. E. N. Eccott, R. P. Linstead, J. Chem. Soc. 1930, 905–919. 
54. Olefin Metathesis Theory and Practice. Chapter 2.2. (Ed. K. Grela), John Wiley & Sons, Inc., Hoboken, NY, 2014. 
55. A. K. Chatterjee, T-L. Choi, D. P. Sanders, R. H. Grubbs, J. Am. Chem. Soc., 2003, 125, 11360–11370. 
56. A. F. Littke , L. Schwarz , G. C. Fu J. Am. Chem. Soc. 2002, 124, 6343–6348. 
57. G. Pandey, B. B. V. S. Sekhar, J. Org. Chem. 1992, 57, 4019–4023. 
58. K. Moriyama, M. Takemura, H. Togo, J. Org. Chem. 2014 , 79, 6094–6104 
 
154 References  
 
59. T. Wdowik, C. Samojlowicz, M. Jawiczuk, M. Malinska, K. Wozniak, K. Grela, Chem. Commun. 2013 , 49, 674–
676. 
60. F. Jiang, K. Yuan, M. Achard, C. Bruneau Chem. Eur. J. 2013, 19, 10343–10352. 
61. S. W. Krabbe, M. A. Hatcher, R. K. Bowman, M. B. Mitchell, M. S. McClure, J. S. Johnson, Org. Lett. 2013, 15, 
4560–4563. 
62. D.R. Li, A. He, J. R. Falck Org. Lett. 2010, 12, 1756–1759. 
63. D. Lowicki, A. Bezlada, J. Mlynarski, Adv. Synth. Catal. 2014, 356, 591–595. 
64. S. Abbina, S. Bian, C. Oian, G. Du, ACS Catal. 2013, 3, 678–684. 
65. P. Vitale, F. M. Perna, M. G. Perrone, A. Scilimati, Tetrahedron: Asymmetry 2011, 22, 1985–1993. 
66. L. Ren, T. Xu, R. He, Z. Jiang, H. Zhou, P. Wei, Tetrahedron: Asymmetry 2013, 24, 249–253. 
67. S. Rodriguez, B. Qu, K. R. Fandrick, F. Buono, N. Haddad, Y. Xu, M. A. Herbage, X. Zeng, S. Ma, N. Grinberg, H. 
Lee, Z. S. Han, N. K. Yee, C. H. Senanayake, Adv. Synth. Catal 2014, 356, 301–307. 
68. X. Li, D. Leonori, N. S. Sheikh, I. Coldham, Chem. Eur. J. 2013 , 19, 7724–7730. 
69. M. Lamani, G. S. Ravikumara, K. R. Prabhu, Adv. Synth. Catal 2012 , 354, 1437–1442. 
70. C. Guyon, E. Metay, N. Duguet, M. Lemaire, Eur. J. Org. Chem. 2013 , 24, 5439–5444. 
71. A. Orjales, R. Mosquera, A. Toledo, M. C. Pumar, N. Garcia, L. Cortizo, L. Labeaga, A. Innerarity, J. Med. 
Chem. 2003 , 46, 5512–5532. 
72. F. J. Barrios, B. C. Springer,D. A. Colby, Org. Lett. 2013 , 15, 3082–3085. 
 
  
Summary 
 
 
 
In Part A of this thesis we focused on developing new methods for the asymmetric 
hydrogenation (AH) of pyridines, due to the fact that chiral piperidines are ubiquitous motifs in 
many natural products and biologically active compounds. AH represents a versatile, clean and 
atom economic methodology and, since many protocols exist for the preparation of substituted 
pyridines, this technology is foreseen as the most efficient for the synthesis of chiral piperidines.  
We first explored the AH of 2-substituted pyridinium salts with iridium complexes: a high-
throughput screening of chiral phosphoramidites and their combinations with achiral phosphines 
allowed to individuate a phosphine/phosphoramidite complex ensuring full conversions and 
enantioselectivities of up to 82% ee. Using this catalytic system, a mechanistic study was 
performed, which shed light into the elementary steps towards the formation of the chiral 
piperidines and showed that the stereogenic carbon is not formed until the last hydrogenation 
step.  
We next investigated the AH of 3-substituted pyridinium salts, which are much more 
challenging substrates. By means of a Rh-Josiphos complex and the addition of Et3N, different 
substrates were hydrogenated with up to 50% yield and 90% ee. The mechanistic study of this 
system was more complex, as different paths involving a number of dihydropyridines and 
tetrahydropyridines were identified towards the formation of the final piperidine. Among them, 
only one was producing the final piperidine with high enantioselectivity and the main side-
pathway, which was leading to a racemic piperidine, was found to be halted by the addition of the 
base.  
In Part B of the thesis, the possibility of converting Ru olefin metathesis catalysts into AH 
and asymmetric transfer hydrogenation (ATH) catalysts was explored. Many systems had been 
disclosed in the last years for the tandem metathesis–AH or ATH, but for none of them an 
asymmetric version had been reported. When Ru olefin metathesis catalysts were pressurized 
under H2 in the presence of a chiral diphosphine ligand and an alcoholic solvent, chiral Ru 
complexes formed, promoting the AH of methyl 2-acetamidoacrylate with up to 93% ee. 
Additionally, when 1st generation Grubbs catalyst were treated with a base in the presence of a 
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chiral diamine ligand and iPrOH, a chiral catalyst was obtained, which promoted the ATH of 
aromatic ketones with up to 97% ee.  
These two protocols for the conversion of Ru olefin metathesis catalysts into AH and ATH 
catalysts, respectively, were also implemented “one-pot” after an initial metathesis step. In the 
first case, a tandem ring-closing metathesis-AH protocol for the synthesis of 3-methyl-N-
tosylpiperidine with 86% ee was developed. In the second, the cross metathesis of 4-
vinylacetophenone followed by ketone ATH was achieved in one pot with 87% ee. 
Although it is clear that these technologies still need further development and optimization, 
we believe that the advances presented on the AH of pyridines and the tandem metathesis–
AH/ATH protocols will broaden the understanding of these fields and open new lines of 
investigation. 
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